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Abstract
ii
Stabilisation of telomere length is considered to be an essential step in cellular 
immortalisation in vitro and in human cancers. The telomerase ribonucleoprotein reverse 
transcriptase catalyses the addition of new telomeric repeat sequence to the ends of linear 
eukaryotic chromosomes and counteracts the cell division associated telomeric attrition 
that leads to cellular senescence. Its expression has been detected in approximately 85% of 
all human malignancies but is not detectable in the majority of normal somatic tissues and, 
therefore, telomerase represents an attractive target for the development of novel molecular 
therapeutics. Although telomerase activity is modulated on a number of levels, a primary 
level of regulation is the transcription of the telomerase sub-unit genes. In the present 
study, I describe the development of a transcriptionally directed cytotoxic gene therapy 
approach targeted against telomerase positive cancer cells. Transfection experiments using 
fragments of the human telomerase RNA component (hTERC) and the human telomerase 
reverse transcriptase (hTERT) promoters revealed large differences in promoter activity 
between mortal cells and cancer cells. The promoter fragments were sub-cloned into 
plasmids containing the coding sequence of nitroreductase (NTR), a bacterial enzyme that 
catalyses the chemical reduction of the non-toxic pro-drug CB1954 resulting in the 
formation of a powerful bi-functional alkylating agent that kills both dividing and non­
dividing cells. Stable cell lines harbouring hTERC-NTR and hTERT-NTR expression 
vectors were sensitised to CB1954 to an extent that was dependent on hTERC and hTERT 
promoter activity, with cell lines that had high promoter activities showing significant 
sensitisation, while those with low promoter activities were not significantly sensitised. 
The hTERC-NTR and hTERT-NTR expression constructs were cloned into adenovirus 
(Ad) delivery vehicles and the efficiencies of infection and expression of NTR were 
characterised in infected cell lines. The major RNA species that was expressed in infected 
cells was a splice variant that encoded a truncated NTR protein, but the function of NTR 
was not significantly impaired. Infection with the Ad-hTERC-NTR and Ad-hTERT-NTR 
gene therapy vectors resulted in a sensitisation to CB1954 that was dually dependent on 
promoter activity and infection efficiency. Two cancer cell lines that had high hTERC and 
hTERT promoter activities were significantly sensitised to CB1954, while a mortal foetal 
lung fibroblast cell strain and a normal adult human mammary epithelial strain, in addition 
to a bladder cancer cell line with low promoter activity, were not sensitised despite 
efficient infection with adenovirus. Therefore, the data presented herein support the further 
development of telomerase-nitroreductase expression vectors for anti-cancer gene therapy.
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1 INTRODUCTION
1.1 Immortality and cancer
Recent insights into tumour cell molecular biology and the tumour micro-environment 
have provided a wealth of possibilities for the development of novel mechanism based 
therapeutics. A major aim of cancer research is the identification of pathways and 
characteristics which differ between tumour cells and normal cells. Identification of such 
differences allows for the evaluation and development of mechanism based therapeutics 
targeted against the very features of cancer cells that are associated with malignancy.
One such tumour-associated property that may be predicted to form the basis for a new 
generation of tumour targeted therapeutics, is immortality. Most normal adult human 
somatic cells have a limited replicative lifespan in vitro and in vivo, a feature exemplified 
by the studies of Hayflick (Hayflick 1965). The maximum number of divisions that can be 
achieved is referred to as the Hayflick limit and after this maximum limit, a cell population 
will enter a state of growth arrest termed senescence. In contrast, cell cultures derived from 
malignant tumours commonly exhibit no such limit: they are able to divide indefinitely and 
have escaped from the normal cues to enter senescence. This characteristic is termed 
immortality. The underlying mechanisms of immortality are undoubtedly highly complex 
and almost certainly involve the co-ordinated aberration of multiple pathways for normal 
growth control. However, in recent years, it has become apparent that a central feature of 
immortalised cells is maintenance of the length and function of telomeres, the repetitive 
DNA sequences which cap the ends of linear chromosomes.
1.2 Telomere and telomerase structure and function
1.2.1 Telomere structure and function
1.2.1.1 Role of the telomere in cellular ageing
Telomeres are tandem repeated nucleoprotein sequences, comprising the hexa-nucleotide 
repeating unit (TTAGGG) n in all vertebrates tested (Moyzis et al. 1988; Meyne et al. 
1989), which cap the ends of linear chromosomes and have been implicated in the 
maintenance of genomic stability by prevention of aberrant fusion events. Conventional
Alan E. Bilsland, 2002 Chapter 1: Introduction 2
eukaryotic DNA polymerases mediate DNA replication by a semi-conservative 
mechanism: each strand of a parent molecule is copied such that the daughter chromosome 
comprises one parent strand and one newly synthesised strand. Synthesis of new strands 
occurs only in a 5’-3’ direction from a 3’-5’ template. This means that during DNA 
replication, only one strand (the leading strand) is completely copied. Synthesis of the 
complementary (lagging) strand proceeds in a discontinuous manner by extension of short 
stretches, termed Okazaki fragments, and is initiated from short RNA priming sequences 
which are subsequently removed allowing ligation of the fragments to occur (Sugino et al. 
1972). The removal of the terminal RNA primer from the lagging strand means that the 3’ 
end of the lagging strand is incompletely replicated (Watson 1972; Olovnikov 1973), 
leading to loss of approximately 50-200bp of telomeric sequence with each cell division. 
This loss of telomeric DNA leaves a 3’ G-rich overhanging single stranded species 
(Henderson et al. 1989; Wright et al. 1997) (Figure 1.1).
This phenomenon, termed the end replication problem, is proposed to function as a 
“mitotic clock”, counting the number of cell divisions elapsed. By this model, a cycling 
cell will gradually lose its telomeric DNA until one or more telomeres become critically 
short, signal as DNA damage and induce senescence. By this model, an increasing number 
of individual cells within a cycling population will progressively exit from the cell cycle 
until the onset of widespread growth crisis. Indeed, the observations that mean telomere 
lengths, analysed by Southern blot detection of terminal restriction fragments (TRF), 
shorten with increased population doublings in several normal human fibroblast cell strains 
of varying donor age (Harley et al. 1990) and that telomere length correlates strongly with 
remaining replicative lifespan in human skin fibroblasts (Allsopp et al. 1992; Allsopp et al. 
1995) lend considerable support to the model. It has also been shown that telomere 
attrition in ageing fibroblasts is intrinsically associated with active cell division, but not 
with quiescence, both in vitro and in vivo (Allsopp et al. 1995).
The mechanisms by which telomere attrition activates senescence or apoptosis are not fully 
understood at this time but the studies of Vaziri et al provide some clues as to the nature of 
the process. Up-regulation of p53 activity leading to Cyclin Dependent Kinase inhibition 
by p21WAF1 has been implicated as a major signalling event in cellular senescence 
(reviewed in Bringold et al. 2000; Campisi 2001). In one study, comparison of p53 DNA 
binding activity and p53 dependent p21WAF1 promoter activity in 3 strains of young and 
aged fibroblasts revealed increased p53 DNA binding and p21WAF1 promoter activity in the 
absence of increased p53 protein levels in ageing cells. Similar results were observed when
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investigators examined Ataxia Telangiectasia fibroblast strains, which exhibit accelerated 
telomere attrition and senescence in culture, when compared to fibroblasts from normal 
siblings or unrelated age matched donors. Moreover, fibroblasts grown under hyperoxic 
conditions that accelerated the attrition of telomeres showed similar increases in p53 DNA 
binding and p21WAF1 protein levels when compared with normoxic controls. Finally, the 
investigators demonstrated an interaction between p53 and Poly (ADP-Ribose) Polymerase 
(PARP) in ageing fibroblasts, leading to up-regulation of p21WAF1 and MDM2 and showed 
that incubation with specific PARP inhibitors could extend cellular lifespan (Vaziri et al. 
1996; Vaziri et al. 1997).
1.2.1.2 Telomere structure and regulation of telomere function
In addition to the tandem repeated nucleotide sequence (TTAGGG)n, a large number of 
binding factors present at the telomere are implicated in its function and homeostasis. 
Some of the critical regulators of telomere function are discussed below, while a number of 
the other human telomere binding proteins are listed in table 1.1. Additionally, figure 1.2 
gives a schematic representation of possible interactions of proteins at the telomere. The 
major functions that have been ascribed to telomeres are: (1) prevention of aberrant 
recombination events and genetic instability such as end-to-end fusions. (2) distinguishing 
chromosome ends from DNA damage. (3) telomeres are involved in modification of gene 
expression by gene silencing. (4) a role has been proposed for telomere function in sister 
chromatid separation during anaphase. The available evidence suggests that telomere 
length maintenance, or more specifically, the maintenance of telomere function, is a 
critical determinant of cellular lifespan and fate.
In cells with active telomerase, telomere seeding experiments reveal that telomere lengths 
are subject to homeostatic regulation: exogenously introduced telomeres are extended by 
the telomerase ribonucleoprotein reverse transcriptase, discussed in more detail below, 
which adds TTAGGG repeats to the single stranded 3’ overhang of telomere termini until 
their length is within a range characteristic of the cell type (Barnett et al. 1993). Despite 
heterogeneity between telomere lengths even within the same cell (Lansdorp et al. 1996), 
lengths are kept within tight species specific limits (Kipling et al. 1990), suggesting the 
presence of a sensitive mechanism for maintenance of telomere length.
Factors implicated in this process include the proteins bound on the double and single 
stranded regions of the telomeric DNA, the higher order structure formed by recruitment of
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other proteins by telomere binding proteins, the physical folding back of the telomere into 
looped structures, and the action of telomerase. By the mutual interaction of these factors, 
the telomere is proposed to switch between a “capped” state, in which it is protected from 
the action of nucleases, from the activation of damage response signals and is inaccessible 
to telomerase, and an “uncapped” state, in which it is unprotected and is accessible to 
lengthening by telomerase. A central tenet of this model is that proteins bound along the 
telomeric tract establish a dynamic equilibrium by which telomere length is 
homeostatically maintained. This model predicts that telomere shortening during cell 
division will reduce the number of negative regulatory proteins associated with the 
telomere and thereby increase the probability that a given telomere will switch to the 
uncapped state, allowing extension by telomerase; conversely, extension by telomerase 
will recruit a large number of proteins to the telomere and inhibit further elongation 
(reviewed in Blackburn 2000; Blackburn 2001).
A number of double stranded sequence specific telomere binding proteins that influence 
telomere length and function have been identified in humans and yeast (table 1.1). Among 
these, the protein Raplp (Repressor/Activator Protein 1), is implicated as a central 
negative regulator of telomere length in yeast cells: over-expression of DNA binding 
mutants resulted in increased in telomere length (Conrad et al. 1990) suggesting a mode of 
action involving interaction with other factors which are sequestered by binding mutants. 
Consistent with this finding, Raplp was subsequently demonstrated to recruit the factors 
Riflp and Rif2p to the telomere (Hardy et al. 1992; Wotton et al. 1997). Both factors 
negatively regulate telomere length by an interaction with the carboxyl terminus of Raplp 
and expression either of mutants defective in Raplp interaction, or of carboxyl terminus 
mutated Raplp defective in Rif interaction, increased telomere length. Moreover, cells 
deficient in both Rifl and Rif2 showed a synergistic increase in telomere lengths relative 
to either single mutant. Conversely, over-expression of wild type Riflp and Rif2p can 
reduce telomere length (Wotton et al. 1997). Based on these results, it has been postulated 
that telomere length regulation in yeast relies on a protein counting mechanism dependent 
on the number of Raplp molecules bound along the telomeric tract. Consistent with this, 
mutation of Raplp biding sites increases telomere length (Marcand et al. 1997).
In mammalian cells, the ubiquitous telomeric repeat binding factors TRF1 and TRF2 were 
identified on the basis of their ability to bind the telomere repeat sequence (Zhong et al. 
1992; Chong et al. 1995; Broccoli et al. 1997) and TRF1 has been characterised as a 
functional homologue of yeast Raplp, in terms of its ability to negatively regulate telomere
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length in an inducible over-expression system (van Steensel et al. 1997). Recently, TRF 
proteins were classified as orthologues of the s.pombe Tazl protein that binds double 
stranded telomere sequence and recruits factors for length maintenance (Li et al. 2000). 
The human TRF1 gene codes for a protein of approximately 60kDa with a highly acidic N- 
terminus and a C-terminal Myb-like DNA binding domain. Human and mouse TRF Is 
show greatest homology in the dimerisation and DNA binding domains (Bianchi et al. 
1997; Broccoli et al. 1997). TRF1 binds the telomere as a homo-dimer and bends double 
stranded DNA (Bianchi et al. 1997), a conformation that may favour the formation of the 
“t-loop” structure.
When mammalian telomeres are cross-linked and purified, a proportion adopt a lasso-like 
conformation (the t-loop) in which conformation the single stranded overhang is proposed 
to be sequestered within the duplex region. The presence of a D-loop at the junction of the 
“lasso” suggests the involvement of a strand invasion mechanism (Griffith et al. 1999) 
(Figure 1.3). This might represent a mechanism whereby telomeres can maintain their 
function despite the presence of a single stranded region. The junction of the t-loop is 
bound by TRF2 (Griffith et al. 1999; Stansel et al. 2001), a TTAGGG binding factor 
distantly related to TRF1 that appears to be required for t-loop formation, possibly by a 
helicase-type action (Stansel et al. 2001). TRF2 shares most homology to TRF1 in the 
DNA binding domain (56% identity), homo-dimerises but does not form heterodimers with 
TRF1 (Broccoli et al. 1997) and may facilitate or stabilise the t-loop structure. It is 
proposed that TRF1 and TRF2 inhibit the action of telomerase in cis, possibly by 
generation of the t-loop.
TRFs may also contribute to telomere maintenance by generation of a higher order protein 
structure at the telomere. Interestingly, the human orthologue of Saccharomyces cerevisiae 
Raplp, hRapl, was recently identified (Li et al. 2000). This protein shows homology with 
the yeast Rapl proteins in the C-terminus, in addition to the central Myb domain and an N- 
terminal domain that also has homology with the C-terminal protein interaction domain of 
BRCA1. In contrast to the action of scRaplp, which is mediated by DNA binding and 
recruitment of Rifs to the telomere, hRapl does not directly bind DNA but instead is 
recruited to the telomere by an interaction between its C-terminus and the TRF homology 
domain of TRF2. Over-expression of hRapl resulted in moderately increased telomere 
length, but the nature of its function at the telomere remains to be clarified (Li et al. 2000). 
TRF2 over-expression modulates telomere length in a biphasic manner, with an initial cell 
division dependent decrease in length followed by extension (Smogorzewska et al. 2000).
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Removing TRF2 from the telomere by expression of dominant negative analogues results 
in rapid ATM and p53 dependent cell death (Karlseder et al. 1999) and widespread 
chromosome end to end fusions (van Steensel et al. 1998). Interestingly, in another recent 
study (Kim et al. 2001) in which mutant template sequence not recognised by the telomere 
binding protein TRF1 was synthesised by the expression of mutant telomerase, cells 
underwent apoptosis. These data underscore the essential roles of telomere binding factors 
in the maintenance of normal telomere function.
Tankyrase (TANK1), a TRF1 interacting protein identified in two-hybrid screening, 
contains a PARP domain that ADP-Ribosylates both itself and TRF1 (Smith et al. 1998). 
Tankyrase associates with TRF1 via an interaction between the acidic N-terminus of TRF 1 
and a domain of Tankyrase containing numerous ankyrin repeats that are involved in 
protein-protein interaction. Modification of TRF 1 by PARP activity results in inhibition of 
TRF1 TTAGGG binding activity in vitro. Modification of TRF 1 by tankyrase appears to 
remove TRF1 from telomeres in vivo and promotes telomere elongation (Smith et al. 
2000), although it is unclear whether TRF1 is the only telomeric protein target for 
modification by tankyrase or whether tankyrase is required for telomere extension by 
telomerase under TRF1 inhibited conditions.
It is intriguing that a number of telomere associated proteins have been identified as 
components of DNA damage response pathways. The involvement of PARP activity in 
damage signals is well characterised (reviewed in Herceg et al. 2001) and, while tankyrase 
activity at the telomere has been characterised to date only as a modulator of TRF1, a 
relative of tankyrase, TANK2, has recently been identified (Kaminker et al. 2001). 
TANK2 also interacts with TRF1, but in contrast to the apparent function of tankyrase, 
over-expression of TANK2 resulted in rapid cell death, suggesting that tankyrase family 
proteins may also have a role in integrating damage response signals at the telomere. 
Additionally, the identification of a protective role at the telomere played by the Ku 
proteins, (Samper et al. 2000) that are involved in the non-homologous end-joining 
pathway for chromosome repair, provides another interesting example of the multiple 
pathways required for normal telomere function.
Maintenance of telomere length and function, then, is a complex and regulated process 
involving the interaction of multiple components, critical to the prolonged survival of the 
cell, but in most adult human somatic cells telomere lengths are not maintained, but 
shorten with each cell division. One problem with the classical model of a critical telomere
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length as the cue for cellular senescence is that the simple acquisition of shortened 
telomeres does not mechanistically explain what drives exit from the cell cycle. Indeed, 
cells with active telomerase often have short telomeres and, in experimental systems, can 
continue to divide despite having shorter telomeres than control cells undergoing 
senescence (Yang et al. 1999; Zhu et al. 1999). Another problem is that the classical model 
of telomere structure does not explain why functional telomeres are interpreted as natural 
chromosome ends rather than as double strand breaks. The capping status of a telomere 
may thus define how a telomere is interpreted by components of the DNA damage 
response path, and hence the fate of a given cell. This model of telomere length 
maintenance may help to explain some of these problems.
1.2.2 Telomerase function
1.2.2.1 Identification of telomerase activity
Telomerase activity, characterised as a sequence specific telomere terminal transferase 
activity, was first identified in Tetrahymena thermophila cell extracts (Greider et al. 1985). 
Later identification of activity in Euplotes crassus (Shippen-Lentz et al. 1989), Oxytricha 
nova (Zahler et al. 1988) and human cell extracts (Morin 1989) strongly suggested that a 
telomere terminal transferase activity was widespread amongst eukaryotes. The results of 
in vitro primer extension assays which demonstrated specificity of the activity for 
telomeric sequence, but not irrelevant sequences or telomere complementary sequences, 
suggested that this could provide a mechanism to compensate for the end replication 
problem in the linear DNA of eukaryotic genomes.
Experiments in Tetrahymena revealed that the enzyme responsible was a ribonucleoprotein 
reverse transcriptase, termed telomerase (Greider et al. 1987). It was subsequently 
recognised that the RNA subunit of Tetrahymena telomerase contains a sequence 
complementary to the telomeric sequence that was proposed to act as a template for the 
synthesis of new telomeric repeats (Greider et al. 1989). Support for this model came from 
the identification of putative template sequences in telomerase RNAs of a variety of 
organisms including Euplotes (Shippen-Lentz et al. 1990), mouse (Blasco et al. 1995) and 
human (Feng et al. 1995), and the mapping of the boundaries of the Euplotes template 
region by primer extension assays (Shippen-Lentz et al. 1990). In all cases, the proposed 
template sequence was complementary to the telomere sequence. Telomerase RNA
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component (here referred to as TERC) subunits have now been identified in 35 vertebrate 
species (Chen et al. 2000).
Telomerase, then, is a ribonucleoprotein reverse transcriptase that catalyses the synthesis 
of telomere repeats from an internal RNA template (a schematic representation of the 
proposed activity of telomerase is presented in figure 1.4). The catalytic subunit of 
telomerase was first identified in Euplotes aediculatus (p i23) (Lingner et al. 1997) and the 
same study identified the homologue from Saccharomyces cerevisiae as the EST2p gene, 
deletion of which had previously been demonstrated to result in telomere shortening 
(Lendvay et al. 1996)). Later, the human catalytic subunit was simultaneously cloned by 
several groups (Kilian et al. 1997; Meyerson et al. 1997; Nakamura et al. 1997). Although 
initially referred to by various acronyms (hTRT, hTCS, hEST2), the telomerase reverse 
transcriptase is now designated hTERT. The identification of these two core components 
of the telomerase complex allowed the study of telomerase subunit expression and 
correlation with telomerase activity in human cancers, discussed in more detail below. 
Both subunits are required for enzyme activity and, as discussed below, both have been 
detected at low levels in normal tissues although they are up-regulated in malignancy 
(Feng et al. 1995; Avilion et al. 1996; Kolquist et al. 1998; Ramakrishnan et al. 1998).
1.2.2.2 Studies on the role of telomerase in immortality
The correlation between cellular lifespan and telomere length gave the first indications that 
telomere stability may impact upon development of immortal phenotypes and play a role in 
the progression of cancer in mammalian cells. Additionally, the definition of the yeast 
EST2 gene (ever shorter telomeres), deletion of which is characterised by telomere 
stability defects (Lendvay et al. 1996), as the telomerase catalytic subunit (Lingner et al. 
1997) gave a direct indication that loss of telomerase activity could lead to telomere 
shortening and eventually senescence. The acquisition of telomerase activity is specifically 
associated with stabilisation of telomere length (Counter et al. 1992; Bodnar et al. 1998). 
Moreover, many cancer cells have short though stabilised telomeres (Engelhardt et al. 
1997) and, in the vast majority of cases, express telomerase activity (Kim et al. 1994). This 
strongly suggests that telomerase activity plays a role in the acquisition of cellular 
immortality during cancer progression. Indeed, a study of chromosomal stability, telomere 
length and telomerase activity in pre- and post-immortalised human embryonic kidney 
cells transformed with viral oncogenes showed progressive telomere shortening and 
increased frequency of dicentric chromosomes with increased population doubling number
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as the cells approached crisis. Immortalised cells that escaped from crisis, however, had 
stable telomere length, and specifically expressed telomerase activity (Counter et al. 1992). 
These data, together with the development of the PCR based TRAP assay (Telomere 
Repeat Amplification Protocol) for the sensitive detection of telomerase activity in human 
cell extracts led to the implication of telomerase activity as a critical determinant of 
sustained viability in the vast majority of human tumour cells and immortalised cell lines 
in tissue culture systems (Kim et al. 1994).
Direct evidence that stabilisation of telomere length by telomerase mediates the 
progression to an immortal phenotype came from several studies in which telomerase 
activity was introduced into normal primary cell strains by ectopic expression of hTERT 
with subsequent extension of proliferative life-span (Bodnar et al. 1998; Yang et al. 1999; 
Rufer et al. 2001). Conversely, transfection of dominant negative hTERT analogues, or 
expression of mutant hTERC molecules abrogates telomerase activity in immortal cells 
and, with continued passage, cells enter into senescence or apoptosis (Hahn et al. 1999; 
Zhang et al. 1999). Other powerful evidence of the role of telomerase in cellular 
immortality was presented in the study of Hahn and colleagues (Hahn et al. 1999). The 
investigators were able to induce tumourigenic conversion in normal human epithelial and 
fibroblast cells by the introduction of SV40 large T antigen, oncogenic H-ras and hTERT. 
Importantly, characteristics of full malignant transformation (anchorage independent 
growth, tumour formation in nude mice, indefinite replicative potential) were achieved 
only when all 3 components were present, demonstrating that expression of telomerase, 
although central to cell immortalisation, is not functionally equivalent to malignant 
transformation. This is in-keeping with the results of other studies in which acquisition of 
telomerase activity was shown to be insufficient for acquisition of a malignant phenotype 
(Jiang et al. 1999; Morales et al. 1999). Interestingly, while forced expression of 
telomerase can extend the lifespan of some cell types, the requirements for immortalisation 
may vary between cell types (O'Hare et al. 2001). A requirement for the inactivation of the 
Rb/pl6 pathway in addition to expression of telomerase activity has been reported for 
immortalisation of human epithelial cells (Kiyono et al. 1998).
The model of cellular immortalisation involving telomerase as a step in tumourigenic 
progression in tissue culture systems is represented in figure 1.5. Telomerase activity is 
present during embryogenesis, but is repressed in most adult somatic cells (discussed in 
more detail below). Proliferation of telomerase negative cells leads to a progressive loss of 
telomeric sequence until one or more telomeres reach a critical length, at which time most
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cells will enter senescence (also termed mortality checkpoint 1, or Ml). During 
senescence, the majority of cells cease dividing but occasional, rare, partially transformed 
cells escape from the Ml checkpoint and can continue to divide, although they continue to 
lose telomeric DNA. Cells with critically shortened telomeres progressively exit from the 
cell cycle into a second growth arrested state termed mortality checkpoint 2, or M2. A 
minority of cells, in which expression of telomerase components is either stimulated or de­
repressed, escape from this growth crisis with stabilised telomere length and function. Re­
activation of telomerase activity is thus regarded as a critical late stage in cellular 
immortalisation.
1.2.2.3 Telomerase structure
Telomerase activity can be reconstituted in vitro, minimally, from its 2 core subunits, 
hTERC and hTERT, although other components of the holoenzyme complex play a role in 
the regulation of activity in vivo. Reconstitution of activity has been achieved in several in 
vitro systems (micrococcal nuclease digested cell extracts, rabbit reticulocyte lysate, and 
telomerase negative cell lines) and these studies have enhanced our understanding of the 
structural elements, both of hTERT and hTERC, which are involved in functional 
interaction.
The hTERC gene, mapped to a locus on chromosome 3q26.3 by fluorescence in situ 
hybridisation (Soder et al. 1997), encodes a mature RNA of 451nt in length. The template 
sequence (CUAACCCUAA) lies 46nt downstream from the transcriptional start site (Feng 
et al. 1995). The TERC RNA sequences which have been cloned thus far do not display a 
large amount of primary sequence identity in vertebrates or ciliates, but display a number 
of putative evolutionarily conserved functional domains, based on the predicted secondary 
structure derived from comparative phylogenetic analysis of 35 vertebrate TERCs (Chen et 
al. 2000). Evident in the vertebrate TERCs are 8 short regions of high sequence 
conservation (termed CR1-CR8), which are predicted to fold into 4 conserved functional 
domains via 10 conserved sets of distal, co-variable nucleotides putatively capable of base- 
pairing into helical structures designated P1-P6, P7a & P7b, P8a & P8b (Figure 1.6).
The known functions of the conserved regions and domains, shown in figure 1.6, are as 
follows: both the pseudoknot (CR2/CR3) and the CR4/CR5 domains are proposed to be 
essential for enzyme activity and hTERC/hTERT interaction based on mutational analysis 
using in vitro reconstitution systems (Autexier et al. 1996; Beattie et al. 1998; Tesmer et al.
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1999; Bachand et al. 2001; Bachand et al. 2001); the box H/ACA domain is involved in 
protein interactions other than with hTERT and RNA stability (Mitchell et al. 1999; 
Dragon et al. 2000; Vulliamy et al. 2001). The template sequence (CR1, spanning nt +46 
to +55) of hTERC, is predicted by phylogenetic analysis to lie in a single stranded 
structure accessible by the catalytic subunit and by anti-sense interference (Hamilton et al. 
1997; Pitts et al. 1998). The proposed location of the template sequence is conserved in all 
TERC molecules (Chen et al. 2000).
The hTERT gene, mapped by fluorescence in situ hybridisation to a locus on chromosome 
5pl5.33 (Bryce et al. 2000), comprises 16 exons of sizes varying from 62nt to 1352nt and 
15 introns. The coding region spans over 35kbp (Cong et al. 1999) and hTERT is subject 
to post-transcriptional regulation via alternative splicing (Kilian et al. 1997). The full- 
length transcript is predicted to be translated to the only functional protein and was 
simultaneously cloned by several groups (Kilian et al. 1997; Meyerson et al. 1997; 
Nakamura et al. 1997). TERT translates to a protein of 1132 amino acids and expected 
molecular weight of 127kDa. TERT genes contain motifs characteristic of reverse 
transcriptases, located on individual exons whose locations vary between humans and 
yeast (Harrington et al. 1997; Nakamura et al. 1997). Phylogenetic analysis of the catalytic 
domains of reverse transcriptases places TERT genes in a sub-group of their own among 
RT molecules (Nakamura et al. 1997).
In addition to the conserved RT motifs 1, 2, A, B’, C, D, and E, TERTs contain telomerase 
specific motifs N-terminal to the catalytic domain (T-motifs). Ciliate TERT molecules 
have additional TERT specific motifs CP and CP2. Since the action of hTERT is the 
hTERC-templated addition of the TTAGGG repeat to the telomere terminus, the minimal 
functional requirement is an interaction with the TERC component and the telomere, 
although a number of other proteins probably contribute to the complex. Indeed, the 
chaperone proteins hsp90 and p23 have recently been shown to interact directly with 
hTERT, mediating complex assembly in vitro, although they may remain associated in a 
stable complex after assembly (Forsythe et al. 2001).
Domains of interaction between hTERC and hTERT have recently been mapped using in 
vitro reconstitution experiments. The region spanning nucleotides 44-204 (subsequently 
shown to comprise the template and the entire pseudoknot domain) was identified as the 
minimal functional region necessary for reconstitution of telomerase activity with in vitro 
transcribed hTERC fragments following micrococcal nuclease treatment of telomerase
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positive cell extracts (Autexier et al. 1996). In this study, mutational analysis identified a 
30 nucleotide stretch between ntl70 and nt200 as essential for catalytic activity, although a 
later study demonstrated that certain mutations in this region could reconstitute weak 
TRAP activity and that the interaction with hTERT was unaffected by the modifications in 
immunoprecipitation (Bachand et al. 2001) and band shift experiments (Bachand et al. 
2001b). This region, interestingly, corresponds to the helix P3 which contributes to the 
formation of the pseudoknot domain. It has been reported that ntlO-159, also comprising a 
large part of the pseudoknot domain, are critical and sufficient for telomerase activity 
(Beattie et al. 1998), but a more recent study did not reconstitute activity from the region 
encompassing ntl-159, although hTERC truncated to ntl59 co-immunoprecipitated with 
hTERT confirming the importance of this region in TERC/TERT interaction (Bachand et 
al. 2001).
Recently, it has been proposed that hTERC contains 2 sites of interaction with hTERT 
(Tesmer et al. 1999; Bachand et al. 2001; Bachand et al. 2001). The region encompassing 
nt33-325 contains 2 inactive fragments (nt33-147, containing the template and a large 
portion of the pseudoknot domain, and ntl 64-325, containing a portion of the pseudoknot 
domain and the CR4/CR5 domain) that assemble with hTERT to form an activated 
complex (Tesmer et al. 1999). These data were recently confirmed by Bachand and 
Autexier, (2001), who mapped the independent hTERT binding sites to nt33-147 and 164- 
330.
Functional regions of TERT important for the TERC/TERT interaction and for enzyme 
activity have been mapped by mutational and deletional analysis using rabbit reticulocyte 
lysate reconstitution systems combined with co-immunoprecipitation analysis of human 
and yeast TERTs. Progressive truncation of the N- and C-terminals of Tetrahymena TERT 
resulted in peptides incapable of reconstituting telomerase activity, but defined a minimal 
RNA binding domain between amino acids 195 and 516 containing the ciliate TERT 
specific motifs CPI and CP2 in addition to the T-motif. Additionally, C-terminal 
truncations of hTERT did not affect RNA binding unless the T-motif was disrupted (Lai et 
al. 2001). Further evidence to support the role of these motifs in TERT/TERC association 
comes from the observation that tetrahymena TERT molecules harbouring mutated 
residues within the CPI and T-motifs, but not the reverse transcriptase motifs, greatly 
reduced co-immunoprecipitation of TERC (Bryan et al. 2000).
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While the minimal functional requirement for active telomerase in reconstitution systems 
seems only to be hTERC and hTERT, it is clear that a number of other factors associate 
with the complex in vivo to regulate telomerase activity. Other components of the 
telomerase complex include hTEPl (telomerase protein component 1), identified on the 
basis of its homology with the non-catalytic yeast telomerase sub-unit, p80 (Harrington et 
al. 1997). It has been postulated that hTEPl may perform a regulatory role within the 
telomerase complex, but its function is not known at this time and its expression pattern 
does not correlate with telomerase activity in cell lines or tissues (Harrington et al. 1997; 
Wu et al. 1999), although hTEPl co-purifies with active telomerase in vitro, interacts with 
p53 (Li et al. 1999), and is phosphorylated by PKCa in human breast carcinoma cells (Li 
et al. 1998).
Several recent reports have begun to examine more closely other components of the 
telomerase complex. Small nucleolar RNAs (snoRNAs) are a class of molecules involved 
in pre-rRNA processing and modification. They are divided into 2 groups based on the 
presence either of the box H/ACA motifs or of the box C/D motifs within the RNA which 
mediate protein interaction and assembly of small nucleolar ribonucleoproteins (snoRNPs). 
The telomerase RNA subunit contains boxes H and ACA in its 3’ end (Mitchell et al. 
1999). In vitro assembly of fragments of hTERC revealed binding to the H/ACA specific 
protein hGARl (Dragon et al. 2000). Additionally, dyskerin, a snoRNA interacting protein 
that is mutated in the X-linked form of dyskeratosis congenita and is thought to mediate 
the processing of rRNA, associates with hTERC and with other snoRNPs that possess a 
box H/ACA motif. Mutations in the dyskerin gene in X-linked dyskeratosis can reduce 
cellular levels of hTERC and telomerase activity (Mitchell et al. 1999).
Additional factors, identified by yeast 2-hybrid screening for proteins which interact with 
hTERT, are the molecular chaperone proteins hsp90 and p23. A recent study (Holt et al. 
1999) illustrated that antibodies directed against p23 and hsp90, but not hsp70, could 
immuno-precipitate hTERT and deplete telomerase activity from a rabbit reticulocyte 
lysate reconstitution system. Additionally, incubation of telomerase positive fibrosarcoma 
cells with the hsp90 inhibitor geldanamycin could prevent telomerase activation on re­
entry to the cell cycle from a quiescent state, suggesting that hsp90 is involved in assembly 
of active telomerase complex. Further evidence came from the lack of telomerase activity 
in mortal cell strains infected with hTERT expressing retrovirus in the presence of the 
inhibitor. Although it has been postulated that these components are involved mainly in 
assembly of the telomerase complex, some components of the hsp90 foldasome may
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remain stably associated with the complex and may have roles in telomerase processivity 
(Holt et al. 1999; Forsythe et al. 2001).
These studies have contributed to the development of new concepts of telomerase activity 
regulation which, rather than simply being either on or off is likely to be regulated and 
modulated on multiple levels. A number of the known regulatory pathways that govern the 
expression of telomerase activity are discussed in the following sections.
1.3 Regulation of telomerase activity
1.3.1 Expression of telomerase activity in cancer and normal 
tissues
The advent of the TRAP assay, a highly sensitive RT-PCR assay for telomerase activity 
(Kim et al. 1994) has facilitated the analysis of telomerase activity across large numbers of 
clinical samples of normal and cancerous tissues. Telomerase activity and expression of 
telomerase subunits can be detected in foetal tissue from as early as the blastocyst stage 
during embryogenesis, but are downregulated during embryonic development (Wright et 
al. 1996; Yashima et al. 1998) and are not readily detectable in the majority of normal 
human adult somatic tissues (Kim et al. 1994; Wright et al. 1996). By contrast, the vast 
majority of human tumours express high levels of activity and telomerase is therefore 
considered to be a valid therapeutic target. It should be noted, however, that a number of 
studies indicate that low level telomerase activity exists, and in some cases is regulated, in 
some normal renewal tissues including intestinal crypts (Hiyama et al. 1996), lymphocytes 
(Bodnar et al. 1996), haematopoietic progenitors (Chiu et al. 1996), keratinocytes of the 
epidermal basal layer (Harle-Bachor et al. 1996), endothelial cells (Hsiao et al. 1997) and 
germ line cells (Kim et al. 1994; Wright et al. 1996).
Detection of telomerase activity in normal human tissues was first documented in germ 
cells (Kim et al. 1994; Wright et al. 1996). Shortly after this, several groups examined the 
patterns of expression of telomerase activity in cells of the blood including bone marrow 
haematopoietic progenitors, un-induced and activated T-cells and leukocytes. In a 
comparative analysis of telomerase activity in bone marrow and peripheral blood 
leukocytes from normal donors with activity in leukaemia samples, significant overlap 
between activities in normal and malignant samples was documented. In addition, low but 
significant levels of activity were detected in cellular fractions enriched for granulocytes,
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T-cells, and monocytes and B-cells (Broccoli et al. 1995). Additionally, another study 
documented regulation of telomerase activity during the maturation of haematopoietic 
progenitor cells (Chiu et al. 1996). Cell fractions enriched on the basis of maturation 
associated cell surface markers were analysed for telomerase activity and showed 
comparatively high level expression in early CD71+ progenitors, but not in the most 
primitive (CD34+, CD7110) or more mature (CD34) populations. Stimulation with 
cytokines led to a small and transient increase in telomerase activity in the most primitive 
cells, and a rapid decrease in the early population, suggesting a role associated with 
maturation. Regulation of telomerase activity in the haematopoietic system has been 
reported by other groups: Bodnar and colleagues (Bodnar et al. 1996) described transient 
up-regulation of telomerase activity and hTERC expression with T-cell activation. This 
activation was not dependent on DNA replication or early trans-membrane signalling 
events and therefore it has been proposed that this represents a mechanism for transient 
stabilisation of telomere length to increase the lifespan of T-cells during clonal expansion.
Telomerase activity was detected in normal skin samples in a comparative study of 
telomerase activity in skin squamous cell carcinoma derived cell lines, in vitro 
immortalised cell lines and normal human keratinocytes. Enzyme activity was found to be 
located exclusively in the proliferative basal layer of epidermal tissue by enzyme mediated 
tissue fractionation (Harle-Bachor et al. 1996). A later study showed telomerase activity 
associated with various non-malignant skin conditions including sun exposure, psoriasis, 
and contact dermatitis induced by poison ivy, although TRAP activities of non-malignant 
tissue samples showed considerably lower telomerase activity than basal cell carcinoma, 
squamous cell carcinoma and melanoma samples (Taylor et al. 1996). This study also 
found telomerase enzyme activity in the epidermal layer of new-born foreskin, providing 
confirmation of the earlier report. It has been suggested that telomerase activity may be a 
marker of stem cell populations that have indefinite replicative capacity. In a more recent 
study, however, (Bickenbach et al. 1998) investigators used a double enrichment protocol 
consisting of a nuclear-label retention assay that measures indirectly the proliferation rate 
of sub-populations of primary cells and a collagen IV binding protocol, for enrichment of 
stem-cell populations. In this study, the more rapidly proliferating fraction was identified 
as that which had highest level telomerase activity, in-keeping with other reports which 
suggest that telomerase activity is not concentrated in the most primitive stem cells, but 
rather in cells that are more mitotically active, such as the bulb region of human hair 
follicles (Ramirez et al. 1997) and early haematopoietic progenitors (Chiu et al. 1996).
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Interestingly, recent studies have identified the molecular defects in two forms of the 
hereditary disease dyskeratosis congenita, characterised by premature ageing of rapidly 
proliferating tissues such as hair follicles, skin and blood cells. Sufferers generally exhibit 
defects in wound healing and often die between the ages of 16-50 as the result of bone 
marrow or pulmonary failure. Dyskeratosis is linked either to X-chromosome mutation or 
autosomal mutations. In the case of X-linked dyskeratosis, the mutant X-locus encodes the 
nucleolar protein dyskerin (DKC1), a homologue of the Saccharomyces cerevisiae box 
H/ACA binding protein Cbf5p. It has been demonstrated by immuno-precipitation 
experiments that dyskerin interacts directly with hTERC, presumably through the H/ACA 
motifs and this may influence the stability of hTERC. Indeed, it was previously shown that 
both transcriptional and post-transcriptional mechanisms regulate cellular levels of hTERC 
(Yi et al. 1999), although this study did not address the nature of the post-transcriptional 
regulatory mechanisms. Cells expressing mutant dyskerin have reduced levels of 
telomerase RNA, shortened telomeres, and telomerase activity is not reconstituted by 
expression of hTERT (Mitchell et al. 1999). Interestingly, in a later study of several cases 
of autosomal dyskeratosis, an 821bp deletion was identified on chromosome 3q. In fact, 
further analysis revealed that the terminal 74 bases of hTERC, corresponding to the 
H/ACA domain, were deleted in each case (Vulliamy et al. 2001). It seems, therefore, that 
dyskeratosis is intrinsically linked to malfunctions in telomerase activity and possibly 
telomerase complex assembly. Moreover, symptoms are consistent with premature ageing 
of telomerase positive renewal tissues. This suggests that telomerase activity is necessary 
to provide the cells of a variety of normal tissues with sufficient replicative capacity to last 
the normal human lifespan, but more investigations are necessary to confirm this.
The function of telomerase activity in normal tissues is not clear at this time. The level of 
expression of telomerase activity appears to be insufficient to prevent telomere attrition in 
human lymphocytes (Rufer et al. 1998) and activated T-cells (Bodnar et al. 1996), yet low- 
level activity in normal keratinocytes maintains telomere length (Kang et al. 1998). One 
possibility is that detectable activity arises from low-level activity in many cells within a 
tissue. Alternatively, it may be that rare sub-populations of cells with high levels of 
activated telomerase and stable telomeres are present, but have not been identified due to 
the requirement for cell lysis in the TRAP assay and limitations in the protocols for 
telomere length detection. It has been acknowledged that infiltrating inflammatory cells or 
occult tumour cells in adjacent tissues may confound TRAP results in real tissue samples 
(Hiyama et al. 1995) and for this reason, in situ systems for the detection of telomerase 
subunits that preserve the tissue architecture may be preferable (Soder et al. 1998;
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Yashima et al. 1998; Hiyama et al. 2001). However, the observation that telomerase 
activity is reduced in dyskeratosis patients with a concurrent failure of renewal tissue 
function provides some clues as to the result of malfunctioning telomerase in normal 
tissues.
While telomerase activity is undoubtedly present at low levels in a variety of normal 
human tissues, it is also clear that telomerase activity is up-regulated in the vast majority of 
human tumours and that the specific association of telomerase activity with human cancers 
represents a valid therapeutic target. In the first study utilising the TRAP assay, 90 of 101 
clinical samples from tumours including colon cancer, head and neck squamous cell 
carcinomas, node positive breast cancer, prostate cancers, brain tumours, small cell lung 
cancers, and leukaemias were found to be associated with detectable TRAP activity, but 
most normal somatic tissues, with the exception of germ line tissues were not (Kim et al. 
1994). Similarly, high-level telomerase activity has been detected in every one of the most 
common malignancies, with telomerase activity detectable in an average of approximately 
85% of all samples (reviewed in Shay et al. 1997, Holt & Shay 1999). Notably, various 
studies have addressed the relative telomerase activities between paired normal and 
cancerous tissues in the hope that telomerase positivity may provide a useful general 
marker of malignancy. From this point of view, the childhood disease neuroblastoma 
represents an interesting case: high telomerase activity is significantly correlated with 
amplification of the MYCN locus, considered to be an indicator of a poor prognosis, while 
factors associated with a good prognosis, such as Ha-ras p21 correlate well with low 
activity. Additionally, telomerase activity was low or undetectable in stage IVs tumours, 
which often spontaneously regress. Thus, in the case of infant neuroblastoma, telomerase 
activity may predict clinical outcome (Hiyama et al. 1997).
Table 1.2 gives a brief summary of data derived from telomerase activity studies across a 
range of tumour types. Although the list is not exhaustive, its purpose is to demonstrate a 
trend that telomerase activity is associated with a broad range of malignancies. The 
examples that follow merely serve to illustrate the prevalence of expression of telomerase 
activity in human cancers. A study of malignant and non-malignant skin conditions 
identified weak telomerase activity in 44% of normal samples, but stronger activity in 83% 
of squamous cell carcinomas, 95% of basal cell carcinomas and 86% of melanoma samples 
(Taylor et al. 1996). In another study, telomerase activity was not detected in samples of 
normal liver, but across all histologies 85% of hepatocellular carcinoma samples were 
telomerase positive (Tahara et al. 1995). Detection of telomerase activity in small cell and
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non-small cell lung cancers revealed high level TRAP positivity in 100% of samples from 
primary small cell lung cancers and their metastases, 69.2%-88.5% positivity, varying with 
histology, in primary non small cell samples and 50% positivity in metastases derived from 
non small cell lesions (Hiyama et al. 1995). A survey of neoplastic gastric lesions 
documented telomerase activity in 85% of primary gastric carcinomas and 95% of 
colorectal adenocarcinomas, but not in adjacent tissue samples (Tahara et al. 1995).
While differences in the range of positive samples within some tumour types means that 
more work is needed to evaluate telomerase as a potential general tumour marker before 
absolute conclusions regarding its usefulness for early detection can be drawn, it is clear 
that telomerase activity associates specifically with cancer, that a therapeutic differential 
exists between telomerase activity in normal and malignant tissues, and that telomerase 
represents an extremely attractive target for the development of novel therapies. Indeed, 
telomerase activity can potentially be targeted at a number of levels corresponding to 
levels of regulation. Telomerase regulation and opportunities for therapeutic exploitation 
are discussed below.
1.3.2 Regulation occurs on multiple levels
The current picture of telomerase regulation is complex: enzyme activity is likely to be 
controlled on many levels with multiple pathways converging to modulate the functional 
activity of the holoenzyme. A number of regulatory pathways have already been 
implicated in the normal and aberrant activity of telomerase in human cells. This section 
outlines briefly the major mechanisms involved that will be discussed in more detail 
below, with reference to relevant therapeutic targeting opportunities emerging from our 
current understanding.
Extensive evidence from expression studies suggests that both hTERC and hTERT are 
regulated on a transcriptional level and that this regulation, particularly of hTERT, is a 
major deterministic factor governing the activation of telomerase activity in normal and 
cancer cells. The cloning of the promoter regions for both the hTERC (Zhao et al. 1998) 
and hTERT (Cong et al. 1999; Takakura et al. 1999; Wick et al. 1999) has enabled the 
identification of a number of positive and negative regulators of telomerase transcriptional 
activity. These will be discussed in more detail below.
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Other work has demonstrated that post-transcriptional mechanisms play a role in 
regulating telomerase activity. Kilian et al (Kilian et al. 1997) identified a number of splice 
variants of the hTERT transcript, which are expected to be inactive due to truncations or 
mutations in domains essential for catalytic activity. Interestingly, the hTERTa variant 
contains a deletion in the conserved reverse transcriptase motif A and has been 
characterised as a dominant negative inhibitor of hTERT activity (Colgin et al. 2000; Yi et 
al. 2000). Several studies (Ulaner et al. 1998; Ulaner et al. 2000) have begun to examine 
more precisely the roles of alternative splicing in the regulation of telomerase activity in 
various tissues.
Telomerase activity can be reconstituted in vitro from its 2 essential subunits, hTERC and 
hTERT (Autexier et al. 1996; Weinrich et al. 1997; Beattie et al. 1998; Bachand et al. 
2001; Bachand et al. 2001b), although the enzyme exists in its active form at the telomere 
as a highly ordered multi-subunit complex. Some of the proteins that may interact with the 
telomere or telomerase complexes have intrinsic regulatory functions, such as the PARP 
domains of the TRF1 interacting proteins Tankyrase and TANK2 (Smith et al. 1998; Smith 
et al. 2000; Kaminker et al. 2001). PARP activity is a major mechanism for post- 
translational regulation of the function of nuclear proteins involved in a variety of cellular 
functions such as DNA damage response. The structure of the holoenzyme, therefore, 
represents another level on which telomerase activity is likely to be regulated, and it is 
now clear that other post-translational signalling events acting directly on hTERT or on 
other proteins involved in the complex play a role in regulation of telomerase activity. 
Phosphorylation status of hTERT and hTEPl is involved in modulation of the catalytic 
activity of telomerase: protein phosphatase 2A (Li et al. 1997) and the c-Abl tyrosine 
kinase (Kharbanda et al. 2000) can both act as negative regulators of telomerase function, 
while PKC (Li et al. 1998; Yu et al. 2001) and Akt protein kinase (Kang et al. 1999) can 
act to up-regulate activity.
1.3.3 Transcriptional regulation of hTERC and hTERT expression
1.3.3.1 hTERC transcriptional regulation
hTERC up-regulation has been detected in several major types of human malignancy 
including tumours derived from colorectal cancer (Avilion et al. 1996; Yan et al. 2001), 
cervix (Soder et al. 1998), lung (Avilion et al. 1996), neuroblastoma (Reynolds et al.
1997), ovary (Park et al. 1999), and oesophagus (Hiyama et al. 1999). Feng and colleagues
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(Feng et al. 1995) demonstrated up-regulation of the hTERC signal by RT-PCR in tumour 
cell lines derived from melanoma, leukaemia, lung, colon, and breast cancers, relative to 5 
primary mortal cell strains. Additionally, a study of over 300 tissue samples from normal 
and tumour tissues detected hTERC signals in 43% of squamous cell carcinomas of the 
lung (Soder et al. 1998). In situ hybridisation systems for detection of hTERC (Soder et al. 
1998; Park et al. 1999) clearly reveal hTERC signals concentrated mainly in tumour cells 
within tissues but not in adjacent normal tissue, although Hiyama and colleagues reported 
expression of hTERC in the basal cells of normal oesophageal mucosa and in infiltrating 
lymphocytes (Hiyama et al. 1999).
Indeed, low level hTERC RNA was also detected by Northern blotting in normal ovarian, 
testis, kidney, prostate and liver tissues (Feng et al. 1995), and up-regulation of expression 
of the hTERC component of telomerase has been detected in normal T-lymphocytes during 
activation (Bodnar et al. 1996). Thus, hTERC is expressed in sub-sets of normal tissues at 
lower levels than in malignant cells, suggesting an underlying mechanism for 
transcriptional up-regulation of hTERC during tumorigenesis. Studies of the mechanisms 
underlying hTERC promoter regulation should provide valuable information to enhance 
our understanding of telomerase regulation in normal and aberrant cells.
The cloning of the hTERC promoter region (Zhao et al. 1998) has facilitated the 
identification of a number of regulatory factors. The core promoter is represented in a 
region 272bp upstream of the transcriptional start site, containing elements typical of a pol 
II promoter (CCAAT box, TATA box) (Figure 1.7 (b)) that are highly conserved among 
the proximal promoters of 35 vertebrates (Chen et al. 2000) (supplemental data published 
on e-joumal). The core promoter sequence contains 4 functional sites for up-regulation of 
activity by SP1 and down-regulation by SP3 as determined by binding studies and 
mutational analysis, in addition to transfection experiments (Zhao et al. 2000). The hTERC 
CCAAT box is bound by the trimeric transcription factor NF-y, and binding to this site is 
essential for basal promoter activity, as mutation of the site, or transfection of dominant 
negative analogues of NF-y abrogated basal activity in reporter assays. Transcriptional 
activity can also be modulated by an activity of pRB, the retinoblastoma gene product, by 
a mechanism that is unclear. Other potential sites for modulation of promoter activity 
include putative sites for E2F binding, GATA-1, C/EBP and c-Ets-2. The hTERC gene is 
contained within a 733bp CpG island (66% GC content) that extends into the promoter 
region. Various degrees of methylation of this sequence have been observed in some cell 
lines and tissues, interestingly, while mortal cell strains and normal somatic tissues showed
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no methylation, three immortal cell lines that have a telomerase independent mechanism 
for telomere lengthening (ALT cells) and do not express hTERC showed hyper- 
methylation of the sequence, suggesting that transcriptional silencing by hTERC promoter 
methylation may play a role in selection of the ALT phenotype (Hoare et al. 2001).
1.3.3.2 hTERT transcriptional regulation
Detection of hTERT expression has commonly been achieved with the use of RT-PCR, but 
immunohistochemical detection was recently reported (Hiyama et al. 2001). Using these 
systems, high level hTERT expression has been detected in the majority of major types of 
human malignancy, including renal cell carcinoma (Paradis et al. 2001), oral dysplasias 
and cancers (Kim et al. 2001), squamous cell lung carcinoma (Shibuya et al. 2001), small 
cell lung cancers (Hiyama et al. 2001), colorectal cancers (Hiyama et al. 2001), pancreatic 
cancers (Hiyama et al. 2001) and hepatocellular carcinoma (Hiyama et al. 2001). However, 
several studies have also revealed weak expression in subsets of cells in a variety of 
normal tissues including breast, colon, lung, ovary, prostate, small intestine, spleen, 
stomach, testis, and uterus (Kolquist et al. 1998; Ramakrishnan et al. 1998; Hiyama et al. 
2001) and in normal cell strains derived from breast colon, ovary, pancreas and prostate 
(Ramakrishnan et al. 1998). It is clear, then, that hTERT expression is not exclusively 
restricted to tumour cells and tissues, however strong relative differences exist in the 
expression of hTERT mRNA between normal and cancer samples and it is therefore of 
interest to understand the mechanisms that underlie TERT transcriptional regulation.
The simultaneous cloning of the hTERT promoter region by several groups (Cong et al. 
1999; Takakura et al. 1999; Wick et al. 1999) has facilitated a number of studies into its 
transcriptional regulation. The transcriptional start site has variously been mapped to a 
region approximately 60-112bp upstream of the translational start signal. Figure 1.7 (a) 
gives a schematic representation of the major transcription factor binding sites known to be 
involved in the transcriptional regulation of hTERT. The hTERT promoter is a TATA-less 
sequence, containing 2 functional sites for c-Myc/Max or Mad/Max binding (E-boxes), in 
addition to 5 sites for modulation by SP1 within the proximal promoter. Upstream 
sequences include 4 binding sites recognised by Myeloid Specific Zinc Finger 2 (MZF2), 
an imperfect palindromic Estrogen Response Element involved in activation by ligand 
bound Estrogen Receptor (Kyo et al. 1999; Misiti et al. 2000) with an additional Estrogen 
Receptor half site adjacent to an SP1 binding motif and a site recognised by the Wilms 
Tumour suppressor protein, WT1. The proximal promoter region lies within a CpG island
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that extends into exon2. Another small CpG island is located several hundred bp upstream 
(Wick et al. 1999). Investigations of the possible role of methylation in repression of 
hTERT did not correlate methylation status with hTERT expression, suggesting that 
methylation is not a general mechanism for hTERT promoter repression in telomerase 
negative cells, although treatment of an ALT cell line with the demethylating agent 5-azaC 
could induce hTERT transcription (Devereux et al. 1999; Dessain et al. 2000).
In contrast, hormone mediated modulation of hTERT transcription is likely to represent an 
important mechanism for regulation of telomerase activity in hormone responsive tissues, 
and a number of hormones have been implicated in hTERT regulation. Estrogen up- 
regulates hTERT transcription and telomerase activity, both by direct Estrogen receptor 
binding to an Estrogen Response Element in the hTERT promoter (Kyo et al. 1999; Misiti 
et al. 2000) and by induction of c-Myc mediated activation of transcription (Kyo et al.
1999). Other hormones that can affect hTERT transcription include retinoids that act to 
down-regulate telomerase activity and hTERT transcription via a pathway dependent on 
signalling via the Retinoic Acid Receptor (Pendino et al. 2001).
Various oncoproteins appear to regulate the expression of hTERT. Over-expression of the 
Human Papillomavirus type 16 E6 oncogene in early passage human keratinocytes and 
mammary epithelial cells results in induction of telomerase activity independently of the 
p53 degradation pathway (Klingelhutz et al. 1996). In a recent study, it was demonstrated 
that up-regulation telomerase activity by over-expression of E6 is due to activation of the 
hTERT promoter and that this activation required the presence of the proximal SP1 and c- 
Myc binding sites localised within the first 300bp of the promoter region (Oh et al. 2001). 
Over-expression of c-Myc in primary human mammary epithelial cells and diploid 
fibroblasts up-regulated hTERT mRNA and telomerase activity (Wang et al. 1998). 
Consistent with a view of the Myc/Max heterodimer as a critical regulator of the hTERT 
promoter is the observation that over-expression of c-Myc up-regulates telomerase activity 
and hTERT expression in EBV transformed B-cells (Wu et al. 1999) and that this was 
dependent on the presence of E-boxes in the promoter, although another study concluded 
that the activating effects of c-Myc are context specific and are disabled in some immortal 
cell lines (Drissi et al. 2001). Additionally, the identification of the c-Myc antagonist Mad 
as a repressor of hTERT transcription both by over-expression (Oh et al. 2000) and during 
differentiation of a leukaemia cell line (Xu et al. 2001) suggests that the balance of 
interactions of these factors with the promoter are probably important for hTERT promoter 
regulation. It is clear: that c-Myc is an important regulator of hTERT transcription,
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although maximal promoter activity appears to require the co-operation of c-Myc and SP1 
(Kyo et al. 2000; Oh et al. 2001).
In addition to the identification of transactivators of hTERT transcription, an 
understanding of negative regulators binding at the hTERT promoter is likely to be critical 
to the understanding of TERT regulation during normal development. Negative regulatory 
factors influencing hTERT transcription include p53, which down-regulates hTERT 
mRNA independently of p53 consensus binding motifs in the hTERT promoter, instead 
eliciting its effects through inhibition of SP1 binding (Kanaya et al. 2000; Xu et al. 2000). 
MZF2 specifically binds consensus sequences within the hTERT promoter to down- 
regulate activity (Fujimoto et al. 2000) and the Wilms Tumour suppressor WT1 is also a 
negative regulator of hTERT promoter constructs (Oh et al. 1999). It was recently reported 
that E2F-1 represses hTERT promoter activity and mRNA expression (Crowe et al. 2001).
1.3.4 Post-transcriptional regulation of hTERT
The hTERT gene contains 16 exons, 15 introns and multiple sites for alternative splicing 
(Kilian et al. 1997; Wick et al. 1999). The differential expression of splice variants has 
been detected by RT-PCR in normal and immortal cell lines and tissues. All the splice 
variants other than the full-length transcript are inactive due to insertions, deletions, or 
truncations within the reverse transcriptase motifs (Kilian et al. 1997; Wick et al. 1999) but 
the most well characterised variants a, P, and a+p are expected to complex with hTERC 
since the N-terminal domains regarded as important for hTERT/hTERC interaction are 
unaffected by the mutations. In-keeping with this, expression of the full-length transcript 
correlates with telomerase activity (Yi et al. 2001), while the hTERTa variant is a 
dominant negative inhibitor of telomerase activity (Colgin et al. 2000; Yi et al. 2000). This 
suggests a role for splice variation in post-transcriptional regulation of hTERT expression 
and, therefore, telomerase activity. Studies are ongoing to assess the importance of hTERT 
alternative splicing in the regulation of telomerase activity. Expression of the full-length 
transcript correlates with telomerase activity and with maintenance of telomere length 
during development of foetal heart, kidney, and liver (Ulaner et al. 1998; Ulaner et al. 
2001), and with telomerase activity in uterine neoplasias (Ulaner et al. 2000).
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1.3.5 Post-translational regulation
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Post-translational regulation of hTERT and other components of the telomerase 
holoenzyme undoubtedly affect telomerase activity in cells. A recent study indicated that 
components of the hsp90 foldasome could interact with telomerase components in vitro 
and in vivo to mediate assembly of an active complex (Holt et al. 1999). Interestingly, 
components of the hsp90 chaperone complex are often up-regulated in cancers. In a model 
of prostate cancer progression, it was shown that hsp90, p23, hsp70 and hsp27 were all up- 
regulated in malignant cells relative to parental cells and that the expression of these 
factors correlated with increased telomerase activity in the absence of up-regulation of 
hTERC or hTERT mRNA. Moreover, addition of these foldasome components to extracts 
of parental prostate cells in an in vitro reconstitution system increased telomerase activity, 
suggesting a novel mechanism for up-regulation of telomerase activity whereby increased 
levels of chaperones could increase the amount of properly folded telomerase complex to 
up-regulate activity during cancer progression (Akalin et al. 2001).
While hsp90 and p23 have been shown to be essential for de novo generation of functional 
telomerase complexes, they are not thought to modulate activity after folding, although 
they may remain associated with the complex and play a role in complex stability 
(Forsythe et al. 2001). In fact, a number of proteins may associate with telomerase in vivo, 
including the telomerase associated protein hTEPl. The function of hTEPl is not known at 
this time, however p53 co-immunoprecipitates with hTEPl and down-regulates telomerase 
activity (Li et al. 1999). In this study, p53 mediated regulation was inhibited by moderate 
concentrations of an hTEPl derived peptide, providing evidence that the effect was 
genuinely derived from a post-translational mechanism involving modulation of 
telomerase activity via modification of hTEPl.
It has become increasingly clear in recent years that the phosphorylation state of hTERT 
and other components of telomerase is a major factor that influences telomerase function. 
Regulation of telomerase activity by phosphorylation is mediated by the action of a variety 
of protein kinases. Up-regulation of enzyme activity has been reported through 
phosphorylation by Akt tyrosine kinase (Kang et al. 1999) and by Protein Kinase C 
isoforms a  and £, in breast (Li et al. 1998) and nasopharyngeal cancer cells (Yu et al. 2001) 
respectively, while Protein phosphatase 2A (Li et al. 1997) and the c-Abl tyrosine kinase 
(Kharbanda et al. 2000), a major player in DNA damage response, have been reported to 
down-regulate the activity of telomerase in cell lines.
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Although the signalling pathways that lead to activation or repression of telomerase 
activity by post-translation modification are not well defined at this time, it is increasingly 
clear that these events are important for enzyme activity. Future studies will enhance our 
understanding of the multiple complex pathways that converge to modulate the activity of 
telomerase and may provide novel targets for therapeutic intervention.
1.4 Telomerase therapeutics
1.4.1 Anti-telomerase therapeutics
The unique biology and function of telomerase and the complexity of its regulation afford 
a number of potential targeting opportunities directed at various levels of biological 
regulation. Many of the therapeutic strategies proposed to target telomerase in cancer have 
been tested extensively in vitro, and within available in vivo models, and it seems certain 
that a number of telomerase therapeutics will find their way into clinical trials before long. 
The sections below discuss a number of the possible targets.
1.4.1.1 Targeting transcriptional regulation of hTERC and hTERT 
expression
The ability to interfere with transcription of genes involved in cancer has been seen as an 
attractive approach for the development of novel therapies and, therefore, it is of 
paramount importance to understand the underlying mechanisms governing hTERC and 
hTERT transcription. As described above, transcriptional regulation is the major 
mechanism governing hTERC expression, although post-transcriptional mechanisms may 
play a role in stability of the RNA (Yi et al. 1999). The hTERC promoter can be positively 
regulated by binding of the zinc finger transcription factor SP1 at several sites in the 
proximal promoter, while SP3 down-regulates promoter activity in reporter assays (Zhao et 
al. 2000). The retinoblastoma gene product, pRb, also up-regulates promoter activity by a 
mechanism that is not clear. A critical finding of this study was the central importance of 
the CCAAT box binding factor, NF-y, as a basal transcriptional activator: transfection of 
dominant negative mutants of NF-y A (Mantovani et al. 1994) abrogates basal activity of 
hTERC proximal promoter constructs in a bladder carcinoma cell line (Zhao et al. 2000), 
suggesting a possible strategy for development of transcriptional inhibitors directed against 
the specific activity of NF-y at the hTERC CCAAT box.
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Studies of mechanisms governing hTERT transcription have similarly revealed a number 
of positive and negative regulatory factors. The c-Myc oncoprotein has been found in 
several studies (Wang et al. 1998; Greenberg et al. 1999; Wu et al. 1999) to be a positive 
regulator of TERT transcription. The Myc-Max/Mad-Max network of transcription factors 
are intrinsically involved in the control of cell proliferation, cell cycle progression and 
apoptosis and this signalling network is often deregulated in cancer (reviewed Zhou et al. 
2001). Myc and Mad heterodimerise with Max to form the My c/Max or Mad/Max 
transcriptional regulators that recognise the same DNA sequence and antagonise each 
other’s effects. Induced cellular differentiation of a human leukaemia cell line has been 
found to be associated with a switch from Myc/Max to Mad/Max binding at the TERT 
promoter (Xu et al. 2001) and other studies have also identified Mad as a repressor of 
hTERT transcriptional activity (Oh et al. 2000).
The tumour suppressor protein p53 (Kanaya et al. 2000; Xu et al. 2000) and the cell cycle 
regulator E2F-1 (Crowe et al. 2001) act to negatively regulate TERT transcription; in one 
recent study (Kanaya et al. 2000) introduction of wild type p53 into a cervical carcinoma 
cell line by means of a recombinant adenovirus was shown to down-regulate telomerase 
activity, highlighting one possible therapeutic approach of studies of transcriptional 
regulation. In this study, no obvious growth inhibition or apoptosis as a direct result of the 
classical tumour suppressor effects of p53 was observed, but the investigators did not 
analyse the growth inhibitory effects of chronic suppression of telomerase activity under 
long term culture conditions.
While targeting the transcriptional regulation of hTERC and hTERT at the level of the 
promoter, either by targeted expression or transduction of relevant regulatory molecules or 
by screening for promoter interactive drugs may be a feasible strategy, a more attractive 
approach may be the modulation of upstream signalling events leading to transcriptional 
activation. For instance, it is now clear that regulation of telomerase activity can be 
mediated by differential actions of a variety of hormones. While estrogen and androgens 
are thought to up-regulate telomerase activity, retinoids have been reported to down- 
regulate this activity and induce differentiation of leukaemia cells.
The effects of retinoids can be mediated by signalling through 2 related classes of receptor, 
retinoic acid receptors (RAR) or retinoic X receptors (RXR), in a pathway involving 
cAMP. A panel of promyelocytic leukaemia cell lines expressing variants of the RAR-a 
subunit was used in a study into the effects of retinoids on cellular differentiation and
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telomerase activity (Pendino et al. 2001). The parental cell line differentiates in the 
presence of retinoids, while 2 sub-lines do not. One of the sub-lines, however, is competent 
to undergo maturation via RXR signalling in the presence of cAMP elevating agents. 
Using these cells, Pendino et al were able to dissect the various retinoid signalling 
pathways and to demonstrate down-regulation of hTERT mRNA and telomerase activity 
by RAR dependent signalling in a pathway distinct from differentiation, suggesting that 
retinoids may be therapeutically useful against maturation resistant cells.
Misiti et al (Misiti et al. 2000) identified binding of Estrogen Receptor-a (ER-a) at a 
degenerate sequence for the Estrogen Response Element (ERE) in the hTERT promoter. 
Further analysis demonstrated that ER-a could activate de novo hTERT transcription in 
the presence of estrogen and thereby up-regulate telomerase activity in telomerase negative 
cells derived from oestrogen responsive tissues. Tamoxifen competes with estrogen 
binding at the ER-a and is the chemotherapeutic drug of choice for the treatment of ER-a 
positive breast carcinoma. It has been shown that tamoxifen can down-regulate telomerase 
activity and viability of a human breast carcinoma cell line (Aldous et al. 1999); it may be, 
therefore, that targeting upstream signal pathways leading to promoter activation, such as 
hormone signalling paths, will prove an attractive approach for the treatment of specific 
disease types.
Another therapeutic possibility that has attracted considerable interest recently is the 
development of transcriptionally directed cytotoxic gene therapy using the telomerase 
promoter sequences to drive expression of a therapeutic transgene. A number of tumour 
associated promoter activities such as the prostate specific antigen promoter (PSA) or 
carcinoembryonic antigen promoters (CEA), and regulatable promoters, such as promoters 
based upon the bacterial tet operon (Gossen et al. 1992) have been described and evaluated 
for use in this kind of therapeutic approach, but the specificity and prevalence of hTERC 
and hTERT promoter activity in cancer cells suggests that these sequences may be 
especially well suited to this kind of approach. A number of the systems that have recently 
been proposed are outlined and discussed in a later section.
1.4.1.2 Targeting hTERC and hTERT RNA
The hTERC component of telomerase is an interesting target for a number of anti-sense 
approaches based either on blocking the function of the template region by base pairing or 
by actively targeting the molecule for degradation using (5’-phosphorylated 2’-5’-linked
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oligoadenylate)-linked oligonucleotides (2,5-A oligonucleotides) or hammerhead 
ribozymes. One problem with using RNA molecules as therapeutic agents is their 
instability when administered as drugs. For this reason, ideal anti-sense agents are either 
administered encoded within an expression construct such as a plasmid vector or a virus, 
or as chemically stabilised analogues of the active RNA. A number of approaches have 
been developed to stabilise RNA and some of the stabilised molecules have been applied 
to anti-telomerase studies.
A retrovirus engineered by Bisoffi et al (Bisoffi et al. 1998) to express an oligomer of the 
template sequence (UUAGGG) was demonstrated to potently inhibit TRAP activity, 
decrease telomere length and viability in 2 human kidney carcinoma cell lines, while other 
studies using phosphorothioate stabilised antisense RNA molecules directed against the 
RNA component have demonstrated potent inhibitory effects on telomerase activity. The 
precise mechanism of action of phosphorothioate oligodeoxynucleotides (PS-ODN’s), 
however, has been proposed to be independent of sequence; evidence was presented in one 
study (Matthes et al. 1999) that PS-ODN’s directed against the template region of hTERC 
in fact elicited their effects in a sequence independent manner. Moreover, 
phosphorothioate modification of the backbone of a telomeric sequence primer enhanced 
telomerase activity in TRAP assays; it was suggested that inhibitory effects could be 
attributed to interaction with the primer binding site of hTERT, rather than the hTERC 
template region.
Another approach to targeting RNA that has been described is the use of hammerhead 
ribozymes. Hammerhead ribozymes are short catalytic sequences of RNA 40-50 bases in 
length consisting of a catalytic domain with ribonuclease activity against trinucleotide 
sequences, preferentially GUC, flanked on either side by specific complementary 
sequences that direct the ribozyme to its target RNA (for review, see Lewin et al. 2001). 
Several potential sequences for ribozyme cleavage exist in hTERC and, while not all 
specific sites have been evaluated, a notable target is the GUC trinucleotide inside the 
template region. Several groups have developed ribozymes directed against this sequence 
and the ability of these molecules to down-regulate telomerase activity has been 
demonstrated in 2 endometrial carcinoma cell lines (Yokoyama et al. 1998), 2 melanoma 
cell lines in addition to 3 surgical specimens of melanoma (Folini et al. 2000), and extracts 
of 2 human hepatocellular carcinoma cell lines (Kanazawa et al. 1996), although 
conclusions regarding the influence of hTERC inhibition on cell proliferation and telomere 
length regulation from these studies was more unclear: in the study of Folini et al, no
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significant effects on cell proliferation and telomere length were observed after 20 
population doublings in stable clones of malignant melanoma cells with reduced 
telomerase activity, while Yokoyama et al reported reduction in telomere length and 
slowed cell division in all stable endometrial cell lines tested. Kanazawa et al did not 
evaluate the effects of their ribozyme in vivo.
More recently, Yokayama et al further reported that the 5’ untranslated region of hTERT 
mRNA also presents a suitable sequence for targeting of ribozymes (Yokoyama et al.
2000). Several ribozymes directed against sequences throughout the TERT mRNA were 
developed, but most failed to demonstrate anti-telomerase activity, possibly due to 
secondary structural elements of the hTERT message. Ribozyme directed against the 5’ 
end, however, was able to cleave TERT mRNA and down-regulate telomerase activity. 
Another TERT directed ribozyme (Ludwig et al. 2001), targeted to the T motif of hTERT 
mRNA was able to cleave TERT mRNA, down-regulate telomerase activity and telomere 
length and induce apoptosis in human breast carcinoma cell lines when delivered in an 
adenoviral vector. Moreover, stable clones harbouring the anti-TERT ribozyme showed 
enhanced apoptotic response to the topoisomerase inhibitors doxorubicin and etoposide.
An alternative approach to actively target specific RNA sequences for degradation is by 
the use of 2,5-A oligonucleotides. The 2,5-A moiety activates RNAse L and, therefore, 
incorporation of this moiety to anti-sense oligonucleotides can actively target RNAse L to 
specific RNA sequences. This approach has been successfully used against the hTERC 
component to down-regulate telomerase activity and induce apoptosis of malignant glioma 
cells, both in culture and in subcutaneous and intra-cranial xenograft models (Kondo et al. 
1998; Mukai et al. 2000). Worth noting, however, is that in these studies massive apoptosis 
occurred in the target cell populations within 4-5 days post-treatment, a time period which 
is inconsistent with effects dependent on telomere shortening but resembles more closely 
effects associated with telomere uncapping, discussed below.
1.4.1.3 Targeting post-translational regulation
It is now clear that post-translational modification of constituents of the telomerase 
complex plays an important role in modification of enzyme activity. Specific inhibition of 
PKC using compounds such as bisindolmaleimide or antisense against specific PKC 
isoforms a  and £, respectively, down-regulated telomerase activity in breast (Li et al.
1998) and nasopharengeal (Yu et al. 2001) cancer cells. Consistent with this finding,
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telomerase activity could be down-regulated by the action of protein phosphatase 2A in 
human breast cancer cells (Li et al. 1997). A number of other post-translational 
modification events also influence the activity of telomerase. Phosphorylation by Akt 
protein kinase up-regulated telomerase activity in a human melanoma cell line and activity 
was abrogated by incubation with the kinase inhibitor Wortmannin (Kang et al. 1999). 
While the actions of kinases such as PKC are known to regulate multiple complex 
signalling pathways, it is possible that the expression of specific anti-sense inhibitors of 
kinase action could be targeted to telomerase positive cancer cells to down-regulate 
telomerase activity. Alternatively, high throughput screening systems may identify drugs 
that can specifically abrogate the post-translational enhancement of telomerase activity.
1.4.1.4 Targeting holoenzyme function
Among the first pieces of positive evidence that telomerase inhibitors could be used to 
genuine therapeutic effect were two studies in which dominant negative hTERT mutants 
were introduced into human cancer cells (Hahn et al. 1999; Zhang et al. 1999). The 
investigators were able to demonstrate telomere shortening and, with continued passage, 
cells underwent senescence and apoptotic cell death. The advantage of dominant negative 
mutants over reverse transcriptase inhibitors, discussed below, clearly lies in the specificity 
of inhibition; however, in order to adapt such an approach to a therapeutic environment, 
clearly an appropriate delivery system is a necessity.
A number of investigators have examined strategies based on the use of reverse 
transcriptase inhibitors to down-regulate the functional activity of telomerase. One of the 
most well characterised reverse transcriptase inhibitors currently in use in a therapeutic 
setting is AZT (azidothymidine), a potent inhibitor of HIV-1 reverse transcriptase and, 
therefore, one of the major drugs prescribed for the management of HIV. Although AZT is 
not specifically targeted to telomerase and the activated analogue is a general inhibitor of 
polymerase activity, several studies have examined the effects of AZT on telomerase 
activity in cancer cell lines and have shown an inhibitory effect, although the therapeutic 
value is uncertain. AZT was able to inhibit cloning efficiency in 4 human breast cancer cell 
lines (Melana et al. 1998) and could inhibit telomerase activity in a dose dependant 
fashion, but another study into the effects of AZT on human lymphocytes concluded that 
the telomerase inhibitory effects of AZT were not cytotoxic, but merely led to a transient 
suppression of cellular growth which could be reversed by removal of the drug (Beltz et al. 
1999).
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An interesting compound, which has been identified by screening in silico for compounds 
with pharmacological properties resembling those of the weak telomerase inhibitor 
berberine, is FJ5002 (Naasani et al. 1999). This compound was identified as a considerably 
more potent inhibitor of telomerase activity and has been demonstrated to act in the 
fashion expected of a “classical” telomerase inhibitor: continued passage of cells in the 
presence of FJ5002 led to replication dependent shortening of telomeres with concurrent 
increase in aneuploid metaphases and apoptotic cells. Recently, an additional small 
molecular inhibitor of telomerase activity designated BIBR1532 was characterised. 
Incubation with this compound led to telomerase inhibition, telomere shortening, 
reversible growth inhibition, chromosome end-to-end fusions and senescence with 
concurrent changes in the expression of a number of genes implicated in cell cycle 
checkpoints and senescence, such as up-regulation of p21wafl and MDM2, and down- 
regulation of cyclins A and B. Interestingly, the telomere length regulator TRF1 was also 
up-regulated. The investigators did not observe apoptosis, but rather senescence was 
induced. Cells pre-treated with inhibitors for extended periods exhibited marked decreases 
in tumourigenic potential when injected into nude mice (Damm et al. 2001).
1.4.1.5 Telomere interactive agents
Another way in which telomerase positive cells could be targeted in a manner which is 
specific, but not dependant on telomere shortening is by targeting the telomere cap. In a 
recent study (Kim et al. 2001), it was demonstrated that ectopic expression of template 
mutated telomerase RNAs designed to have sequences not recognised by telomere binding 
proteins led to decreased DNA synthesis and cell proliferation without telomere shortening 
or inhibition of the endogenous telomerase activity in breast and prostate cancer cell lines 
and in a xenograft model. Strategies targeted at telomeric uncapping, then, may represent 
an effective way to target cancer cells more rapidly than by the “classical” effects of 
inhibition of telomerase activity.
A similar approach involving targeting of telomere function is the use of G-quadruplex 
interactive agents as telomerase inhibitors. Formation of the telomeric G-quadruplex, by 
planar stacking of guanine base tetrads in the (TTAGGGG)n sequence (models of G- 
quartet formation reviewed in (Han et al. 2000)), has been characterised in vitro and may 
be involved in several cellular processes including telomere capping and termination of 
telomere elongation by telomerase if it is formed in vivo. Compounds that interact with G- 
quadruplex structures such as substituted acridines, therefore, may represent a new class of
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specific telomere or telomerase targeting agents. Several groups have applied molecular 
modelling approaches to the design of compounds that interact with these sequences and 
have been able to demonstrate inhibition of telomerase activity (Read et al. 2001).
1.4.2 Immunotherapy
Enhancement of the anti-tumour immune response has recently aroused considerable 
interest as a therapeutic approach. The complexity of the immune system, naturally, allows 
for a number of strategies to be employed. One way in which immune responses can be 
specifically targeted to particular antigens that has been demonstrated is by the ex vivo 
manipulation of autologous antigen presenting cells (APCs) such as macrophages or 
Dendritic Cells (DCs). Antigenic peptide sequences are processed by the proteasome of 
APCs and transported to the Endoplasmic Reticulum where they can interact with the 
products of major histocompatibility (MHC) alleles such as the MHC I type Human 
Leucocyte Antigen (HLA) 2. Subsequent budding of the Golgi and transport to the cell 
surface results in the presentation of antigen-MHC complexes for interaction with the T- 
Cell Receptor (TCR) of CD8+ populations of Cytotoxic T-Lymphocytes (CTLs).
It has been demonstrated repeatedly that peptides that interact with MHC molecules can be 
introduced into APCs, either as peptides or as DNA vaccines by the use of expression 
vectors, and thereby enrich specific CTL populations in vitro and in vivo (for review of 
cancer vaccination approaches, see (Minev et al. 1999)). Moreover, it has recently been 
shown that several peptide sequences of the hTERT protein match consensus sequences for 
interaction with HLA2 and can be naturally processed (Vonderheide et al. 1999; Minev et 
al. 2000), suggesting that there may be an endogenous and pre-existing anti-TERT 
immune response which could be enhanced by ex vivo manipulation of autologous APC’s 
to generate a broadly active anti-tumour immune response. Indeed, transduction of 
peripheral blood mononuclear cells from a prostate cancer patient (Vonderheide et al.
1999) with HLA2 interactive sequences from hTERT resulted in an enriched population of 
anti-TERT specific cytolytic T-cells, as judged by dose-response of radiolabel release to 
increasing ratios of effector to target cells, which were able to effectively lyse HLA2+, 
TERT+ tumour cell lines derived from ovarian cancer, malignant melanoma and multiple 
myeloma, in addition to freshly isolated primary tumour cells from patients presenting with 
acute myeloid leukaemia and non-Hodgkins lymphoma, while normal blood cells from the 
same patients were unaffected.
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1.4.3 Transcriptionally directed cytotoxic gene therapy 
approaches
A number of cytotoxic gene therapy strategies based on transcriptional targeting of the 
hTERC and hTERT promoters have been proposed recently; several transgenes, such as 
the pro-drug activating enzymes Herpes Simplex Thymidine Kinase (HSTK) and bacterial 
nitroreductase; apoptotic effectors; the noradrenaline transporter; and the diptheria toxin 
gene have been proposed as candidates for the development of gene therapy approaches. 
The advantages of each system will have to be evaluated thoroughly in future studies.
Majumdar et al (Majumdar et al. 2001) described an hTERT promoter-HSTK expression 
system which sensitised tumour cells derived from osteosarcoma, pancreatic cancer, 
medulloblastoma and fibrosarcoma to the effects of the pro-drug Gancyclovir. In this 
study, three normal human fibroblast cell lines, as well as normal retinal pigmented 
epithelial cells were unaffected. Moreover, in vivo transduction with adenoviral vectors 
containing the expression construct resulted in decreased tumour volumes and prolonged 
survival in mice bearing osteosarcoma derived xenografts with no increase in liver 
enzymes or histopathology associated with a cytotoxic effect on the liver.
Several studies have examined the effects of restricting the expression of apoptotic 
mediators using hTERT promoter sequences. Genes for Bax (Gu et al. 2000), Caspase 8 
(Koga et al. 2000), a novel form of caspase 6 engineered to be constitutively active 
(Komata et al. 2001), and most recently FADD (Koga et al. 2001) have been variously 
expressed with the induction of apoptosis in tumour cell lines derived from malignant 
glioma, malignant melanoma, breast cancer, lung, while expression and apoptosis was not 
detected in normal human cell lines. Efficient cell killing has also been demonstrated using 
both hTERC and hTERT promoters to drive expression of the diptheria toxin A gene 
(Abdul-Ghani et al. 2000) and by using the hTERC promoter to drive expression of the 
noradrenaline transporter gene in glioma cells (Boyd et al. 2001), facilitating the uptake of 
[131I]-MIBG, the drug of choice for treatment of thyroid cancer.
The present study describes the use of the transcriptional regulatory sequences of both 
hTERC and hTERT to drive expression of the bacterial nitroreductase gene, which 
converts the pro-drug CB1954 to a cytotoxic form (Knox et al. 1992). We previously 
described clear differentials in the activity of both promoters between normal and cancer 
cell lines, although hTERC promoter activity was always stronger than that of hTERT, and
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reported efficient cell killing in tumour cell lines, derived from cervical, ovarian, lung and 
colon cancers, which were stably transfected with telomerase promoter-nitroreductase 
constructs. Moreover, sensitisation to the pro-drug CB1954 was retained in vivo in 
xenografts of the stable cell lines. In this model, a single tail vein administration of the 
drug, at concentrations which were not acutely toxic, could significantly reduce tumour 
volumes in cervical and small cell lung cancer cells. However, we observed a dependence 
on high promoter activity which may represent a potential limitation to this kind of 
approach; ALT cell lines tested in our system, as expected, were not sensitised to the 
effects of the drug while most telomerase positive cancer cell lines were, but a subset of 
telomerase positive cancer cell lines having low promoter activities were also not 
significantly sensitised. This suggests that only highly expressing tumour cells may be 
efficiently targeted by this approach (Plumb et al. 2001). These data are presented and 
discussed at greater length in the present study.
One of the most important characteristics of any gene targeted therapeutic strategy must be 
its ability to target cancer cells while leaving normal cells relatively unaffected. From this 
point of view, telomerase is an excellent candidate for transcriptional targeting and the 
initial data from telomerase promoter directed gene therapy systems that have been 
reported shows considerable promise. An efficacious and selective anti-tumour effect has 
been described in a large number of cells derived from tissues of unrelated origin and this 
effect has been preserved in vivo in xenograft models and in adenoviral (Majumdar et al. 
2001; Gu et al. 2000) and cationic (Koga et al. 2000) models of delivery. Moreover, as 
telomerase based targeting potentially provides us with 2 promoters of differing strengths 
and tissue specificity, and since a number of transgene systems have already been 
described, there is the potential for the development of different combinations of promoter- 
transgene constructs for use in different situations. However, the optimisation of gene 
therapy approaches will require combinations of restricted transcription and delivery.
1.4.4 Resistance to telomerase therapeutics
While telomerase activity has been detected in all major human malignancies, it is not a 
prerequisite for tumorigenesis. While it is clear that a few tumour types, including small 
cell lung cancer (Hiyama et al. 1995; Sarvesvaran et al. 1999); and cervix (Soder et al. 
1998) are clear candidates for anti-telomerase therapy, telomerase positivity of clinical 
samples derived from other cancer types such as non-small cell lung cancers and 
endometrial malignancies has been variable. A study of telomerase activity in small cell
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versus non-small lung cancers (Hiyama et al. 1995) recorded high level TRAP positivity in 
100% of samples from primary small cell lung cancers and their metastases but only 
69.2%-88.5% positivity, varying with histology, in primary non small cell samples and 
only 50% positivity in metastases derived from non small cell lesions. The model that was 
proposed to explain this heterogeneity was that large solid tumours that display variable 
frequency of telomerase positivity could contain a fraction of partially transformed, 
telomerase negative mortal cells. Whether or not this would present a problem for 
telomerase based therapies is unclear, as the growth of mortal subpopulations within a 
heterogeneous solid tumour, or the metastases derived from them may be self limiting, 
although it is conceivable that spontaneous immortalising events may occur post-therapy.
A more worrying finding for the evolution of telomerase therapeutics as “universal” anti­
tumour agents is that a number of human cancers contain cells which elongate their 
telomeres by an alternative mechanism, termed the ALT pathway (Bryan et al. 1997) 
which may be associated with telomerase transcriptional repression by methylation of the 
hTERC promoter (Hoare et al. 2001). The ALT phenotype, characterised by the sudden 
appearance of telomeres of heterogeneous length, is believed to be based on a 
recombinogenic mechanism of telomere extension similar to that active in telomerase 
mutant yeast strains which escape senescence (Lundblad et al. 1993). Acquisition of the 
ALT phenotype is associated with acquisition of a novel type of Promyleocytic Leukemia 
Body (PML body) termed the ALT associated PML body, or APB (Yeager et al. 1999). 
These structures have been found to include a number of the human homologues of 
proteins involved in the maintenance of telomere length in the absence of telomerase in 
mutant yeast strains that escape from senescence. Moreover, telomerase activity appears to 
be the dominant mechanism for telomere extension in cell fusion experiments, although it 
is not clear whether the 2 mechanisms can co-exist within the same cell. If the use of 
telomerase inhibitors in cancer therapy is actually comparable to the experimental 
inhibition in yeast strains and if the alternative mechanisms of telomere extension can be 
activated by telomerase inhibition, or are latent within telomerase positive cells, it is 
conceivable that the use of telomerase inhibitors may actually select for the ALT 
phenotype, leading to more recombinogenic forms of cancer.
In order to overcome these potential problems, several options exist: it may be necessary to 
evaluate the use of telomerase inhibitors in combination with other conventional treatment 
modalities. It has been reported (Kondo et al. 1998) that inhibition of telomerase activity 
by stable expression of an anti-TERC RNA increased the sensitivity of human malignant
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glioma cells to cisplatin induced apoptosis in vitro and decreased overall viability, while 
Ludwig et al (Ludwig et al. 2001) showed that an anti-hTERT ribozyme could enhance the 
apoptotic effect of topoisomerase inhibitors. Other studies have also correlated telomerase 
activity and telomere length with sensitivity to conventional chemotherapeutic agents 
although definitive effects remain elusive.
An alternative strategy, applicable to the development of cytotoxic gene therapy and an 
integral part of many systems such as TK/GCV and nitroreductase/CB 1954, is to “target” 
untransduced cells, or cells which are resistant to primary effects of a therapeutic strategy 
with a bystander effect. For the development of this kind of strategy, enzyme/pro-drug 
systems with an active metabolite which can kill both dividing and non-dividing cells, or 
cells which are hypoxic, would be most desirable; thus, systems such as bacterial 
nitroreductase/CB 1954 or horseradish peroxidase/indole-3-acetic acid (Greco et al. 2000) 
are not limited in their efficacy by the proliferation dependence which is characteristic of 
some other systems.
1.5 Aims of the study
1.5.1 Development of an hTERC and hTERT directed cytotoxic 
gene therapy model
Several recent studies have used hTERT and hTERC transcriptional regulatory sequences 
to drive expression of a variety of transgenes in the development of tissue culture models 
of gene therapy (Abdul-Ghani et al. 2000; Gu et al. 2000; Koga et al. 2000; Boyd et al. 
2001; Koga et al. 2001; Komata et al. 2001; Majumdar et al. 2001). This approach is 
attractive, as it will not have the problems of phenotypic lag expected from the use of 
telomerase inhibitors in the clinic (Keith et al. 2001, White et al. 2001 for reviews). The 
development and evaluation of alternative promoter-transgene systems has clear benefits: 
each system has its own advantages and disadvantages and it is of interest to evaluate a 
number of transgenes for use with these promoters. In this study, I document the 
development of a tissue culture model of telomerase directed cytotoxic gene therapy using 
promoter fragments of both hTERC and hTERT to drive expression of the bacterial 
nitroreductase gene in order to sensitise cancer cells to the cytotoxic effects of CB1954. 
The plan of experimentation is presented in figure 1.8.
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1.5.2 Identification of differentials in hTERC and hTERT 
promoter activity in cell lines
Regulation of transcription of hTERC and hTERT genes is thought to be a major 
deterministic factor governing the differential expression of telomerase activity between 
normal and cancer cells (Feng et al. 1995; Avilion et al. 1996; Soder et al. 1998; Yi et al. 
1999; Hiyama et al. 2001). Therefore, it should be possible to detect differences in hTERC 
and hTERT promoter activity between normal and cancer cells in tissue culture systems by 
the use of a luciferase reporter assay. The initial aims of the study were to quantify 
differences in hTERC and hTERT activity between normal and cancer cells, and thereby 
validate the telomerase promoters as tools for the development of a transcriptionally 
directed cytotoxic gene therapy strategy. In chapter 3, the results of transient transfection 
reporter assays using previously characterised hTERC and hTERT promoter sequences to 
drive expression of the firefly luciferase gene in a wide range of normal, cancer and ALT 
cell lines are presented. The results showed a clear differential in activities of both 
promoters between normal and cancer cells and gave an indication of the relative 
efficiency of transgene expression from these sequences between normal and cancer cells. 
Moreover, the hTERC sequence was a stronger promoter in all cancer cell lines tested, yet 
still retained a cancer cell specificity, having high level activity in cancer cells and 
significantly lower activity in normal and ALT cells. From these results, the hTERC and 
hTERT sequences were validated for further study as part of a suicide gene therapy 
approach for therapy of cancer cells.
1.5.3 Bacterial nitroreductase/CB1954
A number of cytotoxic gene therapy approaches based on the use of enzyme/pro-drug 
activation systems have been proposed. Each has its associated benefits and limitations. 
The efficacy of enzyme/pro-drug therapies of cancer will be limited by a number of 
factors: these include the mechanism of action of the activated drug and intrinsic cell 
specific differences in sensitivity to the type of damage induced by it, in addition to the 
levels and specificity of expression of the pro-drug activating enzyme within tumour cells 
and the efficiency and selectivity of delivery.
Several of the systems which have been pioneered are intrinsically dependant on cellular 
replication for maximal cytotoxic effect. It has been postulated that this may be 
problematic for anti-tumour therapy since large solid tumours often contain a fraction of
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viable quiescent cells (Durand et al. 1998; Durand et al. 1998b) that represent a major 
obstacle to effective therapy (reviewed in Brown et al. 1998). Gene targeted systems that 
rely on cellular proliferation are, therefore, likely to be less effective systems than those 
which can target both dividing and non-dividing cells. A good example of such a system is 
bacterial nitroreductase/CB 1954, which has been shown to exhibit efficacy against both 
dividing and non-dividing tumour cells in tissue culture assays (Bridgewater et al. 1995; 
Weedon et al. 2000).
Chapter 4 documents the development and characterisation of a panel of stable cell lines 
expressing nitroreductase under the control of hTERC, hTERT or CMV promoters. Cell 
lines were selected for characterisation on the basis of their hTERC and hTERT promoter 
activities in luciferase assays (chapter 3). Cell survival assays (MTT assay) indicate that 
telomerase promoters could be used to drive high-level expression of NTR in those cancer 
cell lines that had high promoter activities, and thereby sensitise cells to CB1954 treatment 
in a manner dependent on high promoter activity. The hTERC-NTR and hTERT-NTR 
expression constructs are therefore validated for further study using a more realistic model 
of delivery.
1.5.4 Adenovirus gene delivery vehicles
A major problem with genetic therapies at the present time is the inefficiency of gene 
transfer to specific cell populations in vivo. Among the most well characterised vehicles 
for gene delivery are adenovirus vectors. Adenoviruses are associated with infections of 
the upper respiratory tract and eye (reviewed in Shenk 1996, Horowitz 1996). Their 
replication within cells is largely dependent on the expression of the products of the El a 
gene, the first viral gene to be expressed. El a is alternatively spliced into the E la 12s and 
13s gene products, which can mediate up- and down-regulation of host cell and viral gene 
expression by a variety of mechanisms (reviewed in Russell 2000).
The development of first-generation adenoviral vectors, deleted in the El region, which 
can be grown in El trans-complementing cell lines such as the 293 embryonic kidney cell 
line, and the proliferation of simplified systems for cloning into adenovirus (He et al.
1998) has allowed for the development of replication defective adenovirus as a transgene 
delivery vehicle. The efficiency of adenovirus mediated transgene delivery to both 
dividing and non-dividing cells and tissues is good and therefore, adenoviruses are the 
vectors of choice for many gene therapy applications.
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Chapter 5 documents the evaluation of adenovirus a system for efficient delivery of 
transgenes into cell lines used in this study. Using a reporter virus with the E.Coli LacZ 
gene under the control of a CMV promoter, infectivity was assessed in a panel of cell lines 
that have been characterised previously in this study for hTERC and hTERT promoter 
activity. Additionally, cloning of hTERC-NTR and hTERT-NTR expression constructs 
into the El region of an adenovirus 5 backbone is described. The subsequent vectors, Ad- 
hTERC-NTR and Ad-hTERT-NTR are characterised for their ability to transduce cells 
with the NTR expression constructs and to sensitise cell lines to CB1954.
Sequencing of NTR transcripts expressed in a cervical carcinoma cell line revealed the 
correct transcriptional start sites for hTERC and hTERT (Feng et al. 1995; Cong et al. 
1999; Wick et al. 1999), indicating that correct transcription from the hTERC and hTERT 
promoters was retained in the adenoviral backbone. However, the sequences revealed 
alternative splicing of the transcript resulting in a 187bp deletion encoding an in frame 22 
amino acid truncation of the NTR protein in addition to mutation of a further 5 residues. 
Characterisation of the mutation by a variety of bioinformatics approaches did not predict 
any adverse effect on the function of NTR. Expression of NTR was characterised by 
Northern and Western blotting to ensure that expression followed the expected patterns. 
The function of expressed NTR was tested in MTT assays to ensure that the mutant NTR 
retained the ability to sensitise cells to CB1954.
The data indicate that the Ad-hTERC-NTR and Ad-hTERT-NTR gene therapy vectors 
could efficiently transduce a variety of cell lines with NTR and that sensitisation to 
CB1954 was dependent in part on hTERC and hTERT promoter activities and in part on 
infectivity. Additionally, a cervical cancer cell line that was sensitised to the effects of 
CB1954 in MTT survival assays was established as a xenograft model to test the efficacy 
of Ad-hTERC-NTR and Ad-hTERT-NTR transduction followed by CB1954 challenge in 
vivo. The data indicate that adenovirus vectors harbouring hTERC and hTERT-NTR 
expression constructs could sensitise human tumour cells to the effects of CB1954 both in 
vitro and in vivo and, therefore, that telomerase directed gene therapy using the bacterial 
nitroreductase gene represents a valid therapeutic approach for the treatment of malignant 
disease.
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R E M O V A L  O F  R N A P R I M E R S  
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Figure 1.1: The end replication problem for linear eukaryotic chromosomes.
The figure illustrates the end replication problem. Due to the mono-direc tional activity o f  D N A  
polym erm ase , only a single strand o f  a parent D N A  molecule  (the leading strand) is complete ly  replicated. 
Synthesis o f  the other strand (lagging strand) proceeds in a d iscontinuous manner in short stretches termed 
Okazaki fragments.  Synthesis o f  Okazaki fragm ents  is primed from short com plem entary  RN A  sequences 
that are rem oved , allowing ligation o f  the Okazaki fragments. T he  removal o f  the terminal R N A  primer 
m eans that the extrem e term inus o f  the lagging strand template is incompletely replicated.
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Figure 1.2: Schematic representation of possible protein interactions at the telomere.
The figure illustrates a num ber o f the factors know n to in fluence te lom ere  function in (a) S. C erev isae  and (b) 
hum ans. H istone oc tam ers are rep resen ted  by orange cylinders. T e lom eric  and non-telom eric  D N A  regions 
are rep resen ted  by red  and grey tubes. O ther com ponen ts o f the pu tative com plexes are labelled . From  
O ’R eilly et al 1999.
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Figure 1.3: Schematic model of the t-loop at mammalian telomeres.
T he figure show s (a) the old view  and (b) the new  view  o f a possib le  m echan ism  by w hich the single 
stranded  ends o f  m am m alian  te lom eres are d isgu ised  from  the D N A  dam age response m achinery . Som e 
low er eukaryo tes  such as O xy tricha  are know n to have end-b ind ing  p ro te in s that may prevent recogn ition  o f  
the te lom ere as D N A  dam age. It w as recen tly  d iscovered , how ever, that w hen m am m alian  te lom eres are 
c ross-linked  and purified , they adop t a looped  confo rm ation  in w hich  the single stranded  reg ion  is 
sequestered  by a strand invasion m echanism .
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Figure 1.4: Representation of the possible mechanism of telomere extension by telomerase.
T he R N A  com ponen t o f  te lom erase  con ta ins a tem plate  sequence com plem en tary  to 1.5 te lom eric  repeats 
from  w hich new  telom eric  sequence  is reverse transcribed  in a p rocessive m anner. T he m odel that has been 
p roposed  is ou tlined  in the figure. T he tem plate  sequence associates w ith overhanging  single stranded  
te lom ere sequence, a llow ing  reverse transcrip tion  o f  a sing le , new  telom ere repeat to proceed. T he nascent 
repeat then d issocia tes and base-pairs again  w ith a dow nstream  region o f  the tem plate, a llow ing  reverse  
transcrip tion  o f  ano ther repeat to proceed . T hus, by a m echanism  that coup les translocation  and hybrid isation  
to the ca ta ly tic  function  o f  te lom erase , it is possib le  to synthesise large tracts o f  te lom eric  repeats.
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Figure 1.5: Reactivation of telomerase activity as a critical late stage in immortalisation.
By the curren t m odel, the cells o f  an exponen tia lly  g row ing  m ortal cell popu la tion  will con tinue to d iv ide, 
g radually  losing te lom eric  D N A  until the te lom eres o f  individual cells are suffic ien tly  shortened  to activate 
the pathw ays tha t lead to senescence. T hus, an increasing  num ber o f  cells will ex it from  the cell cycle as the 
age o f  the culture increases. A transfo rm ing  event, such as inactivation  o f  the p53 and pR b tum our suppresso r 
p ro teins by SV 40 large T  an tigen  m ay allow  a few  rare cells to bypass senescence and con tinue  to d iv ide, 
w hile con tinu ing  to lose te lom eric  D NA . At a poin t w hen telom eres are critically  shortened , the cell 
popu la tion  undergoes a w idesp read  grow th crisis from  w hich a few  cells that have stabilised  their te lom ere 
length by reactiva tion  o f te lom erase m ay em erge as im m ortal cell lines.
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Figure 1.6: Conserved secondary structure of mammalian telomerase RNA components 
(TERCs).
P hy logenetic  analysis o f  the p roposed  fo ld ing patterns o f  35 m am m alian  T E R C  m olecu les revea ls the 
p red ic ted  conserved  secondary  structu re  rep resen ted  above. Folding o f  the m olecu le  via the helices 
d esigna ted  P1-P8 allow s the conserved  reg ions o f p rim ary sequence  (C R 1-C R 7) to adopt specific , conserved  
functional structures. T he tem plate  sequence lies in a single stranded  region that is accessib le  to an ti-sense  
in terven tion  and to the telom ere. T he pseudokno t dom ain  is im portant for T E R C /T E R T  in teraction  and  for 
enzym e activ ity , as is the d ow nstream  C R 4/C R 5 dom ain . T he box H /A C A  dom ain  is involved in protein  
in terac tions o ther than w ith hT E R T  that m ay be necessary  for RN A  stability.
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(a)
( b )
Figure 1.7: Schematic representation of the regulatory elements of the hTERC and hTERT 
promoter regions.
T ranscrip tion  o f te lom erase  genes appears to be a m ajor level on w hich enzym e activ ity  is regu la ted  and  a 
num ber o f  regu lato rs o f  (a) hT E R T  and (b) hT E R C  transcrip tion  have been identified . T ranscrip tion  o f 
hT E R T  is up -regulated  by estrogen , M yc/M ax, and S P l and is dow n-regu la ted  by M Z F-2 , W T l, M ad/M ax, 
P53, H D A C s and E2F. T he hT E R C  prom oter region con ta ins e lem ents typical o f  a pol ll p rom oter (T A T A  
box, C C A A T  box) that are strongly  conserved  across 35 m am m alian  species. U p-regulation  o f  hT E R C  is 
m ed ia ted  by S P l,  pR b and by N F-Y , w hile transcrip tion  can be repressed  by SP3. T he pathw ays show n can 
also be view ed at h ttp ://w w w .b io carta .co m .
Nucleus
Cytoplasm
Jtton
c o m p le x e s  ■
hTERT 
pronu  
structure
S p l
S P3
Activation -  Sp1, MYC/MAX, Estrogen 
Repression -  MZF 2, WT1, MAD1/MAX, HDAC, p53
TATA
A ctivation  -  Sp1, I 
R epression -  Sp3
ription
Alan E. Bilsland, 2002 Chapter 1: Introduction 47
CHAPTER 3
DEVELOP A PANEL OF 
STABLE NTR GENE 
THERAPY 
CELL LINES FOR 
CYTOTOXICITY ASSAYS
CHAPTER 4
CHAPTER 5
HIGH
PROMOTER
ACTIVITY
LOW
PROMOTER
ACTIVITY
DEVELOP ADENOVIRUS 
EXPRESSION SYSTEM
SELECT CELL 
LINES FOR 
FURTHER STUDY
SCREEN POTENTIALCELL LINES 
BY TRANSIENT TRANSFECTION
CHARACTERISE 
EFFICIENCY OF 
INFECTION AND 
TRANSGENE 
EXPRESSION
EXAMINE CELL 
KILLING BY VIRUS 
DELIVERED 
CONSTRUCTS
TEST EFFICACY OF 
ADENOVIRAL VECTORS IN  
VIVO
TEST STABLE 
CELL LINE 
SENSITIVITY 
TO CB1954 IN  
VIVO
CHARACTERISE 
NTR 
EXPRESSION 
AND DRUG 
SENSITIVITY
Figure 1.8: Plan of investigations undertaken in this thesis.
C hap ter 3 docum ents the q uan tifica tion  o f  d ifferen tia ls  in hT E R C  and hT E R T  p rom oter ac tiv ities betw een 
cancer and m ortal cells. A num ber o f  cell lines w ith low  and high hT E R C  and hT E R T  p rom oter activ ities 
w ere se lected  for the genera tion  o f  stable cell lines w ith the bacterial n itro reduc tase (N T R ) gene under the 
con tro l o f  hT ER C  and hT E R T  prom oters. C hap ter 4 details the validation  o f  hT E R C  and hT E R T  prom oters 
for use in a transcrip tional d irec ted  an ti-can cer gene therapy stra tegy  using the bacterial n itro reductase gene 
to sensitise  cancer cells to the effec ts  o f  the pro -d rug  C B I9 5 4 . In chap te r 5, the hT E R C -N T R  and hT E R T - 
N TR expression  constructs are c loned  into adenov irus gene therapy  vectors to exam ine the effic iency  o f  
in fection , transgene expression  and sensitisa tion  to C B 1954 in a panel o f  cancer and m ortal cells.
Alan E. Bilsland, 2002 Chapter 1: Introduction 48
Telomeric factor Telomere length regulation effect Other effects
TRF1 Negative. Primary mode of action 
probably by recruitment of other 
factors to a higher order complex.
DNA bending action may promote 
configuration favourable for T-loop 
formation.
TRF2 Negative. Overexpression leads to 
transient decrease in telomere 
length.
Contribution to T-loop formation. Protection 
against end-to-end fusions. Inhibition leads 
to cell cycle arrest and apoptosis.
Tankyrase Positive. ADP-ribosylation by 
tankyrase leads to inhibition of 
TRF1 binding.
May modify other nuclear factors by ADP- 
ribosylation. Also found in mitochondria.
Tankyrase 2 Over-expression caused apoptotic cell death.
Raplp Possible negative effects. 
Overexpression caused moderate 
increase in telomere length, 
possibly by titrating out binding 
factors. Recruited to telomere by 
TRF2.
TIN2 Negative. Recruited by TRF1. 
Binding mutants increase telomere 
length in the presence of functional 
TRF1.
POT1 Single stranded end-binding factor. 
Protection of telomere ends. Potl /_ cells 
show rapid loss of telomere and subtelomere 
sequences.
WRN Interaction with Ku heterodimer enhances 
3’, 5’, and blunt end exonuclease activity. 
Possible role in double strand break repair.
Ku70/80 Subunit of DNA-PK. Prevents telomere- 
telomere fusions regardless of telomere 
length. Roles in non homologous end joining 
pathway for double strand break repair.
MRE11A Homologous recombination and double 
strand break repair. Part of Mrel 1-RAD50- 
NBS1 complex.
RAD50 Homologous recombination and double 
strand break repair. Part of Mrel 1-RAD50- 
NBS1 complex.
NBS1 Homologous recombination and double 
strand break repair. Part of Mrel 1-RAD50- 
NBS1 complex.
ATM Mutations in ATM protein in 
Ataxia Telangietasia cells result in 
accelarated telomere attrition.
Roles in signal transduction and cell cycle 
control.
Table 1.1: Protein factors interacting with mammalian telomeres.
The table outlines some of the components of telomere complexes that have been identified to date. Proteins 
identified in mammalian and yeast telomeric complexes have a variety of functions including roles in 
telomere length homeostasis and capping status in addition to roles in telomere repair and recombination and 
positional gene silencing. In addition to the factors shown, components of the telomerase ribonucleoprotein 
reverse transcriptase must interact with the telomere in telomerase positive cells.
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TISSUE
TYPE
HISTOLOGY TRAP +/TOTAL COMMENTS REFERENCES
LUNG Normal (adjacent 
tissue)
3/68 (4%) May represent inflammatory 
infiltrate
Hiyama et al
Small cell 
carcinoma
15/15 (100%) Hiyama et al
Non-small cell 
carcinoma
98/125 (78%) Hiyama et al
SKIN Normal epidermis 4/9 (44%) Weaker activity than 
carcinoma samples
Taylor etal
Basal cell 
carcinoma
73/77 (83%) Taylor et al
Squamous cell 
carcinoma
15/18(95%) Taylor et al
Melanoma 6/7 (86%) Taylor et al
LIVER Hepatocellular 
carcinoma -  all 
stages
28/33 (85%) Strong activity in 22/28 Taharaet al 1995
Normal 0/4 (0%) Taharaet al 1995
Non-malignant 
chronic liver 
dieases
25/46 (54%) Weak activity in all positive 
samples
Taharaet al 1995
GASTRIC Primary gastric 
carcinomas -  all 
histologies
17/20 (85%) Taharaet al 1995
Adjacent tissue 0/20 (0%) Taharaet al 1995
Colorectal
adenocarcinomas
19/20 (95%) Tahara et al 1995
Adjacent mucosa 0/20 (0%) Taharaet al 1995
BREAST Normal 0/6 (0%) Sugino et al 1996
Fibrocystic disease 0/17 (0%) Sugino et al 1996
Carcinoma - all 
histologies
52/71 (73%) Strong activity in 36/52 Sugino et al 1996
Carcinoma - 
invasive ductal
45/54 (83%) Strong activity in 31/45 Sugino et al 1996
Carcinoma -  
invasive lobular
5/11 (45%) Strong activity in 4/5 Sugino et al 1996
Lymph node 
metastasis -  node 
positive
22/30 (73%) Strong activity in 17/22 Sugino et al 1996
Lymph node 
metastasis -  node 
negative
30/41 (73%) Strong activity in 19/30 Sugino et al 1996
Metastatic lesion 7/8 (88%) Strong activity in 3/7 Sugino et al 1996
BLADDER Normal epithelium 0/7 (0%) Lin et al 1996
Dysplasia 1/2 (50%) Low activity Lin et al 1996
Bladder cancer 39/40 (97%) Activity related to clinical 
stage -  16/16 (100%) grade 
3 tumours had high activity, 
62% grade 2 tumours had 
high activity, 20% grade 1 
tumours had high activity.
Lin et al 1996
Table 1.2: Summary of TRAP assay results in normal and malignant human tissues.
The specific association of telomerase activity with human cancer has been documented in almost all human 
malignancies. The table gives a selection of some of the telomerase activity studies that have compared 
normal and malignant tissues.
CHAPTER 2
MATERIALS AND METHODOLOGY
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2 MATERIALS AND METHODOLOGY
2.1 Materials
2.1.1 Plasmid vectors
2.1.1.1 Luciferase reporter plasmids (Chapter 3)
pGL3-Basic; basic, promoter-less cloning vector; negative control for luciferase assay; 
contains the firefly luciferase gene.
pGL3-Control; positive control vector for luciferase assay; contains the firefly luciferase 
gene driven by the SV40 promoter and enhancer sequences.
pGL3-hTERC; hTERC reporter vector; contains the firefly luciferase gene driven by an 
876bp fragment of the hTERC promoter.
pGL3-hTERT; hTERT reporter vector; contains the firefly luciferase gene driven by a 
541 bp fragment of the hTERT promoter.
2.1.1.2 Co-transfection control plasmids (Chapter 3)
pSEAP-Control; positive control vector for SEAP assay; contains the SEAP gene under 
the control of the SV40 promoter and enhancer sequences; used for normalisation of 
transfection efficiency within a single cell line by cotransfection with luciferase plasmids.
2.1.1.3 Nitroreductase gene therapy plasmids (Chapter 4)
pd2NTR-Basic; basic, promoter-less cloning vector; contains the E.Coli nitroreductase 
gene. Generated by Rania Kakani.
pd2NTR-CMV; gene therapy vector for construction of stable cell lines; contains the 
E.Coli nitroreductase gene driven by the CMV immediate early promoter. Generated by 
Rania Kakani.
Alan E. Bilsland, 2002 Chapter 2: Materials and methodology 52
pd2NTR-hTERC; gene therapy vector for construction of stable cell lines; contains the 
E.Coli nitroreductase gene driven by an 876 bp fragment of the hTERC promoter. 
Generated by Rania Kakani.
pd2NTR-hTERT; gene therapy vector for construction of stable cell lines; contains the 
E.Coli nitroreductase gene driven by a 541bp fragment of the hTERT promoter. Generated 
by Rania Kakani.
2.1.1.4 Adenovirus cloning plasmids (Chapter 5)
pShuttle; transfer vector for cloning into pAdeasy-1 by homologous recombination in 
bacteria; contains a multiple cloning site for transgene insertion and the adenovirus 
serotype 5 left and right arms and terminal repeats.
pShuNT; intermediate transfer vector for cloning into pAdeasy-1; the E.Coli 
nitroreductase Sal I fragment from pd2NTR-hTR is ligated into the multiple cloning site of 
pShuttle.
pShuNT-hTERC; transfer vector for cloning into pAdeasy-1; the Hind III fragment of the 
hTERC promoter from pd2NTR-hTR has been ligated upstream of the nitroreductase gene 
in pShuNT.
pShuNT-hTERT; transfer vector for cloning into pAdeasy-1; the Xhol fragment of the 
hTERT promoter from pd2NTR-hTERT has been ligated upstream of the nitroreductase 
gene in pShuNT.
pAdeasy-1; cloning vector for insertion of transgenes into the El region of adenovirus 
serotype 5; contains an E1/E3 deleted adenovirus genome and sequences homologous with 
those in pShuttle.
pAd-NTR-hTERC; gene therapy vector for construction of recombinant adenovirus 
serotype 5 with the bacterial nitroreductase gene under the control of the hTERC promoter 
inserted into the El region of the adenovirus genome.
pAd-NTR-hTERT; gene therapy vector for construction of recombinant adenovirus 
serotype 5 with the bacterial nitroreductase gene under the control of the hTERT promoter 
inserted into the El region of the adenovirus genome.
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2.1.2 Adenovirus vectors
Ad-hTERC-NTR; gene therapy vector; contains the E.Coli nitroreductase coding 
sequence under the control of a 876bp fragment of the hTERC promoter inserted by 
homologous recombination into the El region of an E1/E3 deleted serotype 5 adenovirus.
Ad-hTERT-NTR; gene therapy vector; contains the E.Coli nitroreductase coding 
sequence under the control of a 541 bp fragment of the hTERT promoter inserted by 
homologous recombination into the El region of an E1/E3 deleted serotype 5 adenovirus.
Ad-CMV-LacZ; commercial reporter virus; contains the E.Coli LacZ gene under the 
control of the CMV immediate early promoter cloned into the El region of an E1/E3 
deleted serotype 5 adenovirus.
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2.1.3 Human cell lines used in this study
5637 bladder carcinoma cells
C33-A cervical carcinoma cells
A2780 ovarian adenocarcinoma cells
A549 lung adenocarcinoma cells
GLC4 small cell lung carcinoma cells
Colo320 double minute, colorectal adenocarcinoma cells
HT-29 colon carcinoma cells
SK-LU-1 lung adenocarcinoma cells
SUSM-1 in Vitro immortalised fibroblast cells
WI38 foetal lung fibroblast cells
IMR 90 foetal lung fibroblast cells
HMEC normal human mammary epithelial cells
NHEK normal human adult epidermal keratinocytes
HEK-293 Adenovirus Ela transformed human embryonic kidney cells
BE colon carcinoma cells
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Cell Line Cell Type Telomerase Status (TRAP) Comments
5637 Bladder carcinoma Positive Immortal cell. p53/pRb 
negative.
C-33 A Cervical carcinoma Positive Immortal cell
A2780 Ovarian adenocarcinoma Positive Immortal cell
GLC4 Small cell lung carcinoma Positive Immortal cell
A549 Lung carcinoma Positive Immortal cell, gives rise 
to telomerase negative 
mortal subpopulations.
Colo320DM Colorectal adenocarcinoma Positive Immortal cell
HT29 Colorectal adenocarcinoma Positive Immortal cell
BE Colorectal adenocarcinoma Unconfirmed Immortal cell
SK-LU-1 Lung adenocarcinoma Negative (ALT) Immortal cell
SUSM-1 In Vitro immortalised 
fibroblast
Negative (ALT) Immortal cell
WI-38 Foetal lung fibroblast Negative Mortal cell
IMR-90 Foetal lung fibroblast Negative Mortal cell
NHEK Normal adult epidermal 
keratinocyte
Weakly positive Mortal cell
HMEC Mammary epithelium Negative Mortal cell
HEK-293 Embryonic kidney Positive Immortal cell
Table 2.1: Human cell lines used in this study.
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2.1.4 Tissue Culture Reagents and Glassware
RPMI 1640 growth medium
Minimum Essential Medium (MEM)
Dulbeccos modified Eagles MEM
Penicillin/ streptomycin
L-glutamine (200mM)
Trypsin (2.5%)
Foetal calf serum
Mammary epithelial cell growth medium
10cm Falcon plates 
6-well plates 
96-well plates 
75 cm2 flasks
Life Technologies 
Life Technologies 
Life Technologies 
Life Technologies 
Life Technologies 
Life Technologies 
Autogen Bioclear 
Clonetics
Epidermal keratinocyte cell growth medium Clonetics
Becton Dickinson
Iwaki
Iwaki
Iwaki
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2.1.5 Kits and Enzymes
Kit/reagent:
Superfect transfection reagent 
Luciferase assay system 
Protein assay reagent ,
Great escape SEAP assay system 
Lyse-n-Go PCR reagent 
Taq core PCR kit 
Advantage GC genomic PCR kit 
Advantage2 Taq polymerase mix 
Qiaex II gel extraction kit 
Nucleospin II RNA extraction kit 
NorthemMax blotting system 
Redi-prime II random prime labelling kit 
NE-PER protein extraction reagent 
ECL detection reagents for western blotting 
Adeasy adenovirus cloning system 
Restriction endonucleases and buffers
Supplier:
Qiagen
Promega
BioRad
Clontech
Pierce
Qiagen
Clontech
Clontech
Qiagen
Machery Nagel
Ambion
Amersham
Pierce
Amersham
Qbiogene
Life Technologies
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New England Biolabs
Qiaquick gel extraction kit
Rapid ligation kit
E.Coli DH5a competent cells
S.O.C. medium
Plasmid and cosmid miniprep kit
Qiagen
Roche
Life Technologies 
Life Technologies 
Hybaid
SMART-RACE II cDNA synthesis and PCR kit Clontech
Advantage2 PCR kit 
TOPO-TA cloning kit 
RNAse A
DNA molecular markers 
0.24-9.5kb RNA molecular marker
Clontech 
Invitrogen 
Life Technologies 
Life Technologies 
Ambion
Benchmark protein molecular weight marker Life Technologies
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2.1.6 Chemicals
T ris-hydrochloride
EDTA (Ethylenediamine tetra-acetic acid)
EGTA (ethylene glycol-bis((3-aminoethyl ether)n,n,n’,n’-tetraacetic acid) 
Absolute ethanol 
Propan-2-ol 
Sodium hydroxide
10 % SDS solution (sodium dodecyl sulphate)
Sodium chloride
Poly Ethylene Glycol 6000
Agarose
lOx TBE Buffer
MTT(3-[4,5 -dimethy Ithiazol-2 -y 1] 2,5 -dipheny ltetrazolium bromide) 
Glacial Acetic acid
Tween 20 (polyoxyethylenesorbitan monolaurate)
Bromophenol blue 
Xylene cyanole
Marvel (low fat powdered milk)
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X-gal (5-bromo-4-chloro-3-indolyl-p-D-galactosidase)
100 % methanol
Potassium acetate
DMSO (Dimethyl sulfoxide)
Ethidium bromide
Glycerol
a -32P-deoxyctosine triphosphate
CB1954 (5-aziridin-1 -yl-2,4-dinitrobenzamide)
2-mercapto ethanol 
Geneticin sulphate
30% acrylamide (37.5:1 acrylamide:bis-acrylamide) 
Ammonium persulfate
TEMED (n,n,n’,n’-tetramethylethylenediamine)
Bicinchoninic acid solution 
Copper (II) sulphate
Saturated phenol (25:24:1 phenol:chloroform:iso-amyl alcohol) 
Magnesium chloride 
25% glutaraldehyde 
Potassium ferricyanide
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Potassium ferrocyanide
61
2.1.7 Antisera and hybridomas
R36, rabbit polyclonal antiserum. IgG reactive against E.Coli nitroreductase. A kind gift 
from Dr. Steve Hobbs (CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 
Surrey).
Anti-rabbit-IgG. HRP conjugated secondary. Reactive against rabbit IgG (Cell Signalling 
Technology Cat no. 7071-1).
2.1.8 Oligonucleotides for PCR and sequencing
Oligonucleotide sequences are given from 5’ to 3’ end:
Luc If CTACCGTGGTGTTCGTTTC
Luclr TTTGAATCTTGTAATCCTGAA
Shunt If GGCGTAACCGAGTAAGATTTGG
Shunt lr TGCTGGATGGGCTGTATTGC
AdNTseq5a
Adtranscriptl
Adtranscript2
AdDELr
CATTCCACTAAGGCATTTGATG
CAGAGTGGATGGCAAAACAG
AAAGAATATATAAGGTGGGG
ATCAAACGAGTTGGTGCTCATG
M l3 primer set Cat no. 46-0691/46-0690 (Invitrogen).
p-actin (exon2-3) set Cat no. BAC 1004/BAC 1008 (Maxim biotechnology).
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2.1.9 General laboratory supplies and miscellaneous
Provided by Beatson Institute Central Services:
LB-Medium (Luria-Bertani Medium)
Sterile distilled water
Sterile phosphate buffered saline (PBS)
Sterile PBS + EDTA (PE)
Sterile glassware and measuring pipettes
General:
Ampicillin
Kanamycin
Falcon tubes 50ml and 15ml
Universal containers 5ml, 20ml, 100ml
Micro-centrifuge tubes 1.5ml and 0.5ml
Cell scrapers (rubber policeman)
Pipette tips
X-ray film
Positively charged nylon membrane
Nitrocellulose membrane
Supplier
Sigma
Sigma
Becton Dickinson
Bibby Sterilin
Elkay
Coming
Elkay
Fujifilm
Boehringer-Mannheim
Millipore
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2.1 AO Equipment
Medical Air Technologies Bio-MAT class II microbiological safety cabinet
Scharfe Systems Casy-1 cell counter
Forma Scientific CO2 H2O jacketed incubator
Olympus CK2 phase contrast microscope
Sigma 4K15/ Beckman GS-6R bench top centrifuges
Bio-Rad sub-cell GT electrophoresis gel tank/model 200 power supply
Pharmacia Biotech GeneQuant DNA/RNA calculator
M.J. Research PTC-200 Peltier thermal cycler
Beckman J6-MC centrifuge
Beckman Microfuge-R refrigerated micro-centrifuge 
Turner Designs TD 20/20 luminometer
Alpha Laboratories Molecular Devices/ Dynex technologies MRXII microplate readers
Lab Systems Multidrop microplate filler
Kodak X-Omat 480 RA film processor
Bio-Rad Gel Doc 1000 UV transilluminator
Beckman DU650 spectrophotometer
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Brunswick New Scientific G24/G25 orbital incubators
Atto AE 6450 polyacrylamide gel electrophoresis tank
Atto AE 6675 semi-dry blotting apparatus
2.2 DNA Recombination Techniques
2.2.1 Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) mixtures were made using reagents from the Qiagen 
Taq-core PCR kit. Reactions typically contained lp l template DNA along with final 
concentrations of master-mix components as follows: lx PCR buffer; 0.5pM each primer; 
0.2mM each of dATP, dTTP, dCTP, dGTP; 1 unit Taq polymerase; reaction volumes were 
made up to 25pL with sterile distilled H2O.
Cycling conditions were typically as follows: 1 initial denaturation step at 95°C for 2 
minutes, followed by 25-35 cycles of 95°C 30 seconds (strand denaturation), 60°C-65°C 
(dependent on primer sequence) 30 seconds (primer annealing), 72°C 1 minute (chain 
extension). A final incubation at 72°C for 2minutes was included in all reactions. To 
analyse PCR products, typically 5 pi was run out on a 2% agarose gel containing ethidium 
bromide for UV visualisation of DNA.
2.2.2 Restriction Digests
Restriction endonuclease digestion of plasmid DNA was performed as follows: 20pl 
reactions containing a maximum of 2pg plasmid DNA, lx restriction endonuclease buffer, 
lpl restriction endonuclease (typically lOU/pl). Reactions were made up to a volume of 
25pi with sterile dH20. Reactions were allowed to progress overnight at 37°C.
2.2.3 Gel Extraction
Extraction of restriction endonuclease digested DNA fragments from agarose gels was 
performed using the Qiaquick Gel Extraction Kit (Qiagen), according to the manufacturers 
instructions. Gels were viewed over a UV transilluminator and gel slices containing bands 
of interest were excised with a scalpel and 3x gel volumes of Buffer QG were added and
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incubated at 50°C for approximately 10 minutes until the gel had dissolved. 1 gel volume 
of isopropanol was added and the sample was loaded into a spin column with collecting 
tube and centrifuged at 13000rpm for 1 minute. Flow-through was discarded and 750pl 
Buffer PE (wash buffer) was added to the spin column. The column was spun for 1 minute 
at 13000rpm, flow-through was discarded and the column was spun for a further minute to 
completely remove the wash buffer. DNA was then eluted in 50pl distilled water and the 
eluate was collected in a clean 1.5ml microfuge tube.
2.2.4 Ligation and Transformation
Ligation of restriction endonuclease digested DNA fragments was performed using the 
Roche rapid ligation kit. Typically, restriction endonuclease digested plasmid backbones 
and inserts were mixed at a molar ration of approximately 1:1. Next, 2pi of 5x DNA 
dilution buffer was added and the volume was made up to lOpl with dFLO. lOpl 2x T4 
DNA ligase reaction buffer and, finally, lpl T4 ligase was added and the reaction was 
mixed and incubated at room temperature for 5 minutes, lpl reaction was used for 
transformation of 50pl E.Coli DH5a.
Direct ligation of PCR products into pCR-II was performed using the Invitrogen TOPO- 
TA cloning kit. lp l pCR-II was mixed with 4pl PCR product and incubated at room 
temperature for 5 minutes, lp l stop solution was added and lpl reaction was used for 
transformation of 50pl E.Coli DH5a.
lpl ligation reactions were mixed with 50pl competent E.Coli DH5a for 30 minutes on 
ice. The cells were then placed in a 42°C waterbath for 45 seconds and then returned to ice 
for 2 minutes. At this stage, 150pl S.O.C. medium was added to the transformation 
reaction and the cells were incubated for 1 hour at 37°C in a shake incubator. lOOpl cells 
were spread onto agar plates containing an appropriate antibiotic and incubated overnight 
to allow the development of discrete colonies.
2.2.5 Glycerol Stocks
750pl aliquots of fresh overnight bacterial cultures were mixed with 750pl sterile 50% 
glycerol in Nunc cryotubes and were stored at -70°C. Maxipreps started from glycerol 
stocks used 50pl aliquots in 5ml Luria broth supplemented with appropriate antibiotics.
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2.3 Generation of gene therapy vectors
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2.3.1 Plasmid vectors
Cloning of the plasmid vectors pd2NTR-hTERC, -hTERT, -CMV, and -basic was 
performed by Rania Kakani (Plumb et al).
The promoter-less cloning vector pd2EGFP-l was digested with Notl and EcoRI and the 
3379bp fragment containing the SV40 poly-A signal and the Kanamycin/Neomycin 
resistance gene was isolated. This fragment formed the backbone of the gene therapy 
vectors. A 733bp Notl/EcoRI fragment containing the bacterial nitroreductase coding 
sequence was isolated from the vector pTargetntrl and ligated into the pd2EGFP backbone 
to generate the basic cloning vector pd2NTR-basic.
The 876bp and 541 bp proximal promoter sequences of hTERC and hTERT genes were 
isolated in a 914bp BamHI/Bglll fragment and a 606bp Xhol fragment from plasmids 
containing these sequences which had previously been developed within the laboratory. 
These sequences were ligated upstream of the NTR coding sequence in pd2NTR-basic 
which had been digested with appropriate enzymes to form the plasmids pd2NTR-hTERC 
and pd2NTR-hTERT. An 896bp CMV promoter fragment was isolated by BamHI/Bglll 
digestion of the plasmid vector pRc/CMV. This fragment was inserted upstream of the 
NTR coding sequence to generate the plasmid pd2NTR-CMV. The sequence and 
orientation of all inserts in the final panel of gene therapy vectors was checked by 
restriction digests and sequencing.
2.3.2 Adenovirus vectors
2.3.2.1 Initial cloning of recombinant Ad-hTERC-NTR and Ad-hTERT-NTR 
plasmids.
Cloning of hTERC-NTR and hTERT-NTR expression constructs into the El region of Ad5 
genome was performed using the Adeasy system, as described in He et al (He et al). The 
transfer vector, pShuttle was first linearised with Sail and gel extracted. Next, the 740bp 
Sail fragment of pd2NTR-hTERC containing the coding sequence of bacterial 
nitroreductase, was digested and gel extracted. This fragment was ligated into linear 
pShuttle to generate the vector pShuNT. Insertion of the hTERT and hTERC promoter
Alan E. Bilsland, 2002 Chapter 2: Materials and methodology 67
sequences upstream of the NTR coding sequence was achieved by digestion of the 
plasmids pd2NTR-hTERT and pd2NTR-hTERC with restriction enzymes Xhol and 
Hindlll, respectively, and the 606bp (hTERT promoter) and 889bp (hTERC promoter) 
fragments were isolated and ligated upstream of the NTR gene in Xhol or Hindlll digested 
pShuNT to generate the transfer vectors pShuNT-hTERC and pShuNT-hTERT.
Transfer of expression constructs to the El region of the adenovirus backbone was 
accomplished by electro-co-transformation of the plasmid pAdeasyl and the Pmel 
linearised intermediate cloning vectors pShuNT-hTERC and pShuNT-hTERT. Mixtures of 
plasmids and bacteria were pulsed with 2.8kV in a Hybaid Cell Shock electroporator. 
Homologous recombination occurred in the E.Coli strain BJ5183. Colonies containing 
Kanamycin resistant BJ5183 were selected and minipreps performed. PacI digestion of 
extracted DNA revealed several transformants with the correct banding pattern indicating 
that homologous recombination had taken place. Miniprep DNA from recombinant BJ5183 
was then transformed into DH5a cells for maxipreparation of and long term storage of 
glycerol cryopreserved bacterial cultures. Sequence and orientation of inserts was 
confirmed by PCR using the primers Shunt If  and Shunt lr  in 25 pi PCR reactions 
containing final concentrations of lx PCR buffer; 0.5pM each of the primers; 0.2mM each 
of dATP, dTTP, dCTP, dGTP; 1 unit Taq polymerase; volumes were made up to 25 pL 
with sterile distilled H2O. Sequencing reactions were performed using the Applied 
Biosystems Big Dye Terminator system and reagents (Big dye terminator cycle sequencing 
reaction mixture) according to the manufacturers instructions using the primers shunt I f  or 
shunt lr  in individual sequencing reactions.
2.3.2.2 Large scale preparation of infectious Ad-hTERC-NTR and Ad-hTERT- 
NTR
These manipulations were carried out by Q-Biogene in fulfilment of a contract with 
them.
Generation of infectious adenovirus vectors was performed by transfection of HEK293 
El a trans-complementing cells and harvesting of infectious supernatants. HEK293 cells, 
containing the El a gene were plated out to give 70% confluence on the day of transfection
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and were transfected with 5pg of each of the PacI linearised plasmids Ad-hTERC-NTR 
and Ad-hTERT-NTR using a calcium phosphate transfection.
50pl DNA (O.lpg/pl) was mixed with 169pl (IH2O and 5pi 2M CaCL. An Additional 26pl 
CaCl2 was added after mixing and a second tube containing 250pl HBS (Hepes Buffered 
Saline) was prepared. Air was bubbled through the HBS with a pipette and during this 
time, the DNA/CaCh mixture was added. Cells were removed from incubation and the 
transfection mixture was added drop-wise to the medium. Cells were incubated overnight, 
then the transfection solution was removed and the cells were rinsed in PBS. Cells were 
then incubated for approximately 14 days to allow for the formation of a cytopathic effect 
(CPE). After this stage, small scale amplification was performed using an initial volume of 
0.1ml of crude virus from cell lysate supernatant to infect 105 cells. Virus was released 
from cells by 3 cycles of freeze/thawing between -20°C and 37°C. After several rounds of 
amplification using aliquots of up to 45ml crude virus released in tissue culture supernatant
o
to infect up to 3x10 293 cells, the large-scale adenovirus preparation was performed by 
freeze/thawing to release virus and purification by CsCb banding. Quantification of the 
viral titrations in Viral Particles (V.P.) was performed by measurements of optical density 
(O.D.260) and measurements of Plaque Forming Units (P.F.U.) were performed by plaque 
assay.
2.4 DNA Analysis
2.4.1 Minipreparation of plasmid DNA
Minipreparations of plasmid DNA were performed using the Hybaid Plasmid and Cosmid 
Miniprep kit according to the manufacturers instructions. Briefly, 1.5ml fresh bacterial 
culture was pelleted in a 1.5ml micro-centrifuge tube by centrifugation at 13000rpm for 1 
minute in a Beckman refrigerated micro-centrifuge and the supernatant discarded. The 
pellet was resuspended in 50jnl Pre-Lysis Buffer and vortexed to mix. lOOpl Alkaline Lysis 
Buffer was added to the suspension and mixed by pipetting repeatedly until the solution 
became clear and viscous. Next, 75jil Neutralising Solution was added and mixed by 
vortexing briefly. The tube was spun for 2 minutes at 13000rpm to pellet cellular debris 
and the supernatant was removed to a spin filter.
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Binding Buffer, containing a silica gel matrix was shaken to suspend the silica and 250pl 
was added to the spin filter, pipetting up and down to mix with the sample. The spin filter 
was then centrifuged at 13000rpm for 1 minute and excess liquid gathered in the collection 
tube was discarded and the filter placed back into the tube. 350pl Wash solution, 
containing added ethanol, was added to the filter and the tube spun for 1 minute at 
13000rpm. Excess liquid was decanted and the filter spun again to dry the pellet. The filter 
was then placed in a fresh collection tube and plasmid DNA eluted in 50 pi dH^O by 
centrifugation for 30 seconds at 13000rpm.
2.4.2 Maxipreparation of plasmid DNA
50pL glycerol stock or 0.5mL fresh culture were added into 5ml L-broth containing an 
appropriate antibiotic and were incubated overnight in an orbital shaker at 37°C. The 
following day, cultures were expanded to 100ml and again incubated overnight. Cultures 
were divided into two 50ml falcon tubes and centrifuged at 4000rpm, 4°C for 10 minutes 
in a Beckman GS-6R centrifuge.
Supernatant was then discarded and the cell pellet resuspended in 5ml Solution I (50mM 
Tris-HCL pH8.0, lOmM EDTA pH8.0) by vortexing. With the tubes on ice, 10ml Solution 
II (0.2M NaOH, 1% SDS) was added and the contents gently mixed by inversion. The 
tubes were then incubated on ice for 10 minutes prior to the addition of 15ml Solution III 
(5M Potassium Acetate, 11.5% v/v glacial acetic acid). The contents were mixed 
thoroughly and centrifuged for 10 minutes at 4°C in a Beckman GS-6R centrifuge. 
Supernatant was filtered through a gauze and at least 0.6 volumes of isopropanol added to 
precipitate the DNA.
The pellet was collected by centrifugation at 4°C in a Beckman GS-6R centrifuge, the 
supernatant was removed and the pellet was resuspended in 1ml TE buffer (pH8) 
containing lOpg/ml RNase A, then incubated at 55°C for 30 minutes. After RNAse A 
treatment, the plasmid DNA was precipitated by adding 1ml Solution IV (13.5% 
polyethylene glycol 6000, 1.6M NaCl) and centrifugation at 13000rpm for 5minutes in a 
Beckman micro-centrifuge.
The DNA pellet was next resuspended in 500pi TE buffer and an equal volume of 
saturated phenol added. The mixture was vortexed and spun at 13,000 rpm in a refrigerated 
micro-centrifuge and the aqueous layer was removed to a fresh tube. Phenol extraction was
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repeated and the DNA was precipitated from the final solution by addition of 1ml 100% 
ethanol and centrifugation for 10 minutes at 13,000rpm, 4°C. Finally, the plasmid DNA 
was washed with 1ml of 70% and 100% ethanol and resuspended in 50-100pi TE buffer.
2.4.3 Nucleic acid sequencing
Dideoxy chain termination sequencing reactions were performed by the in house 
sequencing service using the Applied Biosystems Big Dye Terminator system and reagents 
(Big dye terminator cycle sequencing reaction mixture) according to the manufacturers 
instructions. Sequence analyses were performed on ABI-PRISM 373A or 377.
2.4.4 Quantitation of DNA/RNA
Concentrations of nucleic acids in a solution were determined spectrophotometrically 
using a Pharmacia Biotech GeneQuant nucleic acid calculator. The instrument was first 
calibrated using TE only as a blank and samples were transferred to quartz capillary tubes 
for measurement. Optical Density measurements were taken at 260nm. An O.D. 
measurement of 1 at 260 (A26o= l) corresponds to a concentration of approximately 
50pg/ml of double stranded DNA or to a concentration of 40pg/ml for RNA. The ratio 
between the readings at 260nm and 280nm (OD26o-OD28o) provides a measure of the 
sample purity. For DNA samples, an OD26o'OD28o of between 1.8 and 2.0, and for RNA 
samples, an OD26o:OD28o of between 2.0 and 2.2, were taken to be sufficiently pure for all 
techniques used in this study.
2.5 Analysis of Gene Expression
2.5.1 Northern Blotting
Before commencing work, all work surfaces and equipment were thoroughly cleaned with 
RNaseZAP (Ambion).
2.5.1.1 RNA Purification
Extraction of total RNA from human cell lines was performed using the Machery-Nagel 
Nucleospin II total RNA isolation kit according to the manufacturers instructions. Briefly, 
cells grown in culture were trypsinised to release them from the tissue culture surface and
Alan E. Bilsland, 2002 Chapter 2: Materials and methodology 71
were resuspended in 10ml ice cold PBS. The suspension was then spun down at 1200rpm 
for 6 minutes and the supernatant aspirated. The cell pellet was then rinsed further by 
resuspension in a further 1ml ice cold PBS and the cell suspension was stored on ice.
Cell suspensions were transferred to DEPC-treated micro-centrifuge tubes and pellets were 
recovered by centrifugation at 13,000 rpm for 1 minute. The supernatant was removed and 
cells were lysed by vortexing in 400pi cell lysis buffer (buffer RA1) containing 4pi 2- 
mercaptoethanol. 300pl 100% ethanol was added and mixed by vortexing to precipitate 
nucleic acids and the entire contents of the tube were transferred to a spin filter and 
centrifuged at 10,000rpm for 1 minute. Next, lOpl DNase I was added to 90pl Dnase 
reaction buffer and 95 pi of the reaction mix was added directly to the central membrane of 
the spin filter for 15 minutes at room temperature. The DNase reaction was stopped by 
adding 500pl buffer RA2 (DNase stop solution) and centrifuged at 13,000rpm for lminute. 
The spin filters were next washed twice by addition of 600pl, then 350pl of wash buffer 
(RA3) containing added ethanol, followed by centrifugation at 13,000rpm for lminute and 
2minutes, respectively. RNA was eluted in lOOpl RNase free dt^O and quantified by 
spectrophotometry.
2.5.1.2 Sample and gel preparation
The day before electrophoresis, 25pg or 30pg equivalent RNA samples were mixed with 
0.1 volumes of 5M Ammonium Acetate and 2.5 volumes of 100% ethanol, then 
precipitated overnight at -20°C. On the day of electrophoresis, samples were centrifuged at 
13000rpm at 4°C for 15 minutes to pellet the RNA and the supernatant was decanted. After 
this, the tubes were spun again briefly and residual fluid removed. The pellets were then 
air dried and resuspended in 5 pi RNase free water. 15 pi formaldehyde loading dye was 
added to each sample and the RNA was denatured for 15 minutes at 65°C in a thermal 
cycler. The tubes were briefly spun in a micro-centrifuge and stored on ice until ready to 
load.
For a 150mL denaturing gel, 135ml RNase free H2O was added to 1.5g agarose and melted 
in a microwave oven for 2 minutes. The molten gel was equilibrated to 55°C in a waterbath 
then, in a fume hood, 15mL lOx denaturing gel buffer (Ambion) containing formaldehyde 
was added. The gel was poured into a casting tray to a thickness of approximately 0.6cm 
and allowed to set.
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2.5.1.3 Electrophoresis and blotting
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Specific RNA’s were separated by electrophoresis at 5V/cm for approximately 2.5 hours in 
lx MOPS gel running buffer (Ambion) then transferred to a positively charged nylon 
membrane using a downward transfer apparatus. Construction of the transfer apparatus 
was as follows: a 4cm stack of dry paper towels was laid out on a flat area of bench. On 
top of these, 2 pieces of dry 3 mm Whatman blotting paper, cut to a size slightly larger than 
the gel were laid. On top of the dry blotting paper, 3 pieces of blotting paper, pre-wet in 
transfer buffer (Ambion) were laid out and rolled out flat with a sterile pipette to remove 
any air bubbles. Next, the positively charged nylon filter, pre-soaked in transfer buffer, 
was laid on top and rolled out flat. On top of the filter, the gel was laid out and rolled flat 
and on top of the gel, 3 more pieces of pre-wet blotting paper were rolled out. Finally, 3 
long pieces of blotting paper were rolled out and placed with one end in a reservoir of 
transfer buffer, to act as a bridge for the downward flow of buffer, and the entire apparatus 
was weighted with the casting tray and a 100ml bottle.
Transfer was allowed to continue for 1.5 hours before disassembly of the apparatus. 
Immediately after disassembly, the filter was washed in lx MOPS running buffer then the 
RNA was UV cross-linked to the membrane in a Stratagene UV Stratalinker 2400.
2.5.1.4 Pre-hybridisation and Hybridisation
Ultrahyb pre-hybridisation/hybridisation buffer (Ambion) was first warmed to 68°C in a 
water bath, then 20ml was added to a large roller bottle. The membrane was added to the 
bottle, unrolled, and allowed to pre-hybridise for 1 hour at 42°C. After pre-hybridisation,
T9P-dCTP labelled probe was added to the bottle, as described below, and allowed to 
hybridise to the target RNA overnight at 42°C.
2.5.1.5 32P Labelling of DNA probes
Labelling of DNA probes was performed using the Redi-Prime II kit according to the 
manufacturers instructions. The nitroreductase DNA probe was generated by digesting the 
plasmid pd2NTR-hTERC with Sail (Gibco) and gel extraction of the 740bp fragment 
which spans the entire coding sequence of the nitroreductase gene. The control DNA 
probe, ribosomal 18s, was supplied by Ambion. The probe was diluted to a concentration 
of 25ng/pl (lOng/pl for the 18s) and lpl was added to 44pl TE buffer. The probe was
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denatured at 95°C for 5 minutes in a thermal cycler then allowed to cool on ice. The entire 
tube contents were spun down, transferred to a Redi-prime tube and flick-mixed. In the 
radioactive suite, 5pi 32P-dCTP (1.85MBq total activity) was added to the tube and the 
contents mixed and transferred to a 37°C heated block for 10 minutes. After this 
incubation, 2pl 0.5M EDTA (pH 8.0) was added to the tube to stop the labelling reaction 
and the contents were denatured by incubation for 5 minutes at 100°C in a boiling 
waterbath. After this step, the tube was incubated on ice for 5 minutes, then the contents 
were briefly spun down. The entire contents of the tube were added to a roller bottle 
containing prehybridised positively charged nylon filters with cross linked RNA.
2.5.1.6 Washing filters and autoradiography
After overnight incubation at 42°C, the hybridisation mixture was decanted and the filter 
was subjected to 1 wash for 15 minutes at 65°C with 0.1% SDS, 2x SSC buffer (diluted 
from stock solution of 20x SSC (3M sodium chloride, 0.3M sodium citrate, pH 7.0), 
followed by a further 2-3 washes in 0.1% SDS, O.lx SSC at 65°C. After each wash, and 
prior to removal from the bottle, the counts from the bottle were monitored with a geiger 
counter. When the counts reached approximately 30cps, the filter was removed and 
allowed a flat wash in 0.1% SDS, O.lx SSC at room temperature in a plastic basin on an 
orbital shaker. When specific bands were detectable and the counts from the bands were 
approximately 5-10cps, excess fluid was blotted from the filter and it was wrapped in 2 
pieces of Saran wrap.
To perform auto-radiography, in the dark room, 1 sheet of Fujifilm X-ray film was placed 
in contact with the filter inside an auto-radiography cassette and the cassette was left for 1- 
2 days at -70°C. Films were developed in a Kodak X-Omat 480 RA processor.
2.5.2 Rapid Amplification ofcDNA Ends (RACE)
2.5.2.1 First strand cDNA synthesis
RNA samples were extracted from virus infected C33-A cells, as described in section 
2.4.1.1, and cDNA libraries were constructed using the SMART RACE cDNA 
amplification kit (Clontech). The reactions produced 2 cDNA libraries for each sample,
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5’RACE ready cDNA and 3’RACE ready cDNA (the incorporation of an extended 3’ 
primer (SMART oligo) which anneals to extra nucleotides added by the terminal 
transferase activity of Superscript reverse transcriptase allows for the generation of 
complete 5’ ends). For the first strand synthesis of 5’ RACE ready cDNA, lpl RNA was 
mixed with lp l 5’cDNA synthesis primer (CDS), lpl SMART II oligo and 2pl dH20. For 
preparation of the 3’ RACE ready cDNA, lpl RNA was mixed with lpl 3’CDS and 3pi 
dH20 in 0.5ml micro-centrifuge tubes. Both tubes were incubated at 70°C for 2 minutes 
then cooled for 2 minutes on ice. The tubes were briefly spun to collect liquid at the 
bottom of the tubes and the following was added to each tube: 2pl 5x first-strand buffer, 
lp l DTT (20mM), lpl dNTP mix (lOmM) lpl superscript reverse transcriptase. The tubes 
were then incubated for 15 minutes at 42°C. The reactions were then diluted with lOOpl 
Tricene-EDTA buffer, heated for 7 minutes at 72°C and stored at -20°C.
2.5.2.2 5’ and 3’ RACE
All amplifications were carried out using components of the SMART-RACE and 
Advantage2 Polymerase mix kits (Clontech). For amplification of the 5’ and 3’ ends of 
NTR cDNA, reverse transcribed from mRNAs of Ad-hTERC-NTR and Ad-hTERT-NTR 
infected cells, 2.5pl cDNA was mixed with final concentrations of the following in a 50pl 
reaction. For the 5’ RACE reactions, 2.5pl 5’RACE ready cDNA with lx Universal Primer 
Mix, 0.2pM Shuntlr, lx Advantage 2 PCR buffer, 0.2mM each dNTP, lp l Polymerase 
mix and dH20  to 50pl.
For amplification of the 3’ ends, reactions contained the following: 2.5pi 3’RACE-ready 
DNA, lx  Universal Primer Mix, 0.2pM AdNTseq5a, lx Advantage2 PCR buffer, 0.2pM 
each dNTP, lp l polymerase mix and dH20  to 50pl. The amplifications were allowed to 
progress for 35 cycles of 94°C 30 seconds, 68°C 30 seconds, 72°C 3 minutes. After 
amplification, size and specificity of the amplification products was checked by 
electrophoresis of 5 pi samples on a 2% ethidium bromide-agarose gel.
PCR reactions were directly cloned into the plasmid pCRII (TOPO-TA cloning kit 
(Invitrogen) for transformation in DH5a, maxipreparation of plasmid DNA and sequencing 
of the 5’ and 3’ ends of the Ad-hTERC-NTR and Ad-hTERT NTR transcripts. Sequencing 
reactions were performed by the Beatson sequencing service using the Applied Biosystems 
Big Dye Terminator system and reagents (Big dye terminator cycle sequencing reaction 
mixture) according to the manufacturers instructions. Individual sequencing reactions of
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the 5’ end contained one of the primers M13f, or M13r, while sequencing of the 3’ end 
used the primers M13f, M13r, Adtransl, or Adtrans2.
2.5.3 Western blotting
2.5.3.1 Protein Purification and Quantitation for Western Blotting
Purification of the cytoplasmic protein fraction for Western blotting was achieved using 
the NE-PER differential nuclear and cytoplasmic protein extraction kit provided by the 
Pierce chemical company according to the manufacturers instructions. Briefly, medium 
was aspirated from a 75cm2 flask of cultured cells and the cell layer rinsed once in PBS. 
Cells were scraped off in 1.5ml PBS using a rubber policeman and transferred to a 1.5ml 
micro-centrifuge tube. The cell pellet was collected by centrifugation at 500rcf, 4°C, for 3 
minutes and the supernatant was removed with a pipette.
200pl ice cold CER I (Cytoplasmic Extraction Reagent) was added and the pellet was 
vortexed for 15 seconds at the maximum setting to mix. The tube was incubated for 10 
minutes on ice. Next, 11 pi ice cold CER II was added and the sample was vortexed for 5 
seconds then incubated for 1 minute on ice. Next, the sample was vortexed again for 5 
seconds then spun down at 16000rcf for 5 minutes to pellet nuclei. The supernatant 
(cytoplasmic fraction) was removed to a clean, pre-chilled tube and stored at -70°C until 
quantitation.
Quantitation of cytoplasmic protein extracts was accomplished by BCA/Cu (II)S0 4  assay 
using a 6 point BSA standard with concentrations 80pg/ml, lOOpg/ml, 200pg/ml, 
400pg/ml, lOOOpg/ml, 2000pg/ml. Undiluted samples and samples diluted 1:10 were 
incubated for 30 minutes at 37°C alongside BSA standards in a solution of BCA/Cu 
(II)S04, after which time colorimetric changes were quantified using a Dynex MRX II 
microplate reader.
2.5.3.2 Western Blotting
20pg protein equivalents were made up to 3lpl with dlUO and 2.5pi 2-mercapto ethanol + 
16.5pl 3x Loading Buffer (6% SDS, 30% glycerol, lOOmM tris pH 6.8, 0.01%
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bromophenol blue) was added to each. Samples were denatured at 100°C for 10 minutes in 
a thermal cycler then placed briefly on ice, spun down briefly and left on ice until ready to 
load. Cellular proteins were electrophoresed in a 12% SDS-polyacrylamide gel with 5% 
stacking gel for approximately 2.5 hours at 200V in 1L lx Running Buffer (25mM tris, 
0.2M glycine, 0.1% SDS, pH8.3). After SDS-PAGE, the top, bottom and sides of the gel 
were trimmed with a scalpel and the proteins were blotted onto Millipore nitrocellulose 
membrane previously prepared by soaking for 1 minute in 100% methanol, rinsing for 1 
minute in distilled water and soaking in lx transfer buffer (48mM tris, 40mM glycine, 
0.037% SDS) diluted in 20% methanol.
6 pieces of 3mm Whatman blotting paper were soaked in Transfer Buffer and placed onto 
to the bottom conductive plate of a semi-dry blotting apparatus and rolled out to remove 
bubbles. Next, the Millipore filter with gel on top was placed on top of the blotting paper 
and on top of that, a further 6 pieces of 3mm Whatman blotting paper soaked in Transfer 
Buffer were rolled out. The proteins were transferred for 1 hour at 20V. After transfer, the 
blotting apparatus was dismantled and the filter was blocked overnight at 4°C in TBS-T 
(0.7% tween 20) containing 5% non-fat dried milk.
The following day, filters were probed for 2 hours at room temperature with a 15ml of 1:50 
dilution of primary antibody in TBS-T containing 5% milk. After probing with the primary 
antibody, filters were washed 3 times for approximately 10 minutes each with TBS-T, then 
probed for 1 hour with 20 ml of a 1:3000 dilution of Horse Radish Peroxidase (HRP) 
conjugated secondary anti-rabbit IgG antibody. Following probing with the secondary 
antibody, filters were washed 3 times for approximately 10 minutes each with TBS-T then 
bound HRP was detected using ECL western blotting HRP detection reagents (Amersham) 
according to the manufacturers instructions.
For each filter, 2ml ECL reagent 1 was mixed with 2ml reagent 2 and the entire 4ml 
volume was transferred drop wise to the filter ensuring an even distribution of the 
detection reagents across the filter and the filter was incubated at room temperature for 1 
minute. After 1 minute, excess detection reagent was shaken off the filter and the filter was 
wrapped in 1 thickness of Saran wrap. The HRP signal was detected by exposing 
photographic film to the filter for approximately 1 minute before developing. Transferred 
proteins were stained with amido black for loading controls. Filters were soaked in amido 
black for 5 minutes at room temperature, the rinsed several times with dH20.
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2.6 Cell Culture and reporter gene assays
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2.6.1 Maintenance and storage of mammalian cell lines
All cell lines were routinely cultured in 75cm2 flasks containing 20mL appropriate growth 
medium, typically supplemented with 2mM L-glutamine, 10% FCS and 2.5mL 
penicillin/streptomycin solution. WI-38 and IMR-90 cells were supplemented with 20% 
FCS. HMEC and NHEK normal adult cell lines were maintained in complete mammary 
epithelial and keratinocyte growth media, respectively, obtained from Clonetics. Cells 
were trypsinised for subculturing with 3mL trypsin (0.25%) diluted in PE (PBS + EDTA) 
then resuspended to an appropriate concentration in growth medium. All cell lines were 
regularly tested for mycoplasma contamination.
For long term storage, cells were typically resuspended to a concentration of lx l0 6 
cells/ml in growth medium supplemented with 10% FCS and 10% DMSO. lmL aliquots of 
cell suspension were cooled to -70°C overnight, then transferred to liquid nitrogen. To 
recover cells from liquid nitrogen, cryovials were warmed to 37°C then the contents were 
transferred to 19mL warm growth medium in a 75cm2 flask and incubated overnight. The 
next day, medium containing DMSO cryopreservant was removed and normal, complete 
medium was added back.
2.6.2 Transient transfection
Cells were trypsinised and seeded into 6-well plates the day prior to transfection at a 
concentration sufficient to give 60-80% confluence on the day of transfection. For a single 
well, on the day of transfection, 3pg of each plasmid DNA, pGL3-Basic; pGL3-Control; 
pGL3-hTERC; or pGL3-hTERT (see section 2.1.1) was mixed with 97pL serum free 
growth medium and 7.5pL superfect transfection reagent (Qiagen) in separate tubes and 
incubated for 15 minutes at room temperature to allow formation of transfection 
complexes. Next, 600pL complete growth medium (10% FCS) was added to the 
transfection complexes and the growth medium was aspirated from each cell culture well. 
The cells were incubated for 2 hours in the presence of the transfection reaction mixtures. 
After transfection, cells were rinsed twice in PBS then incubated for 48 hours in 
appropriate growth medium. To ensure reproducibility of transient transfections, all 
transient transfections were carried out in duplicate and were repeated at least 3 times. As 
described below, transfection efficiencies between cell lines were controlled using a semi-
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quantitative PCR assay, and transfection efficiencies within a single cell line were 
normalised both by co-transfection with a second SEAP reporter and by measurement of 
cellular protein equivalents.
2.6.3 Generation of stable cell lines
Human cell lines were seeded the day prior to transfection into 10cm Falcon dishes at a 
concentration sufficient to allow 60-80% confluence on the day of transfection. 10pg of 
each plasmid DNA, pd2NTR-Basic; pd2NTR-CMV; pd2NTR-hTERC; or pd2NTR- 
hTERT (see section 2.1.1) was mixed with 300pL serum free growth medium and 50pL 
superfect transfection reagent (Qiagen) in separate tubes and incubated for 15 minutes at 
room temperature to allow formation of transfection complexes. Next, 3mL complete 
growth medium (10% FCS) was added to the transfection complexes and the growth 
medium was aspirated from each cell culture vessel. The cells were incubated for 2 hours 
in the presence of the transfection reaction mixtures. After transfection, cells were rinsed 
twice in PBS then incubated for 48 hours in appropriate growth medium.
48 hours after transfection, the cells were trypsinised and reseeded at lxlO6 cells per plate 
in appropriate growth medium containing 1 mg/ml G418 (Geneticin-sulphate). Selection 
medium was refreshed every 3-4 days and the cells were grown for approximately 2-3 
weeks until the appearance of stable clones. At this stage, the cells were trypsinised, the 
clones were pooled and the cultures were expanded under selection until sufficient cells 
were present to store in liquid nitrogen. Stable cell lines were routinely cultured under 
selection except during experiments, for which the selection was removed
2.6.4 Luciferase reporter assay
48 hours post-transfection, cells were harvested by scraping from the wells of 6-well plates 
in 1ml PBS. Cells were spun down for 1 minute at 13000rpm and the supernatant was 
decanted. Cells were lysed by vortexing in lOOpl lx Cell Culture Lysis Buffer (Promega) 
and incubated on ice for 10 minutes. The lysates were then spun down for 1 minute at 
13000rpm and kept on ice. Protein concentrations were determined by Bio-Rad assay using 
Bio-Rad protein assay reagent and 2.5pg protein equivalents were used for luciferase assay 
according to the manufacturers instructions. Protein samples were mixed with 25pl 
Luciferase Assay Reagent (Promega) at room temperature and the reactions were placed
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into a Turner Designs TD 20/20 luminometer to measure cumulative luminosity over a 15 
second period.
To ensure reproducibility, all transfections were carried out in duplicate wells and repeated 
at least 3 times. DNA for transfection was carefully quantitated both by 
spectrophotometry, using the Pharmacia Biotech GeneQuant spectrophotometer, and by 
direct visualisation by gel electrophoresis. In each experiment, all constructs were analysed 
together with the basic, promoter-less cloning vector, pGL3-Basic, and with the positive 
control, pGL3-Control, which contains the luciferase gene driven by the SV40 promoter 
and enhancer sequences.
2.6.5 SEAP reporter assay
Normalisation of luciferase reporter assays was performed by several means. 
Cotransfection with a second reporter (in this case, Secreted Alkaline Phosphatase, SEAP) 
is a useful way to control for variation in transfection efficiency within a single cell line. 
The SEAP assay is especially useful, as quantification of SEAP activity can be determined 
from cell culture supernatant and the integrity of the transfected cells is not compromised. 
SEAP assays were performed using the “great escape SEAP assay kit” (Clontech) 
according to the manufacturers instructions.
Cells transfected with luciferase reporters were cotransfected with 1.5pg SV40-SEAP 
reporter per well. 48 hours post-transfection, llOpL cell culture medium was removed 
from each well to a micro-centrifuge tube and centrifuged at 13,000 rpm for 1 minute to 
pellet any cells. lOOpL was removed to a fresh tube. For each sample, 75pL lx dilution 
buffer was added to 25 pL cell culture supernatant and mixed in a 0.5pL micro-centrifuge 
tube. The samples were incubated at 65°C for 30 minutes then cooled on ice for 2 minutes 
before equilibrating to room temperature. lOOpL assay buffer was added to each sample 
and incubated for 5 minutes at room temperature. lOOpL 1.25mM CSPD substrate (diluted 
1:20 in chemiluminescent enhancer) was added to each tube and incubated at room 
temperature for 40 minutes. Cumulative light units were measured over 15 seconds on a 
Turner Designs TD 20/20 luminometer and luciferase activities were adjusted by the 
formula. LuCnormalised L u C Well X (SEAPmean/ SEAP well).
Alan E. Bilsland, 2002 Chapter 2: Materials and methodology 80
2.6.6 Semi quantitative PCR detection of luciferase gene
In order to control for transfection efficiency across cell lines, where the application of a 
second reporter would not be appropriate due to cell specific differences in SV40 promoter 
activity, a semi-quantitative PCR assay for the presence of the luciferase gene in genomic 
DNA extracted from post-transfected nuclei was developed. After luciferase assay 
(described above), the nuclear pellet was collected by centrifugation for 1 minute at 
13000rpm, 4°C and the cell lysate supernatant was removed with an 18 gauge hypodermic 
needle. 50pL Lyse-N-Go PCR compatible DNA extraction reagent (Pierce) was added to 
each nuclear pellet and the nuclei were loosened by vigorously vortexing at maximum 
speed for 15 seconds. The tubes were then placed in a thermal cycler for 3 cycles of 65°C 
30 seconds, 8°C 30 seconds, 65°C 90 seconds, 97°C 180 seconds, 8°C 60seconds, 65°C 
180 seconds, 97°C 60 seconds, 65°C 60 seconds, 80°C 10 minutes. Cycling conditions 
were according to the manufacturers instructions with slight modifications (cycle number 
increased from 1 to 3, duration of final 80°C incubation modified from a final hold step to 
10 minutes).
Standard amplification reactions typically contained lpL nuclear lysate as template in a 
total volume of25pL, together with final concentrations of lx PCR buffer; 0.5pM each of 
the primers Luc If  and Luclr; 0.2mM each of dATP, dTTP, dCTP, dGTP; 1 unit Taq 
polymerase; volumes were made up to 25 pL with sterile distilled H2O.
Reactions for the amplification of luciferase were allowed to progress for 25 cycles of: 
strand denaturation at 95°C for 30 seconds; primer annealing at 60°C for 50 seconds; 
primer extension at 72°C for 40 seconds. Reactions for the amplification of p-actin were 
allowed to progress for 25 cycles of 94°C 1 minute, 60°C lminute, 72°C lminute. The 
primers (LucIf, Luclr) used in the amplification of luciferase are given in section 2.1.8, 
the forward and reverse genomic control primers for the amplification of p-actin were 
supplied by Maxim Biotechnologies (catalogue numbers BAC 1004/1008).
2.6.7 Adenovirus infection of mammalian cell lines
Human cell lines were seeded into 6-well plates the day prior to infection at a density 
sufficient to give approximately 80% confluence the following day (typically 4-5x105 cells
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per well in 2ml appropriate growth medium). The cells were incubated at 37°C overnight 
in humidified incubators at an appropriate percentage CO2 .
On the day of infection, growth medium was removed from one of the wells and the cells 
were trypsinised and counted. Adenovirus infection suspensions were prepared by 
adjusting the concentration of infectious units in PBS such that 100pi contained an 
appropriate multiplicity of infection (M.O.I.) (either 1, 10, 50, or 100 plaque forming units 
(P.F.U.) per cell in lOOpl in all experiments). Cells were incubated in the presence of 
lOOpl of virus suspensions for 1 hour at 37°C with rocking of the culture vessel every 15 
minutes.
After the 1 hour, the virus suspension was aspirated, fresh growth medium containing 2% 
FCS for infectivity assays, or 10% FCS for cytotoxicity assays was added back to the cells 
and the cells were incubated for an appropriate period prior to downstream assays.
2.6.8 Lac Z reporter assay for adenovirus infectivity
Cells were infected with a CMV-LacZ adenovirus, as described above, for 1 hour at 37°C 
at a multiplicity of infection of either 1,10, 50, or 100 P.F.U. per cell. Following infection, 
cells were incubated overnight in fresh growth medium containing 2% Foetal Calf Serum. 
24 hours post-infection, the medium was aspirated from the cells and the cell layer was 
rinsed 3 times with 4°C PBS. The cells were then fixed by incubation on ice for 20 minutes 
in 4ml of fixative solution per well containing 0.2% glutaraldehyde, 5mM EGTA, 2mM 
MgCh in ice cold PBS.
Next, the cells were rinsed a further 3 times in 1ml PBS and after the last rinse, staining 
solution was added (500pg X-Gal, 2.5mM K3Fe(CN)6, 2.5mM K4Fe(CN)6  in 25mL PBS). 
The cells were incubated in staining solution for 24 hours in the dark. In order to assess the 
efficiency of virus mediated transgene transduction to cell layers, the following day the 
staining solution was removed and the cells were rinsed with PBS, then the proportion of 
blue cells was assessed. For each multiplicity of infection, 5 random fields were counted at 
20x objective of a Zeiss phase contrast microscope using a 21mm diameter counting 
graticule. Typically, 500-1000 cells per well were counted and all experiments were 
repeated at least twice.
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2.7 MTT assay
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Cell lines or cells treated with individual viruses or at different multiplicities of infection 
were trypsinised and seeded in triplicate into the central 10 columns of flat bottomed 96 
well plates (80 wells per plate) at a density of 800-1000 cells per well. For assays with 
more than one cell line, cells were seeded in the first 4 rows only (40 wells per cell line). 
The outer columns on either side were left as blanks, containing growth medium only. 
Each independent cell line or treatment was therefore seeded into one half of a 96 well 
plate and was set up in triplicate. Cells were incubated at 37°C in an appropriate 
concentration of CO2 and allowed to divide for 2 days prior to drug administration. On the 
day of the drug challenge, 4-fold serial dilutions of CB1954 were prepared in cell growth 
medium to give 8 concentrations with an initial concentration of 400pM. Thus, the 
concentrations of CB1954 in the titration were as follows: 400pM, lOOpM, 25 pM, 
6.25pM, 1.56pM, 0.39pM, 0.098pM, 0.024pM. The medium was aspirated from wells 
using an 18 gauge hypodermic needle attached to an aspirator and the drug was titrated 
across the central 8 columns of each 96 well plate by adding lOOpL volumes of a single 
concentration to each of the wells in a single column. The column on either side of the 
plate which was not exposed to drug served as an untreated control against which the 
cytotoxic effects of CB1954 could be estimated. Cells were incubated at 37°C for 24 hours 
in the presence of the drug, after which the drug was aspirated and the cells were fed with 
200pL of fresh growth medium and allowed to recover for a further 3 days, replenishing 
the medium daily.
At the end of the recovery period, medium was aspirated and 200pL fresh medium was 
added, in addition to 50pl of 0.5% MTT in PBS (Sigma). Cells were incubated for 4 hours 
in the dark, then the medium and MTT was aspirated. The purple MTT-formazan product 
in the bottom of each well was dissolved in 200pL DMSO and 25pL Soreensons Glycine 
Buffer ( 0.1M glycine, 0.1M NaCl, pH 10.5) using a Labsystems Multidrop plate filler and 
OD measurements were made at 570nm using a Molecular Devices microplate reader. For 
an individual experiment, each data point on kill curves were plotted as the mean 
percentage of the untreated control, calculated across triplicate plates (each consisting of 4 
individual values) for each independent drug concentration. In order to determine the IC50 
values for various treatments, the 50% y-intercept value for each individual plate was 
calculated using the Softmax 2.32 analysis package and the mean of these triplicate 
measurements was taken to be the IC50. Sensitisation values for individual treatments are
Alan E. Bilsland, 2002 Chapter 2: Materials and methodology 83
taken to be the fold difference between the IC50 values for stable cell lines harbouring a 
basic promoter-less vector and those harbouring telomerase or CMV promoter gene 
therapy vectors (or, in the case of virus infected cells, between the IC50 values of the mock 
infected cells and those which were infected by a gene therapy adenovirus). All 
experiments were repeated at least 3 times and final sensitisation values presented are the 
means and standard errors derived from all 3 independent experiments.
2.8 Software analysis packages
2.8.1 Sequence analysis, restriction fragment analysis and primer 
design
All sequence analysis, development of cloning strategies, restriction fragment analysis and 
primer design were performed using Vector NTI 6.0 (Informax).
2.8.2 Optical density analysis for micro-titre assays
The Softmax 2.32 microplate analysis package was used for analysis of raw and analysed 
data from microtitre assays and to derive IC50 values for data sets.
2.8.3 UVgel documentation
Analysis and photography of ethidium bromide agarose gels visualised under UV was 
accomplished using the Bio-Rad UV gel doc 1000 UV transilluminator with Molecular 
Analyst software.
CHAPTER 3
DIFFERENTIAL ACTIVITIES OF THE 
TELOMERASE hTERC AND hTERT 
PROMOTERS IN NORMAL AND 
CANCER CELLS
• Semi-quantitative detection of luciferase gene in 
transfected nuclei.
• hTERC and hTERT promoters are more active in 
cancer cells than mortal cells.
• hTERC and hTERT promoters are not universally 
strong in cancer cells.
• hTERC is a stronger promoter than hTERT.
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3 Differential activities of the telomerase hTERC 
and hTERT promoters in normal and cancer cells.
3.1 Abstract
The hTERC and hTERT sub-units of telomerase are differentially regulated at a 
transcriptional level between normal and cancer cells. Therefore hTERC and hTERT 
promoter reporter constructs should restrict transgene expression to cancer cells. 
Luciferase assays using a 541bp hTERT promoter construct and an 876bp hTERC 
promoter construct indicated that tumour derived cell lines had higher activities for both 
promoters than two mortal foetal lung fibroblast cell strains or two telomerase negative 
ALT cell lines. Analysis of a larger panel of cell lines indicated that the promoters are not 
universally strong in cancer cell lines and that promoter activities of some human cancer 
cell lines more closely resemble those of ALT or mortal cells. The hTERC promoter was a 
stronger promoter than hTERT in all cell lines. These data validate the use of hTERC and 
hTERT promoter sequences in a transcriptionally directed cancer gene therapy strategy, 
but also suggest that not all cancer cells will necessarily be effectively targeted by 
cytotoxic genes under the control of these promoters. However, it might be possible to 
overcome possible problems arising from low level transgene expression in therapeutic 
models using hTERT promoter constructs with the use of the hTERC promoter.
3.2 Introduction
The hTERC component of telomerase is present at low levels in a number of tissues, 
including embryonic kidney cells and primary B-cells (Avilion et al. 1996), foetal lung and 
skin tissue, sinovial cells and adult prostate tissue, testis, ovary, brain, spleen, liver and 
kidney (Feng et al. 1995). However, strong up-regulation of hTERC expression in cancer 
has been documented in a number of studies. The levels of hTERC are elevated relative to 
normal tissue during colorectal carcinogenesis (Avilion et al. 1996; Yan et al. 2001) and 
during neuroblastoma progression (Reynolds et al. 1997). Additionally, up-regulation of 
hTERC has been described in cancer cell lines derived from breast, lung and colon cancers 
in addition to leukemia and melanoma cells (Feng et al. 1995; Avilion et al. 1996). In situ
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hybridisation analysis reveals strong hTERC signals concentrated over tumour cells in 
tissue sections, but not over adjacent normal tissue (Soder et al. 1998; Park et al. 1999).
Similarly, the hTERT component of telomerase, which is expressed at lower levels than 
hTERC, is up-regulated in cancer. Most studies of hTERT expression have utilised RT- 
PCR for the detection of hTERT mRNA. Up-regulation of hTERT relative to normal 
tissue has been described in every major human malignancy, including renal cell 
carcinoma (Paradis et al. 2001), oral squamous cell carcinomas (Kim et al. 2001) and 
squamous cell carcinomas of the lung (Shibuya et al. 2001). Immunohistochemical 
detection of hTERT was recently reported in a subset of cells in normal tissues, including 
keratinocytes, lymphocytes, mammary epithelial cells, basal cells of intestinal crypts and 
villi, and basal cells of the oesophageal mucosa. However, strong activity was detected 
specifically in cancer cells from tissue sections of a number of tumour types, including 
small cell lung cancer, non-small cell lung cancer, hepatocellular carcinoma, pancreatic 
duct cell carcinoma, and Wilms tumour (Hiyama et al. 2001).
Thus, both components of telomerase are expressed at low levels in some normal tissues, 
but are up-regulated in cancer. There is considerable evidence that the expression of 
hTERC and hTERT are regulated at a transcriptional level. Therefore, the promoter 
sequences of these genes are potentially useful for the development of transcriptionally 
directed cancer gene therapy strategies. The efficacy of such an approach will depend on a 
number of factors, including the capacity of promoter sequences to drive high level 
transgene expression in specific target cell populations. From this point of view the 
telomerase regulatory sequences are excellent candidates for novel transcriptional targeting 
approaches due to the prevalence and specificity of expression of the hTERC and hTERT 
components in cancer.
The ability of an 876 bp fragment of the hTERC promoter to drive high level expression 
of the luciferase gene in reporter constructs transfected into bladder carcinoma cells was 
previously described (Zhao et al. 1998). An hTERT promoter reporter containing a 541 bp 
fragment of the proximal hTERT promoter, characterised as a region of high activity 
containing a single c-Myc binding site and 5 SP1 binding sites (Cong et al. 1999; Takakura 
et al. 1999; Wick et al. 1999) has been subsequently generated. These plasmid vectors, 
together with a commercial SV40 promoter driven positive control plasmid, pGL3-control, 
and the promoter-less luciferase cloning vector pGL3-basic, were transiently transfected 
into a number of normal and cancer cell lines.
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A number of problems are associated with transient transfection systems for analysis of 
promoter regulation: firstly, within transfected cells, plasmids exist in an artificial 
configuration and copy number that can lead to aberrant function of control elements. 
Hundreds or thousands of plasmid molecules may enter a transfected cell while 
transcription factors may be present only in limited quantities. Thus, relatively few 
plasmids may actually associate with the full complement of factors necessary for normal 
promoter regulation. Moreover, the episomal and non-replicating nature of plasmids may 
lead to a loss of function resulting from the fact that the plasmids are not in an appropriate 
chromatin configuration.
The use of appropriate internal controls is considered to minimise some of the problems 
associated with transient transfection. Common methods used to normalise the results of 
transfection experiments include the use of protein equivalents or co-transfection with, and 
normalisation to, a second reporter such as the secreted form of human alkaline 
phosphatase (SEAP). A drawback to the use of this kind of internal control is that 
sequences in control viral promoter regions included in the internal control plasmid may 
compete for limiting transcription factors. Therefore, while a second reporter can be a 
useful control, it does not diminish the need for experimental repetition. Moreover, the 
activities of commonly used control promoters will vary across cell lines and, therefore, 
these are not good control assays across a range of cell lines. In this study, all experiments 
have been conducted at least three times, all transfections included positive (SV40 
promoter) and negative (no promoter) control luciferase reporter constructs, and assays 
both of protein equivalents and a second SV40-SEAP reporter activity have been evaluated 
as systems to minimise transfection artefacts. No significant differences were observed 
between patterns of activity of the promoter constructs within single cell lines whether 
protein equivalents or SEAP assay was used. Therefore, all data presented herein are the 
results obtained with 2.5pg protein equivalents. Additionally, a semi-quantitative PCR 
assay that compares the relative quantities of reporter gene in post-transfected nuclear 
extracts has been developed to allow for analysis of transfection efficiency across cell 
lines.
The data presented in this chapter show clear differences in the transcriptional activity of 
both hTERC and hTERT promoters between normal and cancer cell lines which may be of 
therapeutic value and, additionally, the hTERC promoter is demonstrated to be the stronger 
of the two, supporting the use of both sequences in further studies of telomerase directed 
gene therapy.
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3.3 Control experiments minimise issues of transfection 
efficiency
3.3.1 Development of a semi-quantitative PCR assay for 
transfection efficiency.
While co-transfection with a second reporter is a useful tool for normalisation of the 
activities of different transfected constructs within individual cell lines, the activities of 
commonly used control promoters, such as CMV or SV40, can vary between cell lines and, 
therefore, it is not an appropriate control for transfection efficiency between cell lines. 
During the exponential phase of PCR amplification, the amount of product formed is 
directly related to the amount of input DNA; this has been exploited recently for the 
development of quantitative real-time PCR systems based on measurements of 
fluorescence intensity. For this reason, it was decided that a semi-quantitative PCR assay 
for detection of the luciferase gene in genomic DNA extracts from post-transfected nuclei 
would give a reasonable indication of transfection efficiencies between cell lines. The use 
of this approach assumes the fulfilment of several key criteria: genomic DNA must be 
released with a similar efficiency from nuclear pellets of all samples; the assay must be 
genuinely semi-quantitative and therefore able to detect transfection of different amounts 
of input DNA; finally, detection must be within the exponential phase of the PCR 
amplification. Figures 3.1, 3.2 and 3.3 show the results of experiments designed to 
evaluate the validity of this assay based on these criteria.
Figure 3.1 shows an experiment designed to determine a cycle number at which detection 
of the luciferase gene in genomic DNA extracts from post-transfected nuclei would still be 
within the exponential phase of amplification: genomic DNA was released from post­
transfected nuclear pellets in 50pl of the PCR compatible cell lysis reagent “Lyse-n-go”, as 
described in materials and methods, lpl aliquots were amplified alongside high (10ng) and 
low (lOpg) concentrations of pGL3 control plasmid for 20-35 rounds of amplification. 
While the band intensities of the products of the high input concentrations of plasmid DNA 
appeared to plateau between 25 and 35 cycles, the low concentrations had not reached the 
plateau phase even after 35 cycles and the band intensities of the standards did not overlap 
at any cycle number. Samples of genomic DNA extracted from the nuclei of cells
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transfected with 3fig of luciferase positive control plasmid were amplified in parallel for 
25 cycles. The band intensities of these products were considerably less than those of the 
high concentration of standard at all cycle numbers and greater than those of the low 
concentration standard, except at the highest cycle number. Based on these results, an 
optimal cycle number of 25 cycles was selected for future experiments.
The next requirement that had to be satisfied was to ensure that genomic DNA containing 
tranfected luciferase plasmids could be extracted from the nuclear pellets of post­
transfected cells with a similar efficiency across all samples assuming standard 
transfection conditions. To this end, 11 samples were transfected with 3pg pGL3 plasmid 
and 48 hours later, samples were lysed according to the luciferase assay protocol. Nuclear 
pellets were spun down and DNA released into 50 pi Lyse-n-go. Reactions containing lpl 
nuclear extract were amplified for 25 cycles and the products were run out on an agarose 
gel. Figure 3.2 shows the similarity in band intensities of products of the reactions 
containing post-transfection nuclear extract, providing evidence that the DNA extraction 
protocol used in this assay can efficiently and consistently release DNA from the nuclei of 
multiple samples.
In figure 3.3, the semi-quantitative characteristics of the assay are evaluated: 5637 cells 
were transfected in duplicate with a titration of pGL3 control plasmid (either DNA with no 
transfection reagent, lanes 3 and 4; lOOng, lanes 5 and 7; 500ng, lanes 9 and 11; or 
2500ng, lanes 13 and 15). 48 hours later, genomic DNA was extracted from nuclear pellets 
and amplified. The increase in band intensity with increasing amounts of input DNA (lanes 
3, 4, 5, 7, 9, 11, 13, 15) indicated that the assay could detect relatively large differences in 
transfection efficiency. Loading controls are shown in the lower panel. As a control to 
prevent artefacts arising from the presence of DNA in transfection mixtures that may not 
have entered the cell, 2 wells were incubated in the presence of DNA but with no added 
transfection reagent (lanes 3 and 4). The absence of a band in these products indicated that 
the assay detected exclusively DNA that had been internalised. As an additional control to 
ensure that products were amplified from DNA extracted from the nuclear pellet, rather 
than contaminating DNA from the cytosolic supernatant, DNA was extracted from the 
cytosolic fractions of the lysate using the Qiaex II gel extraction kit and these extracts were 
subjected to amplification. The banding pattern in lanes 5-16 indicated that the majority of 
DNA in the samples was found in the nuclear DNA extracts, but small amounts could be 
extracted from the supernatant at higher transfected plasmid concentrations. That the 
clean-up removed PCR inhibitors is supported by the presence of a weak band in the
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supernatant sample in lane 18; no DNA was transfected in these cells, but the lysate was 
spiked with 50ng pGL3 control plasmid prior to the clean-up. These results indicated that 
PCR detection of luciferase could distinguish large differences in transfection efficiency 
and, together with the results in figure 3.land 3.2, suggested that the assay had a useful 
application as a part of a larger overall approach to minimising problems associated with 
transfection efficiency.
Figure 3.4 shows an example of the application of this assay to transfection experiments. 
Mean promoter activities of duplicate wells in this representative experiment in 5637 
bladder carcinoma, C33-A cervical carcinoma and A549 lung adenocarcinoma cells are 
shown in figure 3.4(a): in this experiment, 5637 cells had an hTERC promoter activity 
some 79 times greater than that of hTERT, while this value was 35 and 4 for A549 and 
C33-A cells, respectively. C33-A cells had the greatest hTERC and hTERT activity of all 3 
cell lines, approximately 30-fold greater than either 5637 or A549 for the hTERT promoter 
and approximately 1.8- and 4-fold greater than 5637 and A549, respectively, for the 
hTERC promoter. The figure also illustrates the variation which was observed for the 
SV40 promoter between cell lines, lending strength to the argument that co-transfection 
with a second reporter driven by a strong promoter such as SV40 is not an appropriate 
control for transfection efficiency between cell lines. In 5637 cells, the SV40 promoter was 
stronger than both hTERC and hTERT, while in A549 cells SV40 activity was greater than 
hTERT but of a similar level to hTERC. Lastly, in C33-A, both hTERC and hTERT 
promoters were stronger than the constitutively active SV40 promoter.
Figure 3.4 parts (b) and (c) illustrate the use of semi-quantitative detection of the luciferase 
gene in DNA extracted from post-transfected nuclei as a control for transfection efficiency: 
(b) shows that all luciferase band intensities, both within cell lines and between cell lines, 
were similar, while (c) shows the P-Actin loading control. The similarity of band 
intensities provides strong evidence that observed differences in promoter activities 
between cell lines were due to genuine, cell-specific regulation of promoter activity and 
not due to major differences in transfection efficiency. This approach was applied to all 
transfection experiments described in this chapter and all samples from all cell lines 
exhibited similar band intensities both within and between cell lines suggesting that 
transfection efficiencies were broadly similar between cell lines, with the exception of 
Colo320dm and BE cells which demonstrated average band intensities across samples of 
approximately 2-fold higher and lower, respectively, than other cell lines. The luciferase
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assay data for these 2 cell lines have not been modified, since the assay is not a direct 
measure of transfection efficiency.
3.4 Differential activities of the telomerase hTERC and 
hTERT promoters in normal and cancer cells.
3.4.1 The hTERC and hTERT promoters are more active in cancer 
cell lines than mortal and ALT cells
Since transcriptional regulation of telomerase genes has been proposed to be a major 
mechanism involved in the transition to an immortal phenotype in cancer progression, it is 
of considerable interest to begin to understand how hTERC and hTERT promoters 
function in normal and cancer cells. In order to directly compare differences in promoter 
activity between normal and cancer cell lines, a transient transfection approach was 
adopted: 3pg luciferase reporter plasmids containing fragments of either the hTERC or 
hTERT promoter were transfected into a panel of mortal and cancer cell lines. 3pg each of 
hTERC-luciferase, hTERT-luciferase, SV40-luciferase and a basic luciferase cloning 
vector lacking a promoter were transfected into each cell line used in each experiment. 
5637 cells were included in all experiments alongside other cell lines in order to ensure 
that relative differences in promoter activities observed between cell lines were repeatable. 
To control for possible differences in transfection efficiency of the different constructs 
within a single cell line a second reporter was employed, as described above, and to ensure 
observed differences between the luciferase activities of cancer and mortal cell lines tested 
were not due to differences in transfection efficiency across cell lines, a semi-quantitative 
PCR assay described above, was employed. Figures 3.5 and 3.6 show the summary of 
experimental data for the (a) hTERC and (b) hTERT promoters in mortal and cancer cell 
lines.
There is a clear differential in the activities of both promoters between normal and cancer 
cell lines, with hTERC promoter activities for the telomerase positive cancer cells 
illustrated in figure 3.5(a) lying in the range between 249.7 light units (5637 bladder 
carcinoma) and 2002.7 light units (A2780 ovarian adenocarcinoma). 2 other cell lines, 
Colo320dm (colorectal carcinoma) and GLC 4 (small cell lung cancer) had comparatively 
high promoter activities of 1957 and 1479 light units respectively, although it should be 
noted that luciferase specific semi-quantitative PCR detected a higher transfection
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efficiency in Colo320dm than in other cell lines. The mortal foetal lung fibroblast cell 
strains IMR90 (60.1 light units) and WI38 (6.1 light units) had low promoter activities 
within the ranges of 4.2-fold (smallest difference) to 33.4-fold (largest difference) lower 
than the cancer cell lines for IMR-90 and 40.8-fold (lowest) to 328-fold (highest) for WI- 
38. This gave a clear indication that the hTERC promoter is a valid target for therapeutic 
strategies.
The hTERT promoter (figure 3.5(b) was in all cases less active than hTERC, but the 
differential in activity could be considered to be more pronounced, in that the mortal 
fibroblast strains showed no luciferase activity above background light levels (0.7 light 
units for IMR-90 and 0.09 light units for WI-38). In contrast, the cancer cell lines had 
luciferase activities ranging from 29.3 light units (GLC4) to the extremely high activity of 
Colo320dm (833.6 light units). Again, it should be noted that Colo320dm had a higher 
transfection efficiency than other cell lines which had lower hTERT activities (41.2 light 
units for A2780 and 79.4 light units for C33a). The fold differences between mortal and 
cancer cell hTERT promoter activities could not be precisely quantified, as light units 
detected in the mortal cells were not above background and were not integers.
Although these experiments demonstrated a valid therapeutic window for the use of both 
telomerase promoters, the analysis of a larger panel of cancer cell lines, as shown in figure 
3.6, revealed a large variation in the capacity of these promoters to drive transgene 
expression between cancer cell lines. The hTERC promoter (figure 3.6(a)) was highly 
active in the 5 cell lines discussed above (5637; C33-A; A2780; Colo320dm; GLC4), but a 
subset of immortal cell lines displayed much lower activities more comparable with mortal 
cells. BE colon carcinoma cells and the ALT cell line SK-LU-1 had luciferase activities of 
0.2 (background levels) and 3.4 (approximately half that of the mortal strain WI-38), 
respectively, while 2 other telomerase positive cancer cell lines, A549 and HT-29, also had 
low activities of 69.6 light units and 83.5 light units respectively. Surprisingly, the ALT 
cell line SUSM-1, which has been shown to shut off hTERC promoter activity by 
methylation (Hoare et al. 2001), showed a low to moderate activity of 143 light units, 
suggesting that transient transgene expression from the exogenously introduced hTERC 
promoter is possible in this cell line.
As shown in figure 3.6(b), 5637 cells, which had a moderate activity for the hTERC 
promoter had very low hTERT activity (4 light units), as did A549 (2.9 light units), HT-29 
(2.1 light units), SUSM-1 (2.7 light units) and BE (background levels). These levels of
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activity were within the range of 7- to 397-fold lower than the highly active cancer cell 
lines and, therefore, were more similar to the activities of mortal cell strains. This suggests 
that strategies for cytotoxic transgene expression based exclusively around the hTERT 
promoter may be limited in the range of cells that can be efficaciously targeted and 
suggests a role for use of the hTERC promoter in circumstances where hTERT cannot 
effectively target expression.
2.4.2 The hTERC promoter is more active than hTERT in cancer 
cell lines
Figure 3.7 shows a summary of the activities of the hTERT promoter relative to hTERC 
derived from 3 independent experiments across the cell lines in this model. Although a 
relative figure could not be quantified in those 4 cell lines (WI-38, IMR-90, BE, SK-LU-1) 
which had only background levels of hTERT promoter activity, the remaining 9 immortal 
cell lines all had high hTERC activity which ranged from 2.9-fold (colo320dm) to 66.8- 
fold (5637) greater than hTERT. Most cell lines had an hTERC:hTERT ratio in the range 
of approximately 20- to 40-fold difference (HT-29, 24.9-fold; A549, 28-fold; A2780, 32.6- 
fold; GLC4, 34.8-fold; SUSM-1, 43-fold, in ascending order) but colo320, C33-A and 
SuSa cells all had hTERT activities comparable to hTERC (2.9-fold, 4.1-fold and 5.7-fold 
respectively). The range of activities between these two promoters suggests that the 
hTERC promoter drives higher level expression of transgenes than the hTERT promoter 
and may therefore ultimately prove more useful than hTERT for particular therapeutic 
settings.
Thus, not only is the hTERC promoter validated for use in transcriptionally based 
therapeutics, but the probability arises that exclusive use of the hTERT promoter in 
telomerase gene therapy may limit the target range to exceptionally highly TERT 
expressing tumour cells. Therefore, the development of a double-edged system using both 
hTERC and hTERT promoters allows an element of choice and may be preferable to a 
strategy based upon a single expression construct.
3.5 Discussion
The data presented here show large differences in the activity of both the hTERC and 
hTERT promoters between mortal and cancer cells. These data are consistent with the idea 
that the components of telomerase are differentially regulated at a transcriptional level
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between mortal and cancer cells and lend weight to the argument that these promoters may 
prove useful for transcriptionally directed anticancer gene therapy strategies. Both hTERT 
and hTERC were stronger promoters in cancer cells than in normal cells, with fold 
differences in activity between mortal and cancer cells of up to 328-fold for the hTERC 
promoter while effectively no hTERT activity was detected in mortal cell strains. These 
differences were not the result of large differences in transfection efficiency (as assayed by 
semi-quantitative PCR) but, rather, reflected cell specific regulation of the activity of the 
hTERC and hTERT promoters.
The hTERC and hTERT promoters are not universally strong promoters in cancer cell 
lines. Analysis of 13 cancer, ALT and mortal cell strains revealed a range of activity 
within cancer cell lines which are likely to be the result of regulation by undefined cell 
specific factors. Interestingly, A549 lung adenocarcinoma cells have previously been 
shown to give rise to mortal subpopulations with no detectable telomerase activity when 
plated out as single cells (Katakura et al. 1997), suggesting that a fraction of these cells 
may have no promoter activity, thereby masking the activity of positive cells in 
transfection experiments.
The relationship between telomerase holoenzyme activity and transcriptional regulation of 
telomerase components is not absolute: numerous other post-transcriptional and post- 
translational regulatory mechanisms such as alternative splicing (Kilian et al. 1997; Ulaner 
et al. 2000) phosphorylation (Li et al. 1997; Li et al. 1998; Yu et al. 2001), the action of 
hsp90 and p23 chaperone proteins (Holt et al. 1999; Akalin et al. 2001), hTERT 
multimerisation (Beattie et al. 2001), and telomere capping status (reviewed in Blackburn 
2001) may modulate enzyme activity. Therefore, low telomerase activity detected by 
TRAP assay does not necessarily preclude the use of transcriptionally directed gene 
therapy against telomerase positive cancer cell lines. An essential component of 
efficacious gene therapy systems, however, is the ability to drive high level transgene 
expression in a target cell population. An interesting outcome of this study, therefore is the 
observation that the hTERC promoter can consistently drive higher level luciferase 
expression than hTERT.
Figure 3.1: Determination of cycle number for semi-quantitative PCR amplification of the 
luciferase gene from post-transfected nuclear extracts.
PCR reactions containing either water (lane 1), lOng or lOpg (lanes 2-9) o f pGL3control plasmid were 
allowed to proceed for 20 cycles (lanes 2 and 3), 25 cycles (lanes 4 and 5), 30 cycles (lanes 6 and 7), or 35 
cycles (lanes 8 and 9). In parallel, reactions containing lp l nuclear DNA extract from 5637 cells transfected 
with 3pig pGL3control, as described in materials and methods, were amplified for 25 cycles. Relative band 
intensities of the 2 control standards and the transfected samples at 25 cycles confirmed that the detection 
was still within the exponential phase of amplification. Experiments were repeated 3 times. The figure shows 
a representative gel.
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Figure 3.2: Validation of the equal efficiency of the DNA extraction protocol between 
samples for semi-quantitative PCR.
5637 cells were transfected with 3|ig pGL3 plasmid DNA and 48 hours later, cells were lysed according to 
the luciferase assay protocol. Nuclear pellets were collected and DNA was extracted in 50pl “lyse-n-go”. 1 pil 
aliquots were amplified for 25 cycles. The similarity in band intensities in lanes 3-13 indicated that the DNA 
procedure was of similar efficiency across multiple samples.
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Figure 3.3: Semi-quantitative PCR detection of luciferase gene in post-transfected nuclear 
extracts detects a titration of transfected DNA.
5637 cells were transfected with a titration o f pGL3control plasmid (transfection reagent with either no DNA, 
lOOng, 500ng, or 2500ng) and 48 hours later cells were lysed according to the luciferase assay protocol, 
genomic DNA was extracted from nuclear pellets and lp l extract was amplified for 25 cycles (lanes 3, 4, 5, 
7, 9, 11, 13, 15). Increasing band intensities with increasing input DNA confirmed the semi-quantitative 
nature of the assay. To ensure that the reaction primarily detected DNA extracted from nuclei, the cytosolic 
(protein) supernatant fraction was cleaned with the QiaEx II gel extraction kit and the cleaned samples were 
subjected to amplification (lanes 6, 8, 10, 12, 14, 16). Spiking the cytosolic fraction o f one o f the 
untransfected samples with 50 ng plasmid DNA prior to clean-up (lane 18) revealed a weak band, confirming 
that the cleaning process removed any PCR inhibitors. Detection o f the (3-Actin gene revealed similar 
quantities o f genomic DNA in all samples. Experiments were repeated 3 times. The figure shows a 
representative gel.
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Figure 3.4: Semi-quantitative detection of luciferase gene in post-transfected nuclear 
extracts reveals similar transfection efficiency between cell lines.
(a) shows the results o f a single luciferase assay in 5637 bladder carcinoma, C33-A cervical carcinoma, and 
A549 lung adenocarcinoma cells. Cells were transfected in duplicate with each o f hTERC-and hTERT- 
luciferase in addition to SV40-luciferase and a basic, promoter-less vector. Bars represent the mean and 
standard error o f the duplicates, (b) shows the detection o f luciferase gene from post-transfected nuclear 
extracts. Lanes 1-10 are 5637 cells, lanes 11-20 are C-33A cells and lanes 21-30 are A549 cells. Lanes 31 
and 32 are no template and lOng plasmid DNA controls. Lanes 1,2,11,12,21,22 are extracts from cells 
transfected with hTERC-luciferase; extracts from lanes 3,4,13,14,23,24 were transfected with hTERT- 
luciferase, while the cell extracts in lanes 5,6,15,16,25,26 and 7,8,17,18,27,28, respectively, were transfected 
with SV40-luciferase and the basic vector. Cells whose extracts are shown in the empty lanes 
9,10,19,20,29,30 were incubated with DNA but no transfection reagent. The similarities in band intensity, 
both for different constructs within a single cell line and for constructs between cell lines, suggests that the 
observed differences in light units in the luciferase assay reflect genuine cell-specific differences in promoter 
activity and not large differences in transfection efficiency, (c) shows the control detection of P-actin. Lane 
numbers are identical to those in (b).
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Activities of the hTERC, hTERT and SV40 promoters in 3 cancer cell lines
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Figure 3.5: Differential activities of the hTERC and hTERT promoters between mortal and 
cancer cell lines.
C ells w ere transfec ted  in duplicate  w ith  3 p g  p lasm id  D N A  con ta in ing  the luciferase gene  under the con tro l o f
(a) hT E R C  or (b) hT E R T  prom oters and incubated  for 48h. C ells w ere lysed and 2 .5 p g  pro tein  equ ivalen ts 
w ere ca lcu la ted  using  B io-R ad  p ro tein  assay reagent. R elative light un its in 2 .5  p g  eq u iv a len ts  w ere 
quan tified  in a lum inom eter (T u rner D esigns T X 20 /20 ) fo r each o f 5637  b ladder carc inom a, C 33-A  cerv ical 
ca rc inom a, A 2780 ovarian  adenocarc inom a, C olo  320dm  colorectal adenocarc inom a, G L C 4 sm all cell lung 
cancer, W I-38  and IM R -90 foetal lung fib rob last cells. A ll experim en ts w ere repeated  at least 3 tim es and 
included  positive (S V 40) and negative (p rom o terless) contro l luciferase plasm ids. R esu lts show n are from  a 
rep resen ta tive  experim en t fo r each cell line. 5637  cells w ere included  in each experim en t as a con tro l fo r 
re la tive p rom o ter ac tiv ities be tw een  cell lines. T ransfection  effic iencies w ere checked  by sem i-quan tita tive  
PCR.
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Figure 3.6: hTERC and hTERT promoters are not universally strong in cancer cell lines.
Cells were transfected in duplicate with 3^ig plasmid DNA containing the luciferase gene under the 
control of (a) hTERC or (b) hTERT promoters and incubated for 48h. Cells were lysed and 2.5fxg 
protein equivalents were calculated using Bio-Rad protein assay reagent. Relative light units of 
2.5pig equivalents were quantified in a lum inometer (Turner Designs TX20/20) fo r each of the 
cancer cell lines 5637 bladder carcinoma, C33-A cervical carcinoma, A2780 ovarian 
adenocarcinoma, Colo 320dm colorectal adenocarcinoma, GLC4 small cell lung cancer, A549 lung 
adenocarcinoma, SuSa testicular teratoma, HT-29 and BE colon carcinoma. Additionally, the 
mortal cell strains W I-38 and IMR-90 foetal lung fibroblast cells and the immortal, telomerase 
negative ALT cell lines SK-LU-1 and SUSM-1 were assayed. All experim ents were repeated at 
least 3 times and included positive (SV40) and negative (promoter-less) control luciferase 
plasmids. Results shown are from  a representative experim ent for each cell line. 5637 cells were 
included in each experim ent as a control fo r relative promoter activities between cell lines. 
Transfection efficiencies were checked by sem i-quantitative PCR.
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RELATIVE ACTIVITIES OF hTERC AND hTERT 
PROMOTERS IN CANCER CELL LINES
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Figure 3.7: The hTERC promoter is stronger than hTERT.
Cells were transfected in duplicate with 3pg plasmid DNA containing the luciferase gene under the control o f  
hTERC or hTERT promoters and incubated for 48h. Cells were lysed and 2.5 pg protein equivalents were 
calculated using Bio-Rad protein assay reagent. Relative light units of 2.5 pg equivalents were quantified in a 
luminometer (Turner Designs TX20/20) for each of the cancer cell lines 5637 bladder carcinoma, C33-A  
cervical carcinoma, A2780 ovarian adenocarcinoma, Colo 320dm colorectal adenocarcinoma, GLC4 small 
cell lung cancer, A549 lung adenocarcinoma, SuSa testicular teratoma, HT-29 colon carcinoma and the 
telomerase negative ALT cell line SUSM-1 were assayed. All experiments were repeated at least 3 times and 
included positive (SV40) and negative (promoterless) control luciferase plasmids. Relative activities of the 
promoters were taken to be the fold difference in light units between the promoters in an individual 
experiment. Results shown are the mean values and standard errors calculated across 3 independent 
experiments for each cell line. Relative values could not be calculated for the cells with only background 
hTERT activity (WI-38, IMR-90, SK-LU-1, and BE). 5637 cells were included in each experiment as a 
control for relative promoter activities between cell lines. Transfection efficiencies were checked by semi- 
quantitative PCR.
CHAPTER 4
DEVELOPMENT OF A TISSUE CULTURE 
MODEL OF hTERC AND hTERT 
DIRECTED ENZYME/PRO-DRUG 
THERAPY USING THE BACTERIAL 
NITROREDUCTASE GENE
• Development of hTERC-NTR and hTERT-NTR gene 
therapy plasmids.
• Generation of stable cell lines harbouring gene 
therapy plasmids.
• Promoter dependent sensitisation to CB1954.
• hTERC-NTR and hTERT-NTR sensitise human 
cancer cells to CB1954 in vivo.
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4 Development of a tissue culture model of hTERT 
and hTERC directed enzyme pro-drug therapy 
using the bacterial nitroreductase gene.
4.1 Abstract
In order to directly address the question whether hTERC and hTERT promoter sequences 
can drive sufficient expression of a therapeutic transgene within cancer cells to validate 
their use in a pre-clinical model of telomerase gene targeted therapy, nine sets of stable cell 
lines harbouring hTERC-NTR and hTERT-NTR plasmids were generated. Cell lines were 
selected on the basis of promoter activities measured by luciferase assay. Expression of 
bacterial nitroreductase was analysed by northern and western blotting in promoter-less, 
CMV-NTR, hTERC-NTR and hTERT-NTR stable cell lines, and the relative efficiency of 
sensitisation to the pro-drug CB1954 by hTERC and hTERT promoter mediated 
expression of bacterial nitroreductase was analysed by MTT assay. Results were compared 
both within and between sets of stable cell lines. Analysis of the fold sensitisation to 
CB1954 by hTERC-NTR and hTERT-NTR expression, across all sets of stables, revealed 
that the cell lines fell into two main groups: those cell lines that were significantly 
sensitised to pro-drug and those that were not. The four cancer cell lines selected for their 
high hTERC and hTERT promoter activities were all significantly sensitised to CB1954, 
as expected, while the other cell lines assayed did not exhibit more than 2-fold 
sensitisation which was not considered significant. Thus, hTERC and hTERT promoter 
activities are predictive of the efficiency of cell killing by hTERC-NTR and hTERT-NTR 
expression combined with CB1954 treatment, and only cell lines with highly active 
hTERC and hTERT promoters are effectively targeted by the approach. These data 
validate the use of hTERC and hTERT promoter sequences for use in combination with the 
NTR/CB1954 suicide gene therapy system.
4.2 Introduction
Cancer therapies are often limited in their efficacy due to a variety of factors. Poor 
circulation and hypoxic non-dividing cell populations within large solid tumours are major 
obstacles to effective chemo- and radiotherapy (reviewed in Brown et al. 1998).
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Additionally, the mechanisms of action of many of the classical chemotherapeutic drugs 
such as alkylating agents, platinating agents, and anti-metabolites are targeted to cellular 
events such as DNA replication that are characteristic of dividing cells, not of tumour cells. 
This often can result in an inability to distinguish tumour cells and rapidly proliferating 
normal cells leading to dose limiting toxicity. Strategies to overcome this have included 
combinatorial treatment regimes in which several cytotoxic agents with different modes of 
action are administered concurrently to increase the overall concentrations of cytotoxic 
drug. However, dose-limiting toxicity still represents a major problem which gene 
therapists hope to overcome by the use of tumour restricted cytotoxic gene therapy. In 
genetically directed enzyme/pro-drug therapies (GDEPT), researchers seek to limit to 
target cell populations the expression of an enzyme whose action is the conversion of a 
relatively non-toxic pro-drug to an active, toxic derivative. These systems were first 
pioneered by the use of the Herpes Simplex Thymidine Kinase gene (HSTK) which 
catalyses the mono-phosphorylation of the guanylate analogue Gancyclovir (GCV). GCV- 
MP can be further phosphorylated to di- and tri-phosphate forms by cellular kinases and 
can then be incorporated into newly synthesised DNA strands. GCV-TP lacks the 3’OH on 
the deoxyribose and 2’C-3’C bond necessary for DNA chain elongation and thereby acts to 
terminate chain extension.
Although HSTK/GCV is in many ways the paradigm for GDEPT, a number of other 
enzyme pro-drug activation systems have been proposed. An attractive system is bacterial 
nitroreductase/CB1954. CB1954 (5-Aziridin-l-yl 2,4-dinitrobenzamide (fig 4.1)) is a weak 
mono-functional alkylating agent that first aroused interest as a potential anti-cancer agent 
on the basis of its effectiveness against the rat Walker tumour (Cobb et al. 1969). 
Subsequent investigations failed to detect such an effect in human tumours and cell lines 
and CB1954 was not considered an appropriate anti-cancer agent until the elucidation of 
the mechanism of its efficacy against the Walker tumour (Knox et al. 1988). These cells 
express an enzyme, DT-Diaphorase which can catalyse the reduction of the 4-nitro 
function of CB1954 to a hydroxlamino derivative which is subsequently acylated in an 
interaction with cellular thioesters to form a powerful bifunctional alkylating agent which 
introduces a high frequency of poorly repaired inter- and intra-strand cross-links into DNA 
(Knox et al. 1991; Friedlos et al. 1992; Knox et al. 1992). The aziridine function of 
CB1954 interacts with the 06 position of deoxyguanine, allowing the activated 
hydroxylamino moiety to interact with a C8 position of deoxyguanine on the opposite 
strand. The human and mouse homologues of DT-Diaphorase possess an inactivating 
Tyrosine to Glutamine mutation at amino acid 104 (Chen et al. 1995). Tissue culture
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assays using human cells with enzyme activity comparable to Walker cells required 
approximately 500-5000-fold higher concentrations of CB1954 to elicit similar cytotoxic 
effects. Moreover, the Kcat value for reduction of the 4-amino group by the rat enzyme was 
shown to be around 6-fold higher than for the human, indicating that the human enzyme is 
less efficient than the rat at the bioactivation of CB1954 (Boland et al. 1991). The 
identification of bacterial nitroreductase as a functional homologue of the rat enzyme has 
renewed interest in the use of CB1954 as part of a GDEPT strategy utilising bacterial 
nitroreductase as the activating enzyme.
In vivo, nitroreductase functions as a homodimer that is complexed with an internal 
molecule of flavin mononucleotide (FMN) which functions as an electron donor in the 2- 
step bio-activation of CB1954 (Parkinson et al. 2000). The system offers a number of 
advantages over the more common systems HSTK/GCV and COD/5-FC. Firstly, bio­
activated CB1954 induces a p53 independent apoptotic response that leads to widespread 
toxicity in both dividing and non-dividing cells (Bridgewater et al. 1995; Weedon et al.
2000). Thus, the system is not limited in its effect to cells that are actively cycling, as is the 
case with HSTK/GCV. Second, the formation of the ultimate cytotoxic species does not 
appear to require the involvement of other cellular enzymes, and hence, the kinetic 
bottleneck that has been proposed to limit the efficacy of HSTK/GCV therapy does not 
occur (Knox et al. 1991; Akyurek et al. 2001). Thirdly, the active species is membrane 
permeable and induced a strong bystander effect in cells that were not transduced with 
enzyme (Bridgewater et al. 1997). The importance of a bystander effect to target 
untransduced neighbouring cells is paramount to the development of these systems as 
genuine therapeutic tools and from this point of view, NTR/CB1954 is an excellent 
candidate for development. Indeed, a recent study which compared directly the 
cytotoxicity and bystander effects of 4 enzyme/pro-drug systems in proliferating thyroid 
carcinoma cells concluded that the bystander effect induced by CB1954 was superior to 
that of GCV (Nishihara et al. 1998). Additionally, the pro-drug CB1954 and its derivatives 
are radio-sensitising agents (Walling et al. 1987), which may enable the development of 
combinatorial therapies. Lastly, CB1954 is one of many drugs which can be activated by 
NTR, suggesting that different drugs may be employed in order to overcome any inherent 
cellular resistance to activated CB1954 derivatives, thereby enhancing the versatility of 
nitroreductase expression systems for GDEPT (Bailey et al. 1996).
NTR has been delivered to human tumour cell lines by stable and transient transfection, in 
retrovirus vectors and, most recently, in an adenoviral vector (Bridgewater et al. 1995;
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Drabek et al. 1997; Green et al. 1997; McNeish et al. 1998; Weedon et al. 2000). An 
efficacious effect has been documented against tumour cells derived from human ovarian, 
pancreatic, colorectal, cervical and small cell lung cancers both in vitro and in vivo 
(Bridgewater et al. 1995; Drabek et al. 1997; Green et al. 1997; McNeish et al. 1998; 
Weedon et al. 2000). Moreover, CB1954 has already been evaluated in clinical trials as a 
potential anti-cancer agent and the drug is well tolerated at comparatively high doses in 
humans. In a recent phase I study of CB1954 as a single agent, investigators were able to 
administer intravenous doses of up to 24 mg/m2 before any significant toxicity was 
observed. Peak serum levels of CB1954 were judged to be sufficient to allow conversion to 
the active species to occur (Chung-Faye et al. 2001).
Transcriptional restriction of expression of NTR has been accomplished using hTERC and 
hTERT promoters in a panel of cell lines having high and low promoter activities (Plumb 
et al). In this chapter, NTR/CB1954 is evaluated as a candidate enzyme/pro-drug therapy 
system for transcriptional restriction by the hTERC and hTERT promoters in stable cell 
line models. Nitroreductase expression constructs with the NTR gene under the control of 
hTERC, hTERT, or CMV promoters, or in basic promoter-less vectors, are stably 
introduced into a panel of 9 cell lines whose promoter activities have been characterised by 
luciferase assay in chapter 3. Cancer cell-specific, promoter dependent regulation of 
expression of NTR limits the cytotoxic effects of CB1954 to those cell lines that had a high 
promoter activity, leaving the cells with low promoter activities broadly unaffected. 
Transcriptional restriction of NTR expression with hTERC and hTERT promoters is 
thereby validated as a potentially useful targeted approach to the cytotoxic gene therapy of 
cancer cells.
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Figure 4.1: Mechanism of bioactivation of CB1954 by bacterial nitroreductase.
The reduction  o f  the 4-am ino  group to a reactive 4-hydroxylam ino in term ediate p recedes acy lation  by 
endogenous th ioesters. The acyla ted  species is a pow erful b ifunctional a lkylating  agent able to induce a high 
frequency o f  poorly  repaired  inter-strand crosslinks betw een deoxyguanine nucleotides. Both 4- 
hydroxylam ino and 2-hydroxylam ino  derivatives are generated  in the first reaction , but only the 4- 
hydroxylam ino  goes on to fom i the ultim ate cytotoxic species (K nox, 1991).
Alan E. Bilsland, 2002 Chapter 4: A model of telomease gene therapy 108
4.3 Development of telomerase-nitroreductase plasmid 
vectors.
A family of plasmid vectors containing the NTR coding sequence under the control of 
either CMV, hTERC, hTERT promoters, or in a basic promoter-less construct were 
developed within the laboratory by Rania Kakani (Plumb et al). Vector feature maps are 
given in figure 4.2. Each vector contained the Kanamycin/ Neomycin resistance gene to 
enable the development of stable cell lines. The purpose of vector construction was to 
enable nitroreductase to be expressed by the telomerase promoters or by the CMV 
promoter in stable cell lines, thereby allowing direct comparisons between the capacity of 
each promoter to drive enzyme expression and sensitise cells to the toxic effects of 
activated CB1954.
PLASMID NAME PROMOTER DESCRIPTION
Pd2NTR-Basic None Basic, cloning vector for generation o f CMV, hTERC and 
hTERT gene therapy vectors. Contains nitroreductase gene. 
Negative control for stable transfection experiments.
Pd2NTR-CMV CMV Contains nitroreductase gene driven by CMV promoter and 
enhancer sequences. Positive control for stable transfection 
experiments.
Pd2NTR-hTERC hTERC Contains nitroreductase gene driven by 876bp fragment o f the 
hTERC promoter. Telomerase gene therapy vector.
Pd2NTR-hTERT hTERT Contains nitroreductase gene driven by 541bp fragment o f the 
hTERT promoter. Telomerase gene therapy vector.
Table 4.4.1: Characteristics of nitroreductase gene therapy vectors.
A description of the construction o f the vectors is given in materials and methods. Vectors were used for the 
development of stable cell lines to enable direct comparisons of the expression of NTR from each promoter 
in a number of cell lines and its effects on sensitisation o f cells to the toxic effects of activated CB1954.
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4.4 Selection and characterisation of stable cell lines 
harbouring nitroreductase gene therapy vectors.
In order to assess the validity of a cytotoxic gene therapy approach using the telomerase 
promoters to drive expression of bacterial nitroreductase, the plasmid vectors described in 
table 4.1 were stably transfected into a range of cell lines. Using superfect transfection 
reagent, 106 cells were transfected in 10cm dishes with 10pg plasmid DNA for each 
plasmid. 48 hours after transfection, cells were selected in 1 mg/ml geneticin-sulphate for 
approximately 2 weeks until the appearance of stable foci. At this point, stable clones were 
pooled and each culture was expanded under selection to give a final total of 4 sets of 
stable pools of clones (basic, CMV, hTERC and hTERT nitroreductase clones) for each of 
9 parental cell lines (5637, C33-A, A2780, GLC4, Colo320dm, A549, HT29, SUSM-1, 
SK-LU-1) (5637, C33-A and A2780 clones generated by Rania Kakani (Plumb et al.
2001)). Due to the limited proliferative lifespan of WI-38 and IMR-90 cells, these could 
not be selected as stables. However, since the results of transfection assays (Chapter 3) 
suggest that the two telomerase negative ALT cells lines (SK-LU-1 and SUSM-1) have 
promoter activities comparable with those of the normal diploid fibroblasts, these have 
been selected for use as surrogate negative control cell lines.
To ensure that nitroreductase was expressed in stable pools and that expression followed 
the expected promoter dependent pattern, each pool was analysed by Northern and 
Western blotting for nitroreductase. The results of Northern blots using 25 pg total RNA 
from each stable pool to detect the nitroreductase transcript are given in figure 4.3. Signals 
consistent with the expected transcript size of approximately lkb were detected in lanes 
corresponding to hTERC-NTR, hTERT-NTR, and CMV-NTR transfected cells. As 
expected, none of the lanes containing RNA extracted from the Basic pools in any cell line 
showed a signal for NTR mRNA. Figure 4.4 shows the detection of a protein species 
consistent with the expected molecular weight of NTR of 24kDa using Western blotting. 
Relative band intensities for individual lanes were comparable in both Northern and 
Western blots.
In the majority of cell lines, the strongest signal was detected in the lane corresponding to 
NTR expressed from the CMV promoter with the hTERC and hTERT promoters giving 
signals of a similar and lower intensity, although hTERC was usually stronger than hTERT 
(5637, C33a, SK-LU-1, A2780). Notable exceptions were A549 cells, which had the 
strongest signal in tthe lane corresponding to the hTERC promoter, with barely detectable
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signal for the CMV and undetectable signal for hTERT. A2780 stable cell lines, despite 
showing high activity of both hTERC and hTERT promoters in transient transfection 
analysis had a low proportion of NTR mRNA relative to total steady state mRNA 
compared with other cell lines. Surprisingly, the NTR signal for the Colo320dm hTERC 
stable pool was of a low intensity compared with hTERT; additionally, hTERT was more 
intense than the CMV signal in this cell line.
4.5 Cancer cell specific, promoter dependent cell killing 
after treatment with CB1954.
The use of stable pools of clones allows for direct comparisons to be made regarding the 
effects of expression of a pro-drug converting enzyme on sensitisation to the pro-drug 
between a number of cell lines. Analysis of cytotoxic cell responses to the pro-drug 
CB1954 was performed by MTT assay in triplicate for each promoter. Cytotoxicity data 
were analysed using Softmax 2.32 analysis software and IC50 values for independent 
experiments were calculated from the mean value of triplicate measurements of the 50% y- 
axis intercept. Table 4.2 gives mean IC50 values for CB1954 sensitivity for cells 
transfected with various promoter-nitroreductase combinations derived from 3 independent 
experiments and Figures 4.5 and 4.6 show representative cytotoxicity curves for sets of 
basic, CMV, hTERC and hTERT clones in each of 5637, HT-29, SUSM-1, SK-LU-1, 
A549, C33a, A2780, GLC4, and Colo320dm. All cell lines were assayed at least 3 times. 
Figures presented are representative curves.
Patterns of sensitisation to CB1954 broadly followed patterns of promoter activity 
described in chapter 3 and were strongly correlated with the results of Northern and 
Western analysis presented in figures 4.3 and 4.4. Analysis of cytotoxicity data revealed 2 
types of response, cell lines that did not respond to CB1954 by NTR expression from the 
hTERC and hTERT promoters (figure 4.5) and cell lines that had a high response (figure 
4.6). The cell lines which had low hTERC and hTERT promoter activities in luciferase 
assays, including 5637, HT29, SK-LU-1 and SUSM-1, did not exhibit significant 
differences between the cytotoxicity curves for the basic promoter-less vector and for those 
containing NTR driven by either hTERC or hTERT. In each of these cases, Northern 
analysis revealed higher intensity signals in the lanes for the CMV promoter and, in­
keeping with this, cytotoxicity curves for the CMV promoters were generally significantly 
different from those of the other promoters.
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The IC50 for the basic promoter in 5637 cells was 171.23pM, while IC50 values for the 
other promoters were 115.55pM (CMV), 110.73pM (hTERC) and 149.03pM (hTERT). 
Therefore, there was no significant sensitisation to CB1954 by expression of nitroreductase 
from any of the promoters and this is reflected in the pattern of the kill curve (Figure 4.5) 
in which the curves for all promoters are tightly packed together. HT29 cells were also not 
significantly sensitised by any promoter, with the largest shift in IC50 being approximately 
2-fold between the basic (227.6 pM) and CMV promoters (109.26).
The remaining cell lines in the group which did not respond to hTERC-NTR or hTERT- 
NTR / CB1954 treatment (SUSM-1 and SK-LU-1) were all sensitised to CB1954 by NTR 
expression under control of the CMV promoter, suggesting that the hTERC and hTERT 
promoters could not drive expression of sufficient levels of nitroreductase to efficiently 
sensitise these cells. Examination of the kill curves for these 2 ALT cell lines show clear 
shifts toward lower drug concentrations for the CMV promoter, but not for either 
telomerase promoter. This is reflected in IC50 values for each promoter. SUSM-1 cells had 
a mean IC50 for the basic construct of 264.77pM, but only 72.48 pM for the CMV, 
reflecting an approximately 4-fold sensitisation. Values for hTERC and hTERT were 
177.77 pM and 130.82 pM, respectively, indicating approximately 2-fold sensitisation, 
which was not considered to be significant. Similarly, SK-LU-1 cells showed an 
approximately 8-fold shift in IC50 between basic (120. lpM) and CMV (14.99pM) 
constructs, but did not display more than 2-fold sensitisation by hTERC (61.81pM) or 
hTERT (70.93 pM).
4 cancer cell lines, all of which had high promoter activities in luciferase assays (C33-A, 
GLC4, A2780, Colo320dm) showed strong responses to CB1954 both when nitroreductase 
was expressed from the CMV promoter, or from either hTERC or hTERT (figure 4.6). 
C33-A cells had a basic IC50 value of 96.06pM that shifted to 2.01 pM for the CMV 
promoter (approximately 45-fold sensitisation), 15.19pM for the hTERC (approximately 
6-fold sensitisation) and 8.59pM for hTERT (approximately 11-fold). Similarly, 
Colo320dm exhibited marked shifts toward lower CB1954 concentrations when NTR was 
transfected in the basic construct (191.42pM), under control of the CMV promoter 
(7.1pM), the hTERC promoter (23.77pM) or of hTERT (13.86pM). These patterns are 
reflected in the shifted curves evident in figure 4.6.
The remaining 2 cell lines in this group, A2780 and GLC4 had lower basic IC50 values 
than any of the other cell lines tested (25.76pM for A2780 and 4.66pM for GLC4), but the
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expression of NTR from the telomerase promoters could still induce a marked sensitisation 
to the pro-drug. A2780 cell IC50 values shifted to 1.26pM for the hTERC promoter and 
5.2pM for hTERT, while GLC4 cells had IC50 values of less than lpM  for both 
telomerase promoters (0.53pM, hTERC; 0.68pM, hTERT). These results indicated that the 
expression of nitroreductase from the hTERC and hTERT promoters could sensitise cell 
lines to the cytotoxic effect of bioactivated CB1954 in a manner that was dependent on the 
level of NTR expression and, therefore, on promoter activity.
Interestingly, A549 cells showed no significant sensitisation to CB1954 by either hTERT 
or CMV promoters, although the hTERC promoter had a strong effect in these cells, 
lending strength to the argument that the hTERC promoter may provide a useful target in 
cases where the hTERT promoter is too weak to drive effective transgene expression in 
specific cells or disease types.
Figure 4.7 gives the summary of sensitisation data for hTERC-NTR and hTERT-NTR 
constructs across the cell lines assayed. Sensitisation values are derived from the fold 
difference between IC50 values for the basic, promoter-less vector and for those in which 
NTR expression is driven by a promoter. Mean values and standard errors were calculated 
from 3 independent experiments in each case. As described above, the cell lines fall into 2 
groups, arranged broadly along the lines of promoter activities detected by luciferase assay 
(chapter 3): those which are significantly sensitised to the effects of CB1954 by expression 
of NTR from hTERC and hTERT promoters (cancer cell lines with strong hTERC and 
hTERT activities), and those which were not (ALT cell lines and cancer cells with low 
hTERC and hTERT activities).
None of the cell lines with low promoter activity (HT29, SK-LU-1, SUSM-1, 5637) 
showed more than 2-fold sensitisation to CB1954 after stable transfection with the 
hTERC-NTR construct. The range in sensitisation was 1.07-fold (HT29) to 1.92-fold (SK- 
LU-1). Therefore, the hTERC promoter did not drive sufficient NTR expression to 
significantly sensitise these cells to CB1954. Similarly, the hTERT promoter showed no 
significant effect on this group of cell, with sensitisation values for all cell lines in the 
range 0.94-fold (HT-29) and 2.11-fold (SUSM-1). These data strongly suggested that the 
low capacity for transgene expression from telomerase promoters in these cell lines 
detected by luciferase assay in chapter 3 limited the expression of nitroreductase and, 
therefore, the bioactivation and associated toxicity of CB1954.
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In contrast, those cell lines shown to have a high promoter activity in chapter 3 (A2780, 
C33-A, GLC4, Colo320dm) all demonstrated strong sensitisation to the effects of CB1954 
when they were stably transfected with hTERC-NTR and hTERT-NTR constructs. A2780 
cells showed mean sensitisation values of 19.4-fold for the hTERC promoter and 4.8-fold 
for the hTERT promoter. In C33-A cells, 6.33-fold sensitisation was achieved using the 
hTERC promoter and 10.9-fold using hTERT, while these values were 9.54-fold and 8.62- 
fold (hTERC) and 8.46-fold and 13.89-fold (hTERT) for GLC4 and Colo320dm cells, 
respectively. A549 cells showed a strong response to CB1954 (6.76-fold sensitisation) 
when NTR was expressed by the hTERC promoter, but were not significantly sensitised 
(1.89-fold) in hTERT-NTR transfected cells, suggesting that the hTERC promoter may 
have the capacity to drive high-level expression of cytotoxic transgenes in certain 
situations where the hTERT promoter is not strong enough. Thus, hTERC and hTERT 
promoters drive expression of bacterial nitroreductase in a tumour specific fashion and 
hTERC-NTR and hTERT-NTR expression constructs can specifically sensitise cancer cell 
lines with high promoter activities to the cytotoxic effects of the pro-drug CB1954.
4.6 hTERT and hTERC promoter activities are predictive 
of sensitisation to CB1954.
Northern and Western blot expression data revealed similar results which were correlated 
with differential sensitivities to CB1954 within a single set of clones when nitroreductase 
was expressed from different promoters. Figure 4.8 shows the results of northern blot 
analysis of the expression of NTR for several individual cell lines in addition to 
representative cytotoxicity curves. Comparison of both parts of the figure for each cell line 
reveals that the level of nitroreductase expression apparently affected the sensitisation of 
cells to CB1954.
In C33-A cells, the strongest nitroreductase signal was observed in both Northern and 
Western blots in the CMV lane, and cells transfected with this construct showed the 
strongest response to CB1954. The hTERC-NTR and hTERT-NTR bands in C33-A cells 
were similar and of a lower intensity than that of CMV-NTR, which is well correlated with 
the cytotoxic effect of CB1954 in these stables. In SK-LU-1 cells, hTERC and hTERT- 
NTR signals were effectively absent, but a strong band was evident in the CMV lane, 
reflecting the pattern of cytotoxicity observed (hTERC and hTERT-NTR do not sensitise
Alan E. Bilsland, 2002 Chapter 4: A model of telomease gene therapy 114
these cells to CB1954, while the CMV promoter could drive sufficient nitroreductase 
expression to generate some 6-fold sensitisation). A549 cells, by contrast, showed a strong 
band in the hTERC lane and a band of lower intensity in the CMV lane with no detectable 
bands in either hTERT or basic lanes. Comparison of the kill curve reveals that hTERC 
directed expression of NTR resulted in the greatest sensitisation to CB1954, with a lesser 
shift in the curve for the CMV promoter and no significant change from the basic in the 
case of the hTERT promoter.
These results indicated that differential promoter activities of the hTERC and hTERT 
promoters in parental cell lines were retained in stable pools of nitroreductase expressing 
clones, and that the telomerase promoters could be used to drive cell specific differential 
expression of the nitroreductase gene and specifically sensitise those cells which had high 
level expression to the effects of CB1954.
4.7 CB1954 sensitivity is retained i n  v i v o  in a xenograft 
model of C33-A-NTR and GLC4-NTR.
This section was conducted in collaboration with Dr. Jane Plumb (Plumb et al. 2001).
In order to address the question of whether hTERC-NTR and hTERT-NTR expressing cell 
lines could be sensitised to CB1954 treatment in vivo, 107 of each of the C33-A and GLC4 
stable cells in 200|fi PBS were introduced by subcutaneous injection into the flanks of 
female athymic nude mice. Six mice were included in each group for analysis. For each of 
C33a and GLC4, 8 groups were included to allow for analysis of each of the Basic-NTR, 
CMV-NTR, hTERC-NTR and hTERT-NTR expressing cells, with and without CB1954. 
After tumour diameter reached at least 5mm, a single injection of 80mg/kg CB1954 (C33- 
A), 40mg/kg (GLC4), or saline control was administered by tail vein injection. Changes in 
relative tumour volumes were monitored daily for a period of 7 days and were estimated 
from calliper measurements with the following formula: volume=d3 x rc/6. The results are 
presented in figures 4.9 (a) (C33-A) and (b) (GLC4).
As expected, no difference was observed between the change in tumour volumes of C33-A 
Basic-NTR over the course of the experiment, whether CB1954 was administered or not. 
Mean relative tumour volumes both for animals with and without CB1954 increased 
approximately 2.25-fold over the course of the experiment. By contrast, the mean tumour 
volumes of animals carrying C33-A CMV-NTR tumours were reduced to 0% of the
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starting volumes after a single tail vein administration of 80mg/kg CB1954 on day 0. 
Tumours, in the control animals, that did not receive CB1954 increased by a factor of 2.47. 
Thus, a single administration of CB1954 to the CMV-NTR animals caused a complete 
regression of the detectable tumour mass. Interestingly, both hTERC-NTR and hTERT- 
NTR expressing tumours also showed a strong response to administration of CB1954, with 
tumour volumes reduced to 66% and 53%, respectively, of the starting volumes at day 1 
while tumours of control animals increased in size by 1.8-fold and 2.2-fold, respectively. 
These data translate to a difference in mean tumour volumes between treated and untreated 
animals at the final time point of 2.7-fold for hTERC and 4.1-fold for hTERT. 
Interestingly, these results were similar to those observed in MTT assays, with the 
telomerase promoters generating strong and similar responses to administration of 
CB1954, while the CMV promoter had the strongest response (in this case, resulting in a 
complete regression).
A second experiment was conducted using animals bearing GLC4 Basic-NTR, CMV-NTR, 
hTERC-NTR, and hTERT-NTR tumours. The GLC4 Basic-NTR cells showed an intrinsic 
sensitivity to CB1954 (figure 4.6 and figure 4.9 (b)) that allowed the dose of CB1954 
administered to be reduced to 40mg/kg. At this drug concentration, a minimal cytotoxic 
effect was observed in the Basic-NTR relative to untreated cells, with an increase in 
tumour volume of approximately 4-fold in the untreated animals and 3-fold in the animals 
treated with CB1954. CMV-NTR tumour volumes increased by 4.8-fold in untreated 
animals and by only 1.6-fold in animals given 40mg/kg CB1954. Thus, the difference in 
tumour volumes at the experimental conclusion was 3-fold. CB1954 treated animals 
bearing hTERC and hTERT-NTR tumours showed final reductions to 39% and 18% of 
initial volume, respectively, while untreated tumours grew by 3.7-fold and 5.1-fold. Thus, 
final changes in tumour volumes of CB1954 treated animals relative to untreated controls 
were 9.5-fold for the hTERC promoter and 28.3-fold for the hTERT promoter.
Taken together, these results strongly indicated that transduction of cell lines in which the 
hTERC and hTERT promoters are highly active with hTERC-NTR and hTERT-NTR gene 
therapy constructs is an effective way to specifically sensitise cancer cells in vivo to the 
cytotoxic effects of CB1954 administration.
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To validate the specificity and efficacy of hTERC and hTERT directed gene therapy, a 
family of plasmid vectors encoding the NTR gene either in a promoter-less vector, or 
under the transcriptional control of hTERC, hTERT, or CMV promoters were developed 
within the laboratory. A panel of cell lines having high and low promoter activities were 
selected for development of stable cell lines harbouring hTERC-NTR and hTERT-NTR 
expression constructs. The expression of bacterial nitroreductase within stable pools was 
evaluated by Northern and Western blotting and the cytotoxic effect of CB1954 
bioactivation by NTR was quantified by MTT assay.
Analysis of gene expression showed that nitroreductase was differentially expressed in a 
promoter dependent manner within sets of stable pools of clones derived from a single 
parental cell line. In general, the expression of nitroreductase in CMV-NTR transfected 
cell lines was greater than in hTERC-NTR or hTERT-NTR transfected cells. Cells stably 
transfected with hTERC-NTR and hTERT-NTR showed similar and lower intensity 
signals, with hTERC promoter signal generally slightly higher than those of hTERT. No 
expression was seen in cells stably transfected with the negative control plasmid, pd2- 
NTR-basic. These results were correlated with the effects on cell sensitisation to the pro­
drug CB1954, with high expression levels generally leading to lower IC50 values and, 
thus, greater cytotoxicity in stable cell lines.
2 groups of cells could be distinguished on the basis of their sensitisation to CB1954 in 
hTERC-NTR and hTERT-NTR transfected stables. Cells having low promoter activities as 
defined by luciferase assay in chapter 3 were generally insensitive to the effects of 
CB1954, while those with higher promoter activities (A2780, GLC4, C33-A, Colo320dm) 
exhibited shifted cytotoxicity curves and lower IC50 values indicating that cell specific 
regulation of hTERC and hTERT mediated expression of NTR sensitised these cells to the 
effects of CB1954.
Moreover, when C33-A cervical carcinoma, and GLC4 small cell lung cancer cells 
transfected with hTERC and hTERT-NTR constructs were introduced into female athymic 
nude mice as human tumour xenograft models, a single tail vein injection of 80mg/kg 
CB1954 to C33-A hTERC-NTR and hTERT-NTR animals was sufficient to reduce tumour 
volume to 66% and 53%, respectively, of the initial volumes. In case of GLC4 cells, 
intrinsic sensitivity to CB1954 allowed the concentration to be reduced to 40mg/kg.
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Animals bearing hTERC-NTR and hTERT-NTR tumours exhibited tumour volumes 
reduced to mean values of 39% and 18% of the original volume, while control tumours 
continued to grow by 3.7-fold (hTERC) and 5.1-fold (hTERT) over the course of the 
experiment.
A number of factors will combine to influence the efficacy of any gene-targeted approach 
to cancer therapy. Specific cell populations will be expected to have variable basal 
sensitivities to the effects of cytotoxic drugs and, therefore, the choice of enzyme/pro-drug 
combination will have a profound impact on the ability to effectively target tumour cells. 
The tumour microenvironment may influence the efficiency of delivery of systemically 
administered drugs or,' depending on their mechanisms of action, their cytotoxic effect. 
Thus, one of the most important characteristics of such a strategy must be the capacity to 
target cycling and non-cycling tumour cells while leaving normal cells relatively 
unaffected.
The ability to restrict transcription of nitroreductase and cell sensitisation to CB1954 to 
cancer cell lines with high telomerase promoter activity by use of the hTERC and hTERT 
promoters supports the use of these promoters as part of a tumour specific expression 
system in gene therapy. Other investigators have employed a variety of transgenes 
including apoptotic mediators, pro-drug activating enzymes, diptheria toxin gene and the 
noradrenaline transporter for the development of hTERC and hTERT gene therapy systems 
(Abdul-Ghani et al. 2000; Gu et al. 2000; Koga et al. 2000; Boyd et al. 2001; Koga et al. 
2001; Komata et al. 2001; Majumdar et al. 2001). The further development of telomerase 
directed gene therapy strategies are supported by studies in monolayers and 3 dimensional 
spheroid tissue culture systems in addition to xenograft models. The data presented in this 
chapter further support the use of these regulatory sequences as part of a cancer specific 
transcriptionally directed gene therapy strategy. Incorporation of the NTR gene in the 
targeting strategy confers a number of attractive features to the model including the 
potential for targeting non-cycling cells and a well characterised bystander effect. These 
results provided essential proof of principle to support the further development of hTERC 
and hTERT directed gene therapy. The hTERC-NTR and hTERT-NTR expression systems 
were therefore validated for further study using adenoviral vectors as a more realistic 
model of delivery.
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Figure 4.2: Feature maps of the nitroreductase plasmid vectors used in the generation of 
stable cell lines.
C onstruction  o f  vectors w as perfo rm ed  by R ania K akani (P lum b et al. 2001), as described  in m ateria ls  and 
m ethods. Each vector co n ta in s  the N TR  coding sequence and K anam ycin /N eom ycin  resistance  gene for 
developm ent o f N TR  ex p ressin g  stable cell lines. N TR  is d riven  by e ither hT E R C , hT E R T  or C M V  
prom oters. A p rom o terless  negative contro l vecto r w as also  included  in the panel as a negative con tro l to 
allow  for the evalua tion  o f  the effic iency  o f  sensitisation  to the pro-drug  by each  prom oter.
Figure 4.3: Northern blot analysis of NTR expression in stable cell lines.
Total RNA was isolated from hTERC-NTR, hTERT-NTR, CMV-NTR and basic-NTR stable cell lines. 25pg 
total RNA was electrophoresed on a denaturing formaldhyde gel, blotted onto positively charged nylon 
membrane and probed with the 32-P dCTP labelled 740bp Sail fragment of pd2NTR-hTR. Bands are 
consistent with the expected NTR transcript size of approximately lkbp. Upper blots, lanes 1-4, 5637 
hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 5-8, A2780 hTERC-NTR, hTERT- 
NTR, CMV-NTR and Basic-NTR stables. Lanes 9-12, C33-A hTERC-NTR, hTERT-NTR, CMV-NTR and 
Basic-NTR stables. Lanes 13-16, A549 hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. 
Lower blots, lanes 1-4, Colo320dm hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 
5-8, SK-LU-1 hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 9-12, SUSM-1 
hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. The control probe for the 18s RNA gene is 
shown in the lower panel o f each blot.

Figure 4.4: Western blot analysis of NTR expression in stable cell lines.
Cell lines transfected with NTR gene therapy vectors were probed using the rabbit anti-NTR antibody R36 
and a commercial HRP-conjugated anti-rabbit antibody. Bands were consistent with the reported 
approximate molecular weight o f 24kDa. (a) HT29 and A549 stables. Lane 1, Benchmark protein standard 
(Gibco). Lane 2, C33-A hTERC-NTR control. Lanes 3-6, HT29 hTERC-NTR, hTERT-NTR, CMV-NTR 
and Basic-NTR stables. Lanes 7-10, A549 hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables,
(b) Colo320dm and 5637 stables. Lane 1, Benchmark protein standard (Gibco). Lane 2, C33-A hTERC-NTR 
control. Lanes 3-6, Colo320dm hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 7-10, 
5637 hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables, (c) C33-A and SUSM-1 stables. 
Lanes 1-4, C33-A hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 5-8, SUSM-1 
hTERC-NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lane 9, Benchmark protein standard 
(Gibco). (d) A2780 and SK-LU-1 stables. Lane 1, C33-A hTERC-NTR control. Lanes 2-5, A2780 hTERC- 
NTR, hTERT-NTR, CMV-NTR and Basic-NTR stables. Lanes 6-9, SK-LU-1 hTERC-NTR, hTERT-NTR, 
CMV-NTR and Basic-NTR stables. Lane 10, Benchmark protein standard (Gibco). Observed relative band 
intensities were consistent with the results o f northern blot analysis.
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Figure 4.5: Cytotoxicity curves of the cell lines that were not sensitised to CB1954.
T he im m ortal cell lines 5637 , SU SM -1, H T 29 and SK -L U -1 w ere not sign ifican tly  sensitised  to C B 1954 by 
expression  o f  N T R  from  hT E R C  (open  c irc les) and hT E R T  (closed  circ les) p rom oters. Each point represen ts 
the m ean and standard  erro r o f cell density  estim ated  by M T T  assay from  trip lica te  p lates and expressed  as a 
percen tage o f  contro l (un trea ted ) cells. A ll assays w ere repeated  at least 3 tim es. T he strongest p rom oter in 
these cell lines is C M V  (closed  triang les). T he cu rves fo r hT E R C  and hT E R T  prom oters are not sign ifican tly  
shifted  aw ay from  those o f  the basic, p rom oterless v ec to r (open triang les).
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Figure 4.6: Cytotoxicity curves of the cell lines that showed significant sensitisation to 
CB1954 by expression of hTERC-NTR and hTERT-NTR.
C 33-A , A 2780, A 549, G L C 4 and C o lo320dm  cells  show ed sign ifican t sensitisa tion  to  C B 1954  w hen N TR  
w as expressed  from  one or both o f the hT E R C  (open c irc les) and hT E R T  (c losed  c ircles) prom oters. Each 
point represen ts the m ean and standard  erro r o f  cell density  estim ated  by M T T  assay from  trip licate  plates 
and expressed  as a percen tage o f  contro l (un trea ted ) cells. A ll assays w ere repeated  at least 3 tim es. D ata 
show n are rep resen tative cy to tox ic ity  curves. In these cell lines, hT E R C  and hT E R T  show ed activ ity  that w as 
able to drive suffic ien t expression  o f  N T R  to sensitise  the ce lls  to  C B 1954. T h is  is show n by the shift in the 
cy to tox icity  curves aw ay from  that o f  the basic  p rom oterless vec to r (open triang les). T he C M V  prom oter 
show ed variab le  activ ity  betw een these  cells.
Figure 4.7: Mean sensitisation to CB1954 by expression of hTERC-NTR and hTERT-NTR in
all stable cell lines.
Sensitisation values are taken to be the fold difference between mean IC50 values derived from triplicate 
plates for basic-NTR transfected cells and those transfected with hTERC-NTR or hTERT-NTR plasmids and 
are calculated from the mean sensitisation values derived from 3 independent experiments. IC50 
measurements within individual experiments were analysed using Softmax 2.32 software and are the mean 
values across 3 plates o f the drug concentration necessary to give a 50% reduction in cell density. Only the 
cell lines with high telomerase promoter activities in chapter 3 are significantly sensitised to CB1954.
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Figure 4.8: Promoter activities predict sensitisation to CB1954 in NTR expressing stable cell 
lines.
Stable cell lines transfected  w ith basic-N T R , C M V -N T R , hT E R C -N T R , o r hT E R T -N T R  w ere exposed  to 
C B 1954  for 24 hours and the cy to tox ic  effect w as quan tified  by  M T T  assay as p rev iously  described . 
C y to tox icicty  cu rves are show n in the left panels. Panels on the right show  the levels o f  N T R  de tec ted  in 
N orthern  blots (figure 4 .3) for each pool o f  stab les. H igh expression  o f  N T R  w as co rre la ted  w ith 
sensitisation  to C B 1954  m anifested  by a sh ift in one or m ore o f  the cy to tox ic ity  cu rves aw ay from  the  basic 
(open triang les) curve. Both hT E R C  and hT E R T  show ed high expression  in C 33-A  cells that w as low er than 
that o f  C M V , reflecting  the pattern o f  the curve. S im ilarly , C M V  w as the only  p rom oter capab le  o f  d riv ing  
sign ifican t expression resulting  in cy to tox ic ity  in SK -LU -1 cells, w hile  in A 549  cells the on ly  strong  
p rom oter w as hT ER C .
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Figure 4.9: Reduction of tumour volume in GLC4-NTR and C33-A-NTR xenografts after i.v. 
injection of CB1954.
Each of the stable cell lines (a) C33-A and (b) GLC4 Basic-NTR, CMV-NTR, hTERC-NTR and hTERT- 
NTR were introduced into the flanks of female athymic nude mice. When tumour diameters reached 
approximately 5mm, animals were administered a single tail vein injection of 80mg/kg (C33-A) or 40 mg/kg 
(GLC4) of CB1954. Tumour volumes were monitored daily for 6 days after administration of CB1954. Each 
point represents the mean and standard error derived from 6 mice per group.
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CELL LINE BASIC (s.e.) pM CMV (s.e.) pM hTERC (s.e.) pM hTERT (s.e.) pM
HT29 227.6 (57.68) 109.26 (41.77) 213.57 (49.6) 242.2 (53.56)
SK-LU-1 120.07 (25.73) 14.99 (6.68) 61.81(11.9) 70.93 (11.94)
SUSM-1 264.77 (22.88) 72.48 (21.1) 177.77 (24.77) 130.82 (25.74)
WI-38 76.84 (21.78) 55.44  (17.1) 60.62  (5.68) 77.09  (10.91)
5637 171.23 (4.45) 115.55 (8.41) 110.73 (3.99) 149.03 (9.36)
A2780 25.76  (15.15) 3 .65 (1.34) 1.26 (0.65) 5.2 (0.38)
C33-A 96 .06  (29.55) 2.01 (0.259) 15.19(0.02) 8.59 (1.38)
GLC4 4.66 (0.81) 0.7 (0.23) 0.53 (0.09) 0 .68 (0.25)
Colo320dm 191.42 (56.51) 7.1 (2.87) 23 .77  (6.84) 13.86 (3.43)
A549 125.49 (20.81) 81 .12  (10.9) 19.12 (3.38) 67.01 (6.03)
Table 4.2: Mean pM IC50 values for the 4 constructs in stable cell lines.
NTR expressing stable cell lines were treated for 24 hours with a titration of CB1954. Mean values and 
standard errors (s.e.) are derived from 3 independent experiments. For a single experiment, IC50 values were 
calculated from the mean value of triplicate measurements of the concentration of CB1954 necessary to give 
a 50% reduction in cell density. Data were analysed with the Softmax 2.32 microplate analysis software.
CHAPTER 5
ADENOVIRUS MEDIATED DELIVERY 
OF hTERC AND hTERT- 
NITROREDUCTASE GENE THERAPY 
VECTORS
• Adenovirus is an efficient vehicle for gene 
delivery to cell lines in this model.
• Cloning and characterisation of Ad-hTERC- 
NTR and Ad-hTERT-NTR gene therapy virus 
vectors.
• Promoter dependent expression of an NTR splice 
variant.
• Ad-hTERC-NTR and Ad-hTERT-NTR sensitise 
human cancer cells to CB1954 in vitro and in 
vivo.
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5 ADENOVIRUS MEDIATED DELIVERY OF hTERC 
AND hTERT-NITROREDUCTASE GENE THERAPY 
VECTORS.
5.1 Abstract
In order to model delivery of hTERC-NTR and hTERT-NTR expression constructs to 
human cancer cells in vitro, the constructs were cloned into the El region of an E1/E3 
deleted adenovirus using the Ad-easy cloning system obtained from Q-biogene (He et al. 
1998) to generate the adenoviruses Ad-hTERC-NTR and Ad-hTERT-NTR. Analysis of 
NTR expression in human cervical carcinoma and mortal human foetal lung fibroblast 
cells infected with Ad-hTERC-NTR and Ad-hTERT-NTR revealed the expected cell 
specific, promoter dependent patterns of NTR expression. However, northern blotting 
seemed to reveal a longer transcript in hTERT-NTR virus infected cells than in the Ad- 
hTERC-NTR infected cells. To clarify the length and sequence of the transcribed RNA 
species, cDNAs were generated and sequenced, revealing a splice variant with an 187bp 
deletion from the expected transcript sequence both for hTERC-NTR and hTERT-NTR. 
The deletion is predicted to encode an in-frame 22 amino acid truncation of the NTR 
protein with an additional 5 amino acid mutation. The deletion was not predicted to 
abrogate the function of NTR, and to confirm that functional nitroreductase was expressed 
in a cancer cell specific manner, 3 cancer and 2 mortal cell strains were infected with the 
hTERC-NTR and hTERT-NTR viruses and subjected to cell survival assays after 
challenge with CB1954. The results indicated that the cells were sensitised to CB1954 in a 
promoter-dependent manner, with a cervical carcinoma cell line and an ovarian 
adenocarcinoma cell line, both of which exhibit high promoter activity, significantly 
sensitised to CB1954. The remaining cancer and mortal cell strains, which have low 
hTERC and hTERT promoter activities, were not sensitised to the effects of CB1954. 
Sensitisation to CB1954 was dependent also on infection efficiency. Thus, adenovirus 
vectors harbouring hTERC-NTR and hTERT-NTR expression constructs sensitise human 
cancer cells to the cytotoxic effects of activated CB1954 in a manner which is dependent 
partly on promoter activity and partly on infectivity.
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Adenoviruses are currently the vectors of choice for a broad range of gene delivery 
systems in gene therapy. Among the attractive features of adenovirus vectors are a broad 
tissue tropism and the ability to infect both cycling and non-cycling cells with a high 
efficiency ((Mashhour et al. 1994) and references therein). Additionally, well characterised 
systems have been in use for a number of years which permit the high titre production of 
replication defective vectors deleted in the El region of the viral genome (first generation 
vectors), which is essential for efficient early gene transcription, by trans-complementation 
in cell lines stably expressing El gene products (Graham et al. 1977; Imler et al. 1996).
In the classical model of adenovirus internalisation and nuclear trafficking, an initial high 
affinity interaction occurs between residues of the terminal knob domain of the trimeric 
viral capsid fibre protein and the primary cellular receptor, hCAR, the human Coxsackie 
and Adenovirus Receptor (Bergelson et al. 1997; Kirby et al. 1999; Roelvink et al. 1999; 
Kirby et al. 2000). Subsequent interactions between cellular a vP3 and a vp5 integrins and 
protruding RGD motifs in the virus capsid protein penton base mediate endocytotic 
internalisation in a pathway dependent on Dynamin (Wickham et al. 1993; Wang et al.
1998). While other cellular adenovirus receptors, such as MHC class I heavy chain, have 
been implicated in non-CAR dependent internalisation pathways (Hong et al. 1997), hCAR 
dependent internalisation is considered to be the primary internalisation pathway in human 
cancer cells when both hCAR and MHC class I heavy chain are expressed (McDonald et 
al. 1999). Indeed, CAR expression has been correlated with adenovirus permissiveness or 
refraction in a number of systems including ovarian cell lines, mouse hepatocytes in vivo, 
and a model of adenovirus gene delivery to differentiated versus non-differentiated airway 
epithelium (Zabner et al. 1996; Zabner et al. 1997; Walters et al. 1999; You et al. 2001).
Penetration of the endosome occurs swiftly following endocytosis and prior to 
endolysosomal fusion in a pathway that involves both a function of the cytoplasmic tail of 
integrin p5 and the activation of the pH dependent adenovirus protease on endosomal 
acidification (Wickham et al. 1994; Greber et al. 1996; Wang et al. 2000). The combined 
action of these events mediates both virus uncoating and membrane permeation leading to 
adenovirus release to the cytosol. The virus subsequently traffics to the nucleus by a 
microtubule dependent mechanism (Suomalainen et al. 1999; Leopold et al. 2000) and 
makes an interaction with nuclear pores via the hexon capsid protein (Greber et al. 1997).
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Trafficking to the nucleus and subsequent transgene expression is rapid, requiring around 1 
hour for 99% of cell-surface bound virus to reach the nucleus and around 24 hours for 
maximal transgene expression (Leopold et al. 1998).
In the nucleus, the alternatively spliced products of the El a gene mediate the initiation of 
transcription of other viral and cellular genes including the viral E2 products which encode 
the polymerase and DNA binding proteins that are essential for virus replication. 
Transcriptional modulation by El a gene products occurs by multiple independent 
mechanisms including displacement of the cellular transcription factor E2F-1 from 
negative regulation by pRB facilitating the transcriptional up-regulation of S-phase 
components (reviewed in Flint et al. 1997). Thus, the wild type adenovirus El gene 
products mediate changes to the cellular environment favourable for productive infection. 
Hence, El deleted adenoviruses are defective in the genes necessary for efficient 
replication and introduction of transgenes of interest into the El region allows for highly 
efficient transduction of target cell populations with genes of interest.
Replication defective adenoviruses are therefore regarded to be excellent gene delivery 
vehicles for use in vitro and in vivo. Indeed, the on-line clinical trials database of the 
Journal of Gene Medicine reports that adenovirus vector clinical trials account for 27.7% 
of current trials in gene transfer (164 of 596 worldwide trials recorded in the database) 
(Wiley & sons (http ://www. wiley. com/le gacy/whileychi/genmed/clinical). However, while 
a number of tissue types have been successfully targeted, the efficiency of first generation 
adenoviral vectors as gene delivery vehicles for the transduction of tissues in vivo is 
limited by at least three major factors.
Firstly, the immunological hurdle to adenovirus gene therapy is considerable. Adenovector 
capsid components are highly immunogenic, inducing widespread activation of cellular 
immune responses that may damage the target tissue and can also limit persistence of 
transgene expression (Yang et al. 1996; Kafri et al. 1998; Molinier-Frenkel et al. 2000). 
Additionally, antigenic transgenes may also elicit an immune response (Yang et al. 1996). 
An important additional problem in humans is the high frequency of previous exposure to 
wild-type adenovirus infections: antibodies to serotypes 1, 2, and 5 are present in around 
40-60% of children (reviewed in Horowitz 1996), and this may limit the efficiency of gene 
transfer even on the first delivery of recombinant vector (Stallwood et al. 2000). Strategies 
developed to overcome this problem include coating the viral capsid with non- 
immunogenic polymers (Fisher et al. 2001).
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Additionally, endogenous gene expression of El deleted adenovirus vectors, while 
severely limited, is not absolutely abolished. The E4 orf6/7 gene product can mediate low 
level transcriptional activation of late gene products leading to enhanced immunogenicity 
and low-level replication (O'Connor et al. 2000). Strategies developed to overcome this 
problem initially focussed on the development of second-generation vectors incorporating 
deletions of both El and E4 genes (Gao et al. 1996), or El and E2 genes (Gorziglia et al. 
1996). However, more recent developments in technology for vector manipulation have 
seen the high titre production of helper dependent, or “gutless” vectors, that have 
essentially the entire wild-type viral genome deleted with the exception of the inverted 
terminal repeat and the packaging signal (Hardy et al. 1997), reviewed in (Morsy et al.
1999). These vectors allow for the incorporation of larger or multiple transgenes and 
display reduced immunogenicity manifested by enhanced transgene persistence in vivo 
(Schiedner et al. 1998).
The efficiency of delivery to target tissues is largely dependent on expression of hCAR. 
Among the tissues to which adenovirus mediated gene delivery has been inefficient due to 
low or undetectable expression of hCAR are differentiated airway epithelium (Walters et 
al. 1999), in addition to alveolar macrophages (Kaner et al. 1999) and the de-differentiated 
cells of human tumours such as some bladder cancer cell lines (Li et al. 1999) and some 
ovarian cancer cell lines (You et al. 2001). The recent identification of hCAR as a 
transmembrane component of tight junctions may help to explain the inefficiency of 
transfer to some polarised epithelial surfaces in vivo as the receptor may be sequestered in 
tight junctions (Cohen et al. 2001). Moreover, recent work indicates that the CAR 
transcript is alternatively spliced, giving rise to a second major variant deleted in the 
transmembrane domain that may act as a soluble receptor to sequester adenovirus particles. 
Several additional deleted and truncated variants are also detectable only by nested PCR, 
although the significance as concerns the fibre binding function is unknown. Interestingly, 
skeletal muscle was shown to express only the smallest of the truncated variants (Thoelen 
et al. 2001). The last several years have seen major advances in the genetic and antibody 
mediated manipulation of adenovirus surface proteins which have enabled retargeting of 
binding specificity of the fibre to alternative cell surface markers such as the folate 
receptor, epithelial cell adhesion molecule, fibroblast growth factor receptor and epidermal 
growth factor receptor (Douglas et al. 1996; Gu et al. 1999; Haisma et al. 1999; Dmitriev 
et al. 2000). This kind of approach may be expected to overcome the limitations to 
adenovirus gene transfer imposed by the hCAR expression profile, and may additionally 
enable the development of vectors incorporating multiple layers of target specificity.
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Several groups have reported the use of adenovectors to deliver pro-drug activating 
enzymes to cancer cells, such as viral Thymidine Kinase, Cytosine Deaminase and, more 
recently, nitroreductase. Most studies place these genes under the control either of 
commonly used control promoters such as SV40 or CMV or of tissue specific promoters 
such as PSA or CEA. While most studies to date remain at the pre-clinical stage, a number 
of clinical protocols have been proposed (Alvarez et al. 1997; Crystal et al. 1997; Morris et 
al. 2000).
In this chapter, a reporter adenovirus expressing the E.Coli LacZ gene under the control of 
the CMV promoter (Ad-CMV-LacZ) is used to demonstrate the efficiency of adenovirus 
mediated gene transfer to cell lines characterised in the preceding chapters. Ad-CMV-LacZ 
efficiently transduced most cell lines and is therefore selected for further study as a 
potential vehicle for transduction of hTERC-NTR and hTERT-NTR expression constructs 
into cancer cell lines. The hTERC-NTR and hTERT-NTR expression constructs previously 
demonstrated to specifically sensitise cancer cells in a promoter dependent fashion to the 
effects of the pro-drug CB1954 are cloned into the El region of an E1/E3 deleted 
adenovirus genome using the commercially available Adeasy system (He et al. 1998) to 
generate the vectors Ad-hTERC-NTR and Ad-hTERT-NTR. Recombinant adenoviruses 
were amplified by Q-Biogene custom services.
Expression of NTR is characterised by northern blotting RNA extracted from a cervical 
carcinoma cell line infected with Ad-hTERC-NTR and Ad-hTERT-NTR and data are 
presented indicating that NTR mRNA expression is initiated at the correct transcriptional 
start sites of the hTERC and hTERT promoters within an adenovirus backbone. NTR 
mRNA was polyadenylated at a site within the adenovirus right arm homology region, but 
the major mRNA species expressed from both hTERC and hTERT promoters was an 
alternative splicing product with a 187bp deletion, in which the terminal 66bp of the NTR 
coding sequence are removed and the rest of the sequence is fused with a stop codon in the 
viral right arm homology domain. The splice variant encoded an in-frame 22 amino acid 
truncation of the NTR protein with an additional 5 amino acid mutation, but this was not 
predicted to affect the function of NTR.
Western blotting detection of NTR in protein extracts of a cervical carcinoma cell line and 
a mortal foetal lung fibroblast cell strain indicated that a protein species of approximately 
the correct apparent molecular weight (24kDa) was expressed in a promoter dependent and 
cell specific manner, yielding high level expression from both telomerase promoters only
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in the cancer cell line. The effects of NTR expression in relation to the sensitisation of 
adenovirus transduced cell lines to CB1954 are investigated and results are presented to 
indicate that adenovirus mediated delivery of hTERC-NTR and hTERT-NTR to normal 
and cancer cell lines can specifically sensitise cancer cells to the effects of CB1954 in a 
manner dependent both on promoter activity and transduction efficiency. Moreover, direct 
intra-tumour injection of human cervical carcinoma xenografts grown in female athymic 
nude mice with Ad-hTERC-NTR and Ad-hTERT-NTR followed by tail vein injection with 
80mg/kg CB1954 resulted in a potent anti-tumour effect with no obvious general toxicity 
in the animals. Therefore, adenovirus vectors harbouring hTERC-NTR and hTERT-NTR 
expression constructs sensitise human cancer cells to the cytotoxic effects of activated 
CB1954 both in vitro and in vivo.
5.3 Evaluation of the efficiency of delivery of adenovirus 
vectors to normal and cancer cell lines.
One of the most common ways to evaluate adenovirus infectivity in cells is by the use of a 
reporter virus harbouring a transgene such as GFP or LacZ, whose product can easily be 
detected in infected cells. In order to evaluate the replication defective adenovirus system 
as an adequate gene delivery system for hTERC-NTR and hTERT-NTR gene therapy, a 
commercially available CMV-LacZ adenovirus was employed.
13 cancer, mortal and ALT cell lines included in earlier analyses for hTERC and hTERT 
promoter activity and sensitivity to CB1954 in stable cell line models of hTERC and 
hTERT-nitroreductase gene therapy were infected for 1 hour at 37°C with a titration of 
CMV-Lac Z adenovirus (0, 1, 10, or 100 plaque forming units (p.f.u.) per cell) in lOOpl. 
After 1 hour, the cells were incubated overnight in low serum and the following day the 
cells were fixed and stained overnight with X-gal at pH 7.4 to detect blue (infected) cells. 
Cells were photographed and those cells staining blue were counted and expressed as a 
percentage of total cells in each of 5 random fields for each concentration of virus. 
Approximately 1000 cells were counted in total for each multiplicity of infection and all 
experiments were conducted at least twice. The mean infectivity for each cell line, derived 
from two independent experiments, is presented in figure 5.1 and representative 
photomicrographs of adenovirus infected cells are presented in figure 5.2.
Figure 5.1 confirms that adenovirus is a highly efficient gene delivery vehicle for 
incorporation in the hTERC and hTERT gene therapy model: while no blue cells were seen
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in any of the mock infected cell lines, the Lac Z adenovirus could transduce several cell 
lines with 100% efficiency at a multiplicity of infection of 100 p.f.u. per cell. 5637, 
SUSM-1, A549, IMR-90, BJ-lhTERT, and WI-38 cells were all transduced in a dose- 
dependent fashion, reaching 100% infectivity at 100 p.f.u. per cell, with minimum 
infectivity at low viral doses of 1 p.f.u. per cell of between 10% (A549) and 23% (SUSM- 
1). That WI-38 cells could be so efficiently transduced is of paramount importance since 
these cells could not be developed as stable cell lines for evaluation of CB1954 induced 
cytotoxicity in hTERC and hTERT gene therapy, and they provide an essential negative 
control by which to evaluate the cancer cell specificity of this approach.
A number of other cell lines were less effectively transduced, including the cancer cell 
lines C33-A, A2780, and GLC4. The percentages of C33-A infected at the 3 virus 
concentrations was 13% at 1 p.f.u., 43% at 10 p.f.u., reaching a maximal infection of 64% 
at 100 p.f.u., while A2780 infection efficiencies ranged between 3.5% at 1 p.f.u. and only 
43.1% at 100 p.f.u per cell. The colorectal adenocarcinoma cell line Colo320dm could be 
infected at efficiencies of 23% (1 p.f.u.), 49% (10 p.f.u.) and 90% (100 p.f.u.) although, as 
described below, these cells were susceptible to widespread acute toxicity which may have 
affected the result. GLC4 cells were among the least efficiently infected of all cell lines, 
showing less than 1% infectivity at both 1 and 10 p.f.u. per cell and reaching a maximal 
value of only 4.6% infected cells at 100 p.f.u. The testicular teratoma line SuSa, were also 
refractive to the virus, with less than 2% infected cells at either 1 or 10 p.f.u. per cell. It is 
interesting to note, since the efficacy of hTERC and hTERT-NTR constructs delivered by 
an adenovirus will depend not only on promoter activity in cell lines but also on 
transduction efficiency, that the cancer cell lines which displayed greatest sensitisation to 
CB1954 in the preceding chapter were all less effectively transduced by adenovirus than 
the cell lines which did not respond.
At the highest multiplicity of infection, acute toxicity was observed in several cell lines. 
The infection efficiency of SuSa testicular teratoma cells could not be determined at 100 
p.f.u. per cell, as no cells remained attached to the wells after overnight incubation in low 
serum. A similar reduction in cell density, although not as pronounced, was observed in 
Colo320dm cells; following overnight incubation prior to staining, the density of cells 
anchored to the growth surface was reduced to approximately 10% of the density of mock 
infected cells. The infectivity of the virus in the surviving fraction of Colo320dm cells has 
been quantified, although it is acknowledged that acute toxicity may mask the true value. 
C33-A cells exhibited a comparatively low degree of vector-induced toxicity (cell densities
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reduced to around 70% of control at 100 p.f.u.), which could be reduced further in the 
assays described below by infection with an upper limit of 50 p.f.u. per cell. No significant 
toxicity was observed in any other cell line.
5.4 Cloning and amplification of the Ad-hTERC-NTR and 
Ad-hTERT-NTR gene therapy vectors using the 
Adeasy system.
A number of commercially available systems can be employed to facilitate the cloning of 
transgenes into the El region of the adenovirus genome. In this study, the Adeasy system, 
which relies on homologous recombination of the adenoviral genome with corresponding 
sequences in a specifically engineered “transfer vector” within a recA+ bacterial strain has 
been employed (He et al. 1998). Figures 5.3 and 5.4 show the cloning strategy that was 
employed in the generation of recombinant Ad-hTERC-NTR and Ad-hTERT-NTR.
The 740bp Sail fragment of pd2NTR-hTERC, containing the complete coding sequence of 
nitroreductase, was isolated by restriction digest, gel electrophoresis and gel extraction and 
was cloned into the Sail site of the transfer vector pShuttle to form the intermediate 
transfer vector pShuNT. Next, the 889bp Hindlll and 606bp Xhol fragments of pd2NTR- 
hTERC and pd2NTR-hTERT, respectively, were isolated and cloned into the Hindlll and 
Xhol sites of pShuNT to generate the transfer vectors pShuNT-hTERC and pShuNT- 
hTERT, containing the NTR coding sequence under the control of hTERC and hTERT 
promoters. The constructs were linearised by digestion with Pmel, which cleaves between 
the left and right arm homology regions of the closed circular plasmid, releasing these in 
the correct orientation for interaction with the corresponding regions of pAdeasy-1.
lpg of each linearised transfer vector was co-transformed with lOOng pAdeasy-1 in the 
BJ5183 E.Coli strain by electroporation in a 2mm cuvette at 2.8KV and plated out 
overnight to allow the growth of transformed colonies. This bacterial strain supports 
homologous recombination by virtue of the presence of the recA protein. Selected colonies 
were inoculated into L-broth and allowed to grow overnight then miniprep DNA was 
extracted and potential recombinant plasmids were transformed into DH5a for stable 
amplification of the plasmid. Presence of the recombined transfer vector in the adenoviral 
backbone was confirmed by restriction digest and the orientation of the promoter in 
relation to NTR was confirmed by sequencing with the primers Shuntlf and Shuntlr.
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Recombinant adenoviruses were amplified on the HEK-293 cell line, which produces El a 
gene products in trans. Amplification and purification of the adenoviruses was performed 
by the custom service of Q-biogene. 293 cells were initially transfected with 5pg 
recombinant adenoviral DNA. 50pl DNA (O.lpg/pl) was mixed with 169pl dEEO and 5pi 
2M CaCE. An Additional 26pl CaCE was added after mixing and a second tube containing 
250pl HBS (Hepes Buffered Saline) was prepared. Air was bubbled through the HBS with 
a pipette and during this time, the DNA/CaCE mixture was added. Cells were removed 
from incubation and the transfection mixture was added drop-wise to the medium. Cells 
were incubated overnight, then the transfection solution was removed and the cells were 
rinsed in PBS. Cells were then incubated for 14 days to allow for the formation of a 
cytopathic effect (CPE). After this stage, small-scale amplification was performed using an 
initial volume of 0.1ml of crude virus from cell lysate supernatant to infect 105 cells. Virus 
was released from cells by 3 cycles of freeze/thawing between -20°C and 37°C. After 
several rounds of amplification using aliquots of up to 45ml crude virus released in tissue 
culture supernatant to infect up to 3xl08 293 cells, the large-scale adenovirus preparation 
was performed by freeze/thawing to release virus and purification by CsCh banding. 
Quantification of the viral titrations in Viral Particles (V.P.) was performed by 
measurements of optical density (O.D.260) and measurements of Plaque Forming Units 
(P.F.U.) were performed by plaque assay.
VECTOR VIRAL PARTICLES/ml PLAQUE FORMING 
UNITS/ml
Ad-hTERC-NTR 2.50xl0u 1.60xl0lu
Ad-hTERT-NTR 1.86xl0n 2.85xlOIU
Table 5.1: Quantification of adenovirus particle titre by O.D. and plaque assay
Adenovirus gene therapy vectors were amplified on 293 cells as described in materials and methods. 
Quantification of viral particles was determined at O.D.26o and infectious units were calculated by plaque 
assay.
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5.5 Characterisation of the expression of NTR in Ad- 
hTERC-NTR and Ad-hTERT-NTR infected cells.
5.5.1 Alternative splicing of NTR transcripts expressed in C33-A
In order to confirm the promoter dependent expression of functional nitroreductase in 
cancer cells, 75 cm2 flasks of C33-A cells were infected for 1 hour at 37°C at a multiplicity 
of infection of 50 p.f.u. per cell with each of the Ad-hTERC-NTR and Ad-hTERT-NTR 
viruses. 48 hours post-infection, corresponding to the day on which pro-drug would be 
administered in an in vitro cytotoxicity assay, RNA or protein was extracted from the cells 
to be used in assays of gene expression. Figure 5.5 shows the results of northern blot 
analysis of the expression of nitroreductase in C33-A cells. Cells infected with Ad- 
hTERC-NTR and Ad-hTERT-NTR (lanes 2 and 3) produced strong signals with the 
hTERC promoter construct generating a more intense signal than hTERT. Both hTERC 
and hTERT promoters generated stronger signals than equivalent amounts of RNA 
extracted from the C33-A-hTERC-NTR stable cell line (lane 1), indicating that the 
efficiency of gene transfer was good even though not all cells would have been transduced 
at this multiplicity of infection (figure 5.1 & 5.2). Mock infected cell RNA (lane 4) did not 
contain any detectable NTR transcript. These results indicated that NTR was expressed in 
C33-A cells following adenovirus transduction in a promoter dependent manner. The size 
of both transcripts was greater than that of the NTR transcript expressed in C33-A- 
hTERC-NTR cells, in-keeping with polyadenylation of the transcript at a signal within the 
adenovirus right arm homology region. Unexpectedly, however, the hTERT-NTR 
transcript migrated at a size approximately 100-200 bases longer than the hTERC-NTR 
transcript.
In order to precisely define the length and sequence of the transcripts, 5’ and 3’ RACE 
reactions were performed using cDNA transcribed from total RNA extracted from Ad- 
hTERC-NTR and Ad-hTERT-NTR infected C33-A cells using the SmartRACE kit 
(Clontech). Figure 5.6 shows gel photographs of the PCR reactions for amplification of the 
5’ (lane 1 (a) and (b)) and 3’ ends (lane 6 (a) and (b)) of the (a) Ad-hTERC-NTR and (b) 
Ad-hTERT-NTR transcripts. The other lanes represent positive and negative internal 
controls. Amplification of cDNA generated from Ad-hTERC-NTR infected cells using
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primers specific for the 5’ end of NTR produced a single, specific band of a size consistent 
with the expected 262bp product of the 5’ amplification (lane 1), as measured against a 
123bp DNA ladder. The Ad-hTERT-NTR 5’ reaction produced a single weak product, 
consistent with the expected size of 244bp (lane 1). It should be noted that several groups 
have reported variation in the transcriptional start site of the hTERT promoter.
The product of the 3’RACE reaction from Ad-hTERC-NTR infected cells (lane 6 (a)) was, 
unexpectedly, approximately 200bp shorter than the predicted product of approximately 
1200bp, while Ad-hTERT-NTR 3’ RACE reaction (lane 6 (b)) unexpectedly produced a 
doublet with one large band migrating at the expected size of approximately 1200bp and 
an extra band some 200bp shorter. In order to precisely define the sequence of each 
transcript, reaction products generated from 5’ and 3’ RACE were directly cloned into 
pCRII-TOPO vector (InVitrogen) which allows direct cloning of PCR products, and grown 
in DH5a cells for DNA maxipreparation of clones and sequencing. Sequence analysis and 
contig assembly of the fragments was performed in Vector NTI suite.
Alignment of the sequences of the hTERC-NTR 5’end RACE product with the predicted 
insert of hTERC-NTR expression cassette (figure 5.7 (a)) confirmed the location of the 
hTERC transcriptional start site proposed by Feng et al (Feng et al. 1995) and indicated 
that the transcription of NTR from the hTERC promoter-NTR expression construct is 
initiated correctly within the adenovirus backbone. Moreover, the transcriptional start site 
defined by the product of the hTERT 5’ RACE reaction (figure 5.7 (b)) lies 64bp upstream 
from the hTERT start codon. This is consistent with previous reports that place the hTERT 
transcriptional start in the region of 60 to 112bp upstream of the ATG (Cong et al. 1999; 
Takakura et al. 1999; Wick et al. 1999). Hence, transcription from both hTERC and 
hTERT promoters was correctly initiated within the adenovirus expression vectors.
Assembly and alignment of the complete 5’ and 3’ sequence contig of the long transcript 
identified in the Ad-hTERT-NTR 3’ RACE reaction revealed that the transcript sequence 
was identical to the predicted sequence for the NTR transcript. (Figure 5.7(c)). However, 
the complete sequences of the short 3 ’ RACE reactions of both Ad-hTERC-NTR and Ad- 
hTERT-NTR transcripts revealed a 187bp deletion from the predicted sequence that 
removes the terminal 66bp of the NTR coding sequence, in addition to a portion of the 
downstream viral sequence (figure 5.7 (a) and (b)).
Alan E. Bilsland, 2002 Chapter 5: Adenovirus delivery of NTR vectors 139
In order to determine at which stage during viral cloning, amplification, or infection the 
deletions had occurred, PCR primers AdNTSeq5a and AdDelR were designed to amplify a 
product that includes the deleted region and in which the deleted region would be easily 
distinguishable from the full length product. In a full length DNA, the amplification was 
designed to give rise to a 762bp product, but reactions containing the deletion amplify a 
575bp product. For each of Ad-hTERC-NTR and Ad-hTERT-NTR, separate PCR 
reactions were performed using the plasmid DNA that was originally transfected into 293 
cells to generate the virus, DNA extracted from the viral particles using Lyse-n-Go 
reagent, and cDNA generated from virus infected C33-A cells. Figure 5.8 shows the 
products of the amplification reactions. Both the plasmid (lanes 2 and 5) and virus (lanes 3 
and 6) DNAs of both Ad-hTERC-NTR (lanes 2-4) and Ad-hTERT-NTR (lanes 5-7) 
amplified a single full length product, indicating that the deletion was not present at any 
stage prior to or during the virus amplification. Amplification products generated from 
infected C33-A cDNA, however, contained 3 identical discrete bands. The largest band 
migrated at a size consistent with the full-length product, while the smallest band migrated 
at a size consistent with the presence of the 187bp deletion and was also the major product 
both in Ad-hTERC-NTR and Ad-hTERT-NTR reactions. An intermediate band of 
approximately 700bp was also identified.
Since both the deleted sequences in the short transcripts and the PCR reaction products of 
both Ad-hTERC-NTR and Ad-hTERT-NTR were identical, the results suggested the 
action of a non-random recombination event, such as alternative splicing. In order to 
address this possibility, the sequence of the full length transcript of hTERT-NTR (figure 
5.7(a)) was used in a search for potential splice donor/acceptor sites using the SPL search 
facility at the Sanger Centre website (http://genomic.sanger.ac.uk/gf/gf.shtml). The results 
are displayed in the results screen copied into figure 5.9. Boxed numbers 687 and 873 
(highlighted in the sequence of figure 5.7 (a)) represent the putative donor/acceptor sites 
that correspond exactly to the deleted region of the short transcripts (figures 5.7 (b) and 
(c)). Therefore, the major NTR mRNA expressed in C33-A after infection with both Ad- 
hTERC-NTR and Ad-hTERT-NTR is a splice variant encoding a 187bp deletion.
5.5.2 In silico characterisation of the product of the short NTR 
splice variant
Analysis of the predicted open reading frames in Vector NTI suite revealed that the deleted 
transcript codes for an in-frame truncation of the NTR protein that removes the terminal 22
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amino acids. The translated product is predicted to contain an additional 5 amino acid 
mutation (191VGHHS - QPPPP) compared with the published sequence, due to fusion of 
the nitroreductase coding sequence with a portion of the viral right arm homology domain 
which contains the stop codon UGA (Figure 5.10). In order to assess whether the truncated 
NTR would be expected to give rise to an inactive phenotype, firstly a search of the 
SWISSPROT database on the NCBI QBLAST server was conducted using the missing and 
mutated sequence to determine if the deleted residues possess homology to any other 
functional proteins. The results of the search indicated that the amino acid sequence has 
homology only with four other bacterial nitroreductase species (figure 5.11). Thus, these 
residues are not conserved in known protein species other than nitroreductases and are 
unlikely to be involved in similar catalytic function of proteins that are functionally 
homologous such as DT-diaphorase.
Using the nnpredict secondary structural prediction tool for comparison between NTR and 
the other nitroreductase sequences identified in the BLAST search did not reveal 
conservation of structural elements in this region (http://www.cmpharm.ucsf.edu/cgi- 
bin/nnpredict.pl) (figure 5.12). Moreover, the mutated region is distal from the active site 
of electron transfer to CB1954 and to the entrance by which CB1954 is predicted to access 
this site. However, It should be noted that two deleted residues, namely R and K may 
interact with the protruding phosphate group of the internally bound flavin mononucleotide 
electron donor and contribute to the stabilisation of its conformation within the binding 
pocket (Parkinson et al. 2000) (figure 5.10). Several other distal residues also orient FMN 
within the binding pocket. Thus, while the site of catalysis is unaffected, theoretically the 
binding of the FMN cofactor may not be optimal. However, the functional studies 
described below do not support the idea that the function of NTR was adversely affected.
Western blot analysis of 20 pg protein extracted from Ad-hTERC-NTR and Ad-hTERT- 
NTR infected C33-A and WI-38, shown in figure 5.13, revealed a single protein species of 
approximately the correct apparent molecular size in lanes 2 and 3, corresponding to the 
Ad-hTERC-NTR and Ad-hTERT-NTR infected C33-A. No signal was detected in the 
mock-infected lane of either cell line (lane 4, C33-A; lane 7, WI-38), or in the Ad-hTERT- 
NTR infected WI-38 (lane 6), but a weak signal was detected in WI-38 infected with Ad- 
hTERC-NTR (lane 5). Together, these results indicated that a truncated nitroreductase 
species was transcribed and translated from the adenoviral vectors in the expected 
promoter-dependent and cell-specific manner and confirmed that the cell-specific 
regulation of the telomerase promoters is retained in an adenoviral backbone.
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5.6 Ad-hTERC-NTR and Ad-hTERT-NTR efficiently 
sensitise cancer cell lines to the effects of CB1954 in 
a promoter dependent and dose-dependent fashion.
In order to determine whether the function of nitroreductase was affected by the truncation, 
and whether the promoter specific responses to CB1954 observed in stable cell lines 
(Plumb et al. 2001, Chapter 4) are retained in parental cell lines expressing nitroreductase 
exogenously introduced by Ad-hTERC and Ad-hTERT vectors, 3 cancer and 2 mortal cell 
lines were infected with both 10 and 50 p.f.u. per cell of each of Ad-LacZ, Ad-hTERC- 
NTR, and Ad-hTERTtNTR for 1 hour at 37°C in 6-well plates. After infection, the cells 
were incubated in growth medium for a further 2 hours then trypsinised and plated out into 
96-well plates (NTR infected cells) for MTT assay, or re-plated into 6-well plates (LacZ 
infected cells). Ad-hTERC-NTR and Ad-hTERT-NTR infected cells were allowed to 
proliferate for 2 days prior to 24 hour challenge with CB1954. On the same day, cells 
infected with LacZ were fixed and stained to give an indication of the percentage of cells 
infected with the adenoviral vectors on the day of drug challenge. All experiments were 
repeated at least 3 times.
Figures 5.14 and 5.15 show representative cytotoxicity curves for the cell lines tested and 
IC50 values for all cell lines with each promoter at each multiplicity of infection are given 
in table 5.2. A clear promoter-dependent and dose-dependent sensitising effect was seen 
only in C33-A and A2780 cells (figure 5.14), while other cell lines were unaffected by the 
combination of Ad-hTERC-NTR or Ad-hTERT-NTR infection and treatment with 
CB1954 (figure 5.15). Thus, the responses of cell lines to Ad-NTR and CB1954 treatment 
fell into two groups: those that were sensitised and those that were unaffected.
The summary of the IC50 values after CB1954 treatment for cells infected with Ad- 
hTERC-NTR and Ad-hTERT-NTR vectors at 10 and 50 p.f.u per cell is given in table 5.2. 
Values are derived from the results of 3 independent experiments for each cell line. C33-A 
cells showed the greatest response to both vectors. The basal IC50 of the uninfected cell 
line was 176.13pM, falling to 33.43pM and 9.76pM after infection with Ad-hTERC-NTR 
and 63.13pM and 35.86|uM when infected with Ad-hTERT-NTR. Thus, adenovirus 
vectors harbouring the telomerase-nitroreductase expression cassettes sensitised C33-A 
cells to the effects of CB1954 in a promoter dependent and dose-dependent fashion. The 
shift in IC50 values is reflected in the pattern of the cytotoxicity curve for C33-A cells
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presented in figure 5.14 (a): the concentration curves for cells infected with the viruses are 
shifted toward a lower drug concentration in a promoter and dose dependent manner, with 
the hTERC promoter generating the strongest response. The only other cell line tested that 
was significantly sensitised to CB1954 was the ovarian adenocarcinoma cell line A2780. 
A2780 had a basal IC50 value of 28.5pM and, therefore, were intrinsically one of the most 
sensitive cell lines assayed. Nevertheless, introduction of Ad-hTERC-NTR resulted in 
decreased IC50 values of 10.69pM and 3.85pM at 10 and 50 p.f.u, respectively, and 
introduction Ad-hTERT-NTR resulted in IC50 values of 17.73pM and 10.86pM at 10 and 
50 p.f.u per cell. Thus, Ad-hTERC-NTR resulted in the greatest sensitisation, reflected in 
the dose-dependent shift of the concentration curve in figure 5.14 (b), while Ad-hTERT- 
NTR resulted in a modest sensitisation of approximately 2.8-fold at the highest infectious 
dose.
A caveat of telomerase directed gene therapy is that it must be tumour specific. In order to 
determine the capacity of the constructs to generate high-level expression of NTR and 
sensitisation to CB1954 specifically in cancer cells, two mortal cell strains were assayed. 
These were WI-38 foetal lung fibroblasts, and HMEC normal human mammary epithelial 
cells. In contrast to the strong sensitisation observed in C33-A and A2780, the two mortal 
cell lines tested were not sensitised to the effects of CB1954 by introduction of Ad- 
hTERC-NTR and Ad-hTERT-NTR. Mock infected WI-38 had an IC50 of 153.63pM that 
was not significantly changed either by introduction of Ad-hTERC-NTR at 10 p.f.u. per 
cell (178.09pM) and 50 p.f.u per cell (164.72pM), or by infection with Ad-hTERT-NTR at 
10 p.f.u per cell (148.6pM) and 50 p.f.u. per cell (174.12pM). Thus, the hTERC and 
hTERT promoters did not drive sufficient expression of NTR to sensitise WI-38 fibroblasts 
to CB1954 (see also western blot in figure 5.13). Additionally, the normal mammary 
epithelial cells (HMEC) were not sensitised to CB1954. HMEC had a basal IC50 of 
31.67pM and were therefore comparatively sensitive to CB1954 prior to transduction with 
Ad-hTERC-NTR and Ad-hTERT-NTR. Expression of NTR from the hTERC promoter 
resulted in IC50 values of 45.38pM at 10 p.f.u per cell and 36.02pM at 50 p.f.u. per cell, 
while the values for cell infected with Ad-hTERT-NTR were 27.76pM (10 p.f.u.) and 
29.65pM (50 p.f.u.). These data indicate that normal mammary epithelial cells are not 
significantly affected by hTERC and hTERT promoter mediated expression of NTR.
No sensitisation was expected by introduction of Ad-hTERC-NTR or Ad-hTERT-NTR 
into the other cancer cell line tested, 5637 bladder carcinoma cells, as these cells had low 
promoter activity in chapter 3 and were not sensitised to CB1954 by expression of NTR
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from hTERC and hTERT promoters in stable cell line models. According to expectation, 
the IC50 values for 5637 were not significantly altered by introduction of the viruses, 
shifting only from 102.86pM (mock infected) to 93.55pM (hTERC, 10 p.f.u.), 73.36pM 
(hTERC, 50p.f.u.), 112.61 (hTERT, lOp.f.u.), and 103.17pM (hTERT, 50p.f.u.). The lack 
of sensitisation to CB1954 is demonstrated by the shape of the cytotoxicity curve in figure 
5.16, in which the concentration curves for all treatments are tightly packed together with 
no dose dependent shifts.
These data indicated that the Ad-hTERC-NTR and Ad-hTERT-NTR vectors could 
transduce cell lines with the NTR expression constructs and that the function of 
nitroreductase was not adversely affected by the truncation characterised in the previous 
section. NTR retained its ability to activate CB1954 and to sensitise cells to the cytotoxic 
effects of activated CB1954. The degree of cytotoxicity was dependent on the levels of 
expression of NTR and, hence, on the hTERC and hTERT promoter activities in 
adenovirus infected cell lines. This is supported by western blot analysis of NTR protein 
expression levels in Ad-hTERC-NTR and Ad-hTERT-NTR infected C33-A cells and WI- 
38 cells (figure 5.13), by the cytotoxicity data for infected mortal and cancer cell lines 
(figures 5.14 and 5.15) and by the promoter activity and cytotoxicity data presented in the 
preceding chapters. C33-A cells, which have high hTERC and hTERT promoter activities 
(chapter 3 and chapter 4) expressed high levels of the truncated NTR that were sufficient 
to sensitise the cells to CB1954 in vitro, while WI-38 cells infected at an equivalent 
multiplicity of infection expressed low (hTERC) and undetectable (hTERT) levels of NTR 
and were not affected by Ad-hTERC-NTR and Ad-hTERT-NTR infection followed by 
CB1954 challenge.
5.7 Telomerase-nitroreductase vectors sensitise cancer 
cells to CB1954 in a promoter dependent and 
infectivity dependent manner.
The efficiency of any gene targeted enzyme/pro-drug activation approach to cancer 
therapy will depend on a number of factors including promoter activity, efficiency of 
transgene transduction within the target cell population, basal susceptibility to the effects 
of the drug and bystander effects. Thus, an important factor to be addressed is the 
relationship between the sensitising effects of the Ad-NTR vectors and the efficiency of 
transduction. In the earlier assessment of adenovirus as a gene delivery vehicle (section
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5.3), cells were infected with a titration of Ad-CMV-Lac Z and incubated overnight in low 
serum to limit cell division prior to staining. In the cytotoxicity assays described above, 
however, the cells are incubated for 2 days under conditions conducive to division to 
ensure that they are in the exponential phase of growth at the time of drug addition. Thus, 
the cells initially infected with virus will have undergone mitosis. Since not all of the cells 
will have been infected and since adenovirus is not integrated into the host genome, it is 
likely that an increasing proportion of the daughter cells in a cycling culture will not 
harbour the expression constructs. In order to address this issue, in parallel with Ad- 
hTERC-NTR and Ad-hTERT-NTR infection, cells were infected with Ad-CMV-LacZ at 
equal multiplicities of infection to the gene therapy vectors. Ad-CMV-LacZ infected cells 
were replated into 6-well plates in parallel with cells plated out for MTT assay and were 
fixed and stained 48 hours post-infection, on the same day as CB1954 challenge, to give an 
indication of the proportion of cells infected on the day of drug administration. The results 
of a representative experiment, including infectivity, IC50 and sensitisation data are given 
in figure 5.16, while figure 5.17 shows the collation of the infectivity and sensitisation data 
for all cell lines assayed.
In C33-A cells, infection with Ad-hTERC-NTR resulted in a mean 7.51-fold (10 p.f.u.) 
and 24.08-fold (50 p.f.u.) sensitisation to CB1954, while infection with Ad-hTERT-NTR 
resulted in only 2.02-fold (10 p.f.u.) and 7.36-fold (50 p.f.u.). Interestingly, Ad-hTERC- 
NTR infected C33-A were more sensitive overall to CB1954 than the equivalent stable cell 
line, despite transduction of only 59.18% (10 p.f.u.) and 80.33% (50 p.f.u.) of cells. In 
contrast, WI-38 cells, which were more easily infected than C33-A (64.95% at 10 p.f.u., 
and 97.81% at 50 p.f.u.) were not sensitised to CB1954 either by Ad-hTERC-NTR (0.91- 
fold and 0.94-fold sensitisation at 10 and 50 p.f.u.) or by Ad-hTERT-NTR (1.09-fold and 
0.99-fold sensitisation at 10 and 50 p.f.u.). This indicates firstly, that the sensitising effect 
of the adenoviral gene therapy vectors was dependent in part on promoter activity and that 
cell lines with low promoter activity are not sensitised to CB1954 even when essentially all 
of the cells are transduced. Additionally, the dose dependent increase in sensitisation 
observed in C33-A cells indicates that the efficiency of gene transfer is an important 
consideration in evaluating the efficacy of the approach.
Further evidence for the importance of transduction efficiency is observable in the 
comparison between A2780-NTR stable cell lines and Ad-NTR transduced A2780. A2780- 
NTR stable cell lines were strongly sensitised to CB1954 in chapter 4, but the effect 
following infection with the NTR viruses was less pronounced. Cells infected with Ad-
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hTERC-NTR were sensitised to the drug by 2.69-fold (10 p.f.u.) and 9.15-fold (50 p.f.u.). 
Infection of A2780 with the hTERT-NTR virus resulted in sensitisation values of only 
1.42-fold and 2.5-fold, which were not considered to be significant. The low values 
observed for A2780 cells presumably reflected the low efficiencies of infection at both 10 
p.f.u. per cell (16.28%) and 50 p.f.u. per cell (33.56%).
Interestingly, while HMEC and 5637 cells were not significantly sensitised to CB1954 
even by infection with 50 p.f.u. per cell Ad-hTERC-NTR, infection efficiencies were 
relatively good in these lines. Sensitisation values for cell lines infected with 50 p.f.u. per 
cell Ad-hTERC-NTR were 1.45-fold (5637) and 0.87-fold (HMEC). Transduction with 50 
p.f.u. of the Ad-CMV-Lac Z virus resulted in infection efficiencies of 94.5% (5637) and 
66.21 % (HMEC). Thus, 3 cell lines were infected at a similar or better efficiency than 
C33-A and A2780, yet the low promoter activities of these cell lines were insufficient to 
sensitise the cells to CB1954. These data are encouraging and demonstrate that Ad- 
hTERC-NTR and Ad-hTERT-NTR vectors could efficiently sensitise cancer cells to the 
effects of CB1954 in both a promoter- dependent and dose-dependent manner.
5.8 Ad-hTERC-NTR and Ad-hTERT-NTR gene therapy 
vectors sensitise human cervical carcinoma cells to 
CB1954 i n  v i v o .
This experiment was performed in collaboration with Dr. Jane A. Plumb, CRC Dept. 
Medical Oncology.
In order to assess the sensitisation of model human tumours to Ad-hTERC-NTR and Ad- 
hTERT-NTR vector administration followed by CB1954 in vivo, 107 C33-A cells in 200pl 
PBS were injected subcutaneously into the flanks of athymic female nude mice. A total of 
7 groups of mice representing untreated controls, CB1954 only, hTERC-NTR and hTERT- 
NTR viruses with and without CB1954, and a CMV-LacZ group to address the efficiency 
of gene transfer in vivo. A total of 6 mice bearing 1 tumour each were included in each 
group. Tumour volumes were monitored until measured tumour diameter reached at least 
5mm, at which time the mice were randomly distributed into groups of 6 and a single intra- 
tumoural injection of 4x108 p.f.u. Ad-hTERC-NTR, Ad-hTERT-NTR and CMV-LacZ in 
lOOpl volume was administered to the tumours of appropriate groups of animals. 24hrs 
after infusion of the virus, a single injection of 80mg/kg CB1954 was administered to mice
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bearing tumours infected with the NTR viruses by tail vein injection. Daily calliper 
measurements of were performed for a further 7 days and tumour volumes were estimated 
from the measurements (volume=d3 x n 16). LacZ tumours were harvested for staining on 
the day of drug injection.
Figure 5.18 shows the mean change in tumour volumes over 7 days from untreated 
xenografts, those of animals injected with drug only, animals whose tumours were injected 
with virus only with no additional drug, or tumours in animals given intra-tumoural Ad- 
hTERC-NTR or Ad-hTERT-NTR on day 0, followed by 80mg/kg CB1954 on day 1. The 
tumours in flanks of control animals that either were untreated, injected intravenously with 
80mg/kg CB1954 without virus, or given a single intratumour injection of AD-hTERT- 
NTR or Ad-hTERC-NTR without CB1954, increased in volume at a similar rate, 
approximately doubling in size over the seven days (range of change in volume 1.97-fold 
to 2.16-fold). By contrast, the mean volumes of tumours that were injected i.t. with Ad- 
hTERC-NTR or Ad-hTERT-NTR on day 0, followed by 80mg/kg CB1954 i.v. on day 1, 
were arrested. The mean change in tumour volume of these animals was just 1.13-fold for 
Ad-hTERC-NTR and 1.22-fold for Ad-hTERT-NTR. Thus, a single injection of 
telomerase-nitroreductase gene therapy vectors coupled to a single CB1954 administration 
resulted in a 40% reduction in tumour volume for the hTERT-NTR virus and a 43% 
reduction in volume for the hTERC-NTR virus. These data indicated that Ad-hTERC-NTR 
and Ad-hTERT-NTR had a selective and efficacious anti-tumour effect in vitro and in vivo 
and strongly support the further development of a telomerase-nitroreductase gene therapy 
system.
5.9 Discussion.
In the preceding chapters, a panel of human cancer cell lines and mortal cell strains have 
been characterised for their relative capacity to drive transgene expression from the 
telomerase hTERC and hTERT promoters and for the ability of hTERC-NTR and hTERT- 
NTR expression vectors to specifically sensitise cancer cells to CB1954 in a promoter 
dependent manner when all cells within a population carry the constructs. A major 
limitation in current gene therapy applications is the efficiency and specificity of transgene 
delivery to target cell populations. While a number of viral and non-viral vector systems 
are currently under development, adenoviruses have been widely used in models of gene 
therapy due to the high efficiency of gene delivery that can be achieved in diverse cell 
types.
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To validate the use of adenovirus vectors for the delivery of hTERC-NTR and hTERT- 
NTR expression constructs, a panel of thirteen human cell lines was infected with a CMV- 
LacZ reporter adenovirus and stained with X-Gal to evaluate transduction efficiencies. The 
results indicated that adenovirus could infect most cell lines with a high efficiency, 
reaching 100% infectivity at high multiplicities of infection (lOOp.f.u. per cell) in six cell 
lines, with maximal efficiencies ranging between 43% and 90% for five other cell lines. 
The use of adenovirus as a vehicle for the delivery of hTERC-NTR and hTERT-NTR 
constructs to human cancer cells was therefore validated by these assays. However, two 
cell lines, including the small cell lung cancer line GLC4 which had a high promoter 
activity and responded well to NTR/CB1954 in the preceding chapters, were almost 
completely refractive to the virus. For this reason, these cell lines were not included in the 
rest of the model.
To model a realistic strategy for delivery of the gene therapy constructs to cells, hTERC- 
NTR and hTERT-NTR expression constructs from the pd2-NTR panel of plasmids 
described in chapter 4 were sub-cloned into the deleted El region of a first-generation 
adenovirus backbone using the commercially available Adeasy system ((He et al. 1998)). 
Amplification and purification of recombinant Ad-hTERC-NTR and Ad-hTERT-NTR 
adenovirus vectors was performed by the custom service of Q-biogene.
Northern blot analysis of expressed NTR transcripts from a human cervical carcinoma cell 
line infected with Ad-hTERC-NTR and Ad-hTERT-NTR indicated that the NTR mRNAs 
were expressed to a high level in a promoter dependent manner with the hTERC promoter 
stronger than hTERT when cells were infected with equivalent infectious doses. However, 
the transcripts migrated at different sizes. In order to characterise the transcripts more 
fully, cDNA was synthesised from total RNA extracted from Ad-hTERC-NTR and Ad- 
hTERT-NTR infected C33-A cells and PCR reactions specific for the 5’and 3’ ends of the 
transcripts were performed. The single product of the 3’ end amplification of the Ad- 
hTERC-NTR transcript and the two products of the 3’ amplification of the Ad-hTERT- 
NTR transcripts were sequenced and revealed a 187bp deletion only present in expressed 
cDNA that corresponded to a putative splicing variant. The mutation encoded by the 
splicing variant translates to a truncated NTR species, but is not predicted to abrogate the 
function of NTR, although some effects on nitroreduction efficiency cannot be ruled out. 
The 5’ ends of the products of both Ad-hTERC-NTR and Ad-hTERT-NTR are in-keeping 
with previous results, indicating that the correct transcriptional start sites of the hTERC 
and hTERT promoters are maintained within the adenovirus backbone.
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Infection of a panel of five mortal and cancer cell lines with Ad-hTERC-NTR and Ad- 
hTERT-NTR resulted in significant sensitisation to CB1954 in two cancer cell lines: an 
ovarian adenocarcinoma line and a cervical carcinoma line. No other cell lines were 
significantly affected by transduction with Ad-hTERC-NTR and Ad-hTERT-NTR. 
Sensitisation of these cell lines was in-keeping with data presented in previous chapters 
and indicated that the expression of NTR following transduction with the Ad-NTR gene 
therapy vectors could specifically sensitise human cancer cells to CB1954 in a manner that 
is dependent in part on promoter activity and in part on infectivity. This is supported by 
western blot analysis of NTR expressed in the mortal foetal lung fibroblast cell strain WI- 
38 compared with the cervical carcinoma cell line C33-A showing low to undetectable 
activity of both promoters in the mortal cell strain, but high level expression in the cancer 
cell line.
The data presented in this chapter and in those preceding therefore support the virus 
mediated delivery of hTERC-NTR and hTERT-NTR expression constructs combined with 
CB1954 as a valid therapeutic approach for cytotoxic gene therapy of human cancer.
Figure 5.1: Mean adenovirus infection efficiency in cancer, mortal and ALT cell lines.
Cell lines were either mock infected, or infected with a titration of Ad-CMV-LacZ at 1, 10, or lOOp.f.u./cell 
for 1 hour. Cells were then incubated overnight in medium containing 2% semm and the next day were fixed 
in glutaraldehyde. Cells were stained overnight at neutral pH and the proportion of infected cells was 
estimated by counting the proportion o f blue cells in 5 random fields at X20 objective (a total o f 500-1000 
cells). Data shown are the means and standard error derived from 2 independent experiments in each cell 
line.
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Figure 5.2: Representative photomicrographs of Ad-CMV-LacZ infected cell lines.
Cells were either mock infected, or infected with a titration o f Ad-CMV-LacZ at 1, 10, or lOOp.f.u./cell for 1 
hour at 37°C. The cells were incubated overnight and the following day were fixed in glutaraldehyde and 
stained overnight with X-Gal. Photomicrographs were taken with a digital camera and the proportion of 
infected cells was estimated by counting 5 random fields at X20 objective. In total, approximately 500-1000 
cells were counted for each treatment. All experiments were repeated at least twice.
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Figure 5.3: Cloning Ad-NTR gene therapy vectors (1): generation of intermediate transfer 
vectors.
T he 740bp Sail fragm ent o f  pd2N T R -hT E R C  w as ligated  in to pShuttle  to generate  the vecto r pShunt, w hich 
con ta ins the N TR  cod ing  sequence. T he 889bp H in d iII fragm ent o f pd2 -N T R -hT E R C  and the 606bp  X hol 
fragm ent o f  pd2-N T R -hT E R T  w ere cloned  into pShunt to generate  the p lasm ids pS H U N T -hT E R C  and -  
hT ER T . T hese  in term ediate  transfer vectors w ere linearised  w ith Pm el for recom bination  into p A d e a s y - l .
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Figure 5.4: Cloning Ad-NTR gene therapy vectors (2): generation of recombinant adenovirus 
genomes.
L inear transfer vectors pS H U N T -hT E R C  and -h T E R T  w ere co transfo rm ed  w ith pA deasy-1 in B J5183 cells. 
Potential recom binan ts w ere selected  and screened  by res tric tion  d igest and sequencing  w ith the prim ers 
Shunt I f  and S h u n tlr . R ecom binants w ere linearised  and tran sfec ted  into H EK -293 cells for large scale 
adenovirus p reparation .
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C33-A CELLS
1
Figure 5.5: Northern blot analysis of NTR expression in Ad-hTERC-NTR and Ad-hTERT-NTR 
infected cervical carcinoma cells.
C 33-A  cells w ere m ock infected , or in fected  w ith 50p .f.u ./ce ll o f  A d-hT E R C -N T R  o r A d-hT E R T -N T R . 
R N A  w as ex trac ted  and 25(Hg w as e lec tro p h o resed  and blo tted  on to  nylon filters. F ilters w ere p robed w ith the 
32P -dC T P  labelled  740bp Sail fragm ent o f pd2 -N T R -hT E R C  (a), or m ouse 18s rR N A  gene (b). Lane 1. C 33- 
A -hT E R C -N T R  stable cell line R N A . L anes 2 and 3. A d-hT E R C -N T R  and A d-hT E R T -N T R  infected  C 33-A  
cells. Lane 4. m ock infected  C 33-A  cells. T he hT E R C  prom oter gave the strongest signal in C 33-A  cells.
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(a) Ad-hTERT-NTR RACE (b) A d-hTERC -NTR RACE
Figure 5.6: 5’ and 3’ RACE reactions for amplification of ends of Ad-hTERC-NTR and Ad- 
hTERT-NTR cDNAs.
cD N A  syn thesis and am plification  o f  5 ’ and 3 ’ ends o f  cD N A s w as perfo rm ed  using  C lon tech  SM A R T - 
R A C E kit. T he reactions generate both 5 ’ and 3 ’ ready  cD N A s, each  o f  w hich has a syn thetic  sequence  added 
at the 5 ’ and 3 ’ ends, respectively , a llow ing  annealing  o f  a “ universal p rim er m ix” ou tside the transcrip t 
sequence and. hence, am plification  o f  the en tire  end. lp g  total R N A  w as used for the initial genera tion  o f 
cD N A  and  2 .5pl cD N A  w as used  in each PC R  reaction . A m plification  o f  the 5 ’ and 3 ’ ends o f  N TR  
transcrip ts w as perform ed using the p rim ers s h u n tlr  (5 ’ am p lifica tion ) and A dN T seq5a (3 ’ am p lifica tion ) in 
add ition  to the 5 ’ or 3 ’ universal p rim er m ix supp lied  w ith kit that anneals to a syn thetic  sequence  added  to 
the cD N A  during  first strand  synthesis. L anes are identical in both panels. L ane 1, 5 ’ end  am plifica tion . 
Lane 6. 3 ’ end  am plification . L anes 3 and 8, con tro l am plifica tion  using both A D N T seq5a  and shunt lr . 
L anes 2 and 7, positive con tro l am plifica tions o f  transferrin  recep to r. Lanes 9 and 10, negative con tro ls  
using one prim er only. Som e non-specific  bands w ere ev iden t in the contro l reactions, but the N T R  5 ’ and  3 ’ 
PC R  y ielded  d iscrete products.
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GAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 
GAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 
OAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 101 200
TTCACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
TTCACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
TTCACATTGAGTCATTATOGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
2 0 1  3 0 0
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
3 0 1  4 0 0
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTCTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
4 0 1  5 0 0
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
5 0 1  6 0 0
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
6 0 1  7 0 0
TACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATCACAG 
TACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATeACAG 
TACCCATCGAAGGTTTTGACGCC 3CCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCGOTAGGTCATCACAG 
7 0 1  8 0 0
CGTTG AAG A TTTTAAC GC TACGCTG C C G A A ATC TCG*I AC .'TTAACCGAAGTGTAAATCTTTCCCGGGGGTACCGTCGACTCGAAG
8 0 1  9 0 0
ATCTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTAT' : C
9 0 1  1 0 0 0
CGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCC 
1 0 0 1  1 1 0 0
CGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACC 1101 1200
GCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGG 
1 2 0 1  1 3 0 0
CACAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAA 
1 3 0 1  1 3 7 0
■ ; ••• I AAAAAAAAAAAAAAAAAAAAAA 
TGCGGTTTAAAACATAAATAAAAAACCAGACTCTGTTTGGATTTGGAT
Figure 5.7: Sequences of Ad-hTERC-NTR and Ad-hTERT-NTR transcripts expressed in C33- 
A cells.
Products o f  the 5 ’ and 3 ’ RACE reactions w ere d irec tly  c loned  into pCR-11 for sequencing  by d ideoxy  chain  
term ination  using the M 13 prim er pair and A dtranscrip t 1 (3 ’ end). A nalysis o f  sequences and contigs w as 
perform ed using  V ector NTI 6. (a) show s the full sequence  o f  the long transcrip t iden tified  in hT E R T  R A C E  
reactions co rrespond ing  to a full length N TR  transcrip t, w hile (b) and (c) (next pages) show  the sequences o f  
the short transcrip ts for hT ER C  and hT E R T  respectively . B oth short transcrip ts have a 187bp deletion  
co rrespond ing  to a splice variant. T he transcrip tional start sites, start codons, the true N TR  stop  codon T A A  
(a) and the T G A  stop codons in the adenovirus backbone in (b) and (c) are show n in en la rged  bold characters. 
A dditionally , the putative splice donor and accep to r sites at nt687 and 873 are h igh ligh ted  in (a).
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GGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCCATTTTTTGTCTAACCCTAACTGAGAAGGGCGTAAAGCTTGTCGACCTCGAGACGCGTGATTTTT 
GGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCCATTTTTTGTCTAACCCTAACTGAGAAGGGCGTAAAGCTTGTCGACCTCGAGACGCGTGATTTTT 
OGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCCATTTTTTGTCTAACCCTAACTGAGAAGGGCGTAAAGCTTGTCGACCTCGAGACGCGTGATTTTT 101 200
C ACATTG AGTC ATTATGG ATATC ATTTCTGTC GC CTT AAAGCGTC ATTCC ACT AAGGC ATTTGATGCC AGC AAAAAACTTACCCC GGAACAGGCCGAGCA 
CACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAGCA 
CACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAGCA 
2 0 1  3 0 0
GATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCAAA 
GATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCAAA 
GATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCAAA 
3 0 1  4 0 0
TCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGA 
TCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGA 
TCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGA 
4 0 1  5 0 0
AGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCACCG 
AGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCACCG 
AGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCACCG 
5 0 1  6 0 0
TAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGGTA 
TAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGGTA 
TAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGGTA 
6 0 1  7 0 0
CCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCG-----------------------------------
AAAG rA  A A G l TG 3TAGGTCATCACAGCG
CCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCG 
7 0 1  8 0 0
TTGAAGATTTTAACGCTACGCTGCCGAAATCTCGTCTGCCGCAAAACATCACCTTAACCGAAGTGTAAATCTTTCCCGGGGGTACCGTCGACTCGAAGAT
8 0 1  9 0 0
----------------------------------------------------------------------------------------------------------------------------------------------------------------- CAGCCGCCGCCGCCATGAGCACCAACTCG
CTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTATCTGTTTTGCAGCAGCCGC03CCG 'ATGAGCACCAACTCG
C AGCC GC CGCCGC C ATGAGC AC C AACTC G
9 0 1  1 0 0 0
TTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCCCG 
TTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCCCG 
TTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCCCG 
1001  1100
TCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTCGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGC 
TCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGC 
TCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGC 
1101  1200
CCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGCA 
CCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGCA 
CCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGGCA 
1 2 0 1  1 3 0 0
CAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAATG 
CAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAATG 
CAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAATG 
1 3 0 1  1 3 7 5
CGGTTTAAAAC ATAAATAAAAAAC CAGAC TCTGTTTG GATTTGGATC AA AAAAAAAAAAAAAAAAAAAAAAAAAA
CGGTTTAAAAC ATAAATAAAAAAC CAGACTCTGTTTGGATTTGGATCAA----------------------------------------------------------
CGGTTTAAAAC ATAAATAAAAAACCAGACTCTGTTTGGATTTGGATCAA
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GAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 
GAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 
OAGTTTCAGGCAGCGCTGCAAGCTTGCGGGGCGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGACGCGTGATTT 101 200
TTCACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
TTCACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
TTCACATTGAGTCATTATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAAAAACTTACCCCGGAACAGGCCGAG 
2 0 1  3 0 0
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
CAGATCAAAACGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTTGCCA 
3 0 1  4 0 0
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
AATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCACGTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCT 
4 0 1  5 0 0
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
GAAGCTGGTTGTTGACCAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCAC 
5 0 1  6 0 0
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
CGTAAAGATCTGCATGATGATGCAGAGTGGATGGCAAAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGACGCGG 
6 0 1  7 0 0
TACCCATCGAAGGTTTTGAC 3CCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATCACAG
TACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCG-------------------------------
TACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAGAAAGGCTACACCAGTCTGGTGGTTGTTCCG
7 0 1  8 0 0
CGTTGAAGATTTTAACGCTACGCTGCCGAAATCTCGTCTGCCGCAAAACATCACCTTAACCGAAGTGTAAATCTTTCCCGGGGGTACCGTCGACTCGAAG
8 0 1  9 0 0
ATCTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTTATGTAGTTTTGTATCTGTTTTGCAGCAG GC »‘ "GCCAT'GAGCACCAACT
------------------------------------------------------------------------------------------------------------------------------------------------------------  CAGCCGCCGCCGCCATGAGCACCAACT
C AGCCGCCGC CGC CATOAGC ACC AACT
9 0 1  1 0 0 0
CGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCC 
CGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCC 
CGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACGCGCATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCC 
1001  1100
CGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACC 
CGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACC 
CGTCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGACTGCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACC 
1101  1200
GCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGG 
GCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGG 
GCCCGCGGGATTGTGACTGACTTTGCTTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTTGACGGCTCTTTTGG 
1 2 0 1  1 3 0 0
CACAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAA 
CACAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGCTGTTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAA 
C AC AATTGG ATTC TTTGACCC GGG AACTTAATGTC GTTTCTCAGCAGC TGTTGGATCTGCGC CAGCAGGTTTCTGCC CTG AAGG CTTC CTC CCCTCCC AA 
1 3 0 1  1 3 8 0
TGCGGTTTAAAAC ATAAATAAAAAAC C AG AC TCTGTTTGG ATTTGG A T   —   --------------------------------------------------------
P 5 3 3TTTAAAA ATAAATAAAAAA< A 3 A rC TG TTT SGATTTGGATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
TGCGGTTTAAAAC ATAAATAAAAAAC CAGACTCTGTTTGGATTTGGAT
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A d-hTERC-NTR Ad-hTERT-NTR
Plasmid Virus Plasmid Virus 123 hp
dH 20 DNA DNA cDNA DNA DNA cDNA Ladder
1 2 3 4 5 6 7 8
Figure 5.8: Amplification across deleted transcript region using virus DNA, plasmid DNA 
and cDNA.
In o rder to de term ine  the source o f  the deletion  in the short N TR transcrip ts. PC R  reactions w ere perfo rm ed  
on the D N A s generated  at each stage o f  the virus c lon ing  (adenov irus genom ic p lasm ids, ex tracted  viral 
D NA  and exp ressed  cD N A ), using the p rim ers A dN T seq5a and A dD elr that generate  a 762bp  am plicon  if the 
full length product is p resent, but a  575bp  am plicon if the dele tion  is present. T he dele tion , in add ition  to tw o 
o ther m inor p roducts including the full length product, w as present only  in the exp ressed  cD N A , suggesting  
the involvem ent o f  a m echanism  such as a lternative splicing.
Figure 5.9: The short NTR expression product in C33-A cells is an alternative splice variant.
In order to determine the reason for the expression o f several transcripts in C33-A cells, the sequence o f thee 
full length hTERT transcript (expected sequence, figure 5.7a) was submitted for a search of splice 
donor/acceptor sites via the SPL search facility on the website o f the Sanger centre. The search results 
indicated that the deleted region was flanked by splicing donor/acceptor sites corresponding precisely to the 
location o f the deletion (compare highlighted nucleotides 687 and 873 in figure 5.7a with the boundaries of 
the deleted region in figure 5.7b and c). The sites at nucleotides 687 and 873 are indicated by boxes in the 
screen shown in the figure.
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1 50
NTRtranslate (1) MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIV
TERTSHORTtranslate (1) MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQY SPS STNSQPWHFIV
Translation of TERTLONGdirect (1) MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIV
hTRtranslate (1) MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIV
Consensus (1) MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIV 
51 100
NTRtranslate (51) ASTEEGKARVAKSAAGNYVFNERKMLDASHVWFCAKTAMDDVWLKLWD
TERTSHORTtranslate (51) ASTEEGKARVAKSAAGNYVFNERKMLDASHVWFCAKTAMDDVWLKLWD
Translation of TERTLONGdirect (51) ASTEEGKARVAKSAAGNYVFNERKMLDASHVWFCAKTAMDDVWLKLWD
hTRtranslate (51) ASTEEGKARVAKSAAGNYVFNERKMLDASHVWFCAKTAMDDVWLKLWD
Consensus (51) ASTEEGKARVAKSAAGNYVFNERKMLDASHVWFCAKTAMDDVWLKLWD 
101 150
NTRtranslate (101) QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF
TERTSHORTtranslate (101) QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF
Translation of TERTLONGdirect (101) QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF
hTRtranslate (101) QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF
Consensus (101) QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF 
151 200
NTRtranslate (151) LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVWPVGHHSVEDFN
TERTSHORTtranslate (151) LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVWPQPPPP-----
Translation of TERTLONGdirect (151) LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLWVPVGHHSVEDFN
hTRtranslate (151) LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLWVPQPPPP-----
Consensus (151) LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVWPVPPPSVEDFN 
201 217
NTRtranslate (201) ATLPKSRLPQNITLTEV
TERTSHORTtranslate (196)
Translation of TERTLONGdirect (201) ATLPKSRLPQNITLTEV
hTRtranslate (196)
Consensus (201) ATLPKSRLPQNITLTEV
Figure 5.10: The NTR splice variant encodes a truncated protein.
A nalysis o f  the expected  products o f  translation  o f  the short N TR  transcrip ts in V ecto r NT1 6 ind icated  that 
the expected  protein  had a 22 am ino  acid C -term inal truncation  (sequences “T E R T  short tran s la te” and “hTR  
transla te” in the figure above). T he deleted  region is show n by blue lettering . A dd itionally , the truncated  
protein  has a 5 am ino  acid m utation  show n in b lack  lettering . T he true sequence (V G H H S) (sequences “ N TR  
transla te” , and “ translation  o f  T E R T  long d irec t” ) is rep laced  by the sequence Q PPPP. T he final am ino  acid 
o f  the m utant sequence is show n in green. In the rep resen ta tion  show n in the next page, single residues 
involved in the ca ta ly tic  in teraction  w ith FM N  are ind icated  in blue and those residues involved  in FM N  
interaction  that are in the deleted  reg ion  (also  in blue) are ind icated  by green letters.
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Figure 5.11: BLAST search for protein regions homologous to the mutated residues of Ad 
NTR.
The 27 deleted and mutated residues were submitted for a BLAST search using Vector NTI 6 online facilities 
in order to determine whether other protein species with similar function show homology in this region. The 
search identified 3 other nitroreductase species that are closely related to E.Coli NTR, but did not identify 
any proteins such as DT-Diaphorase that perform a similar catalytic function. Thus, these residues are not 
likely to be involved in catalysis.
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Figure 5.12: Secondary structure predictions for 3 nitroreductase species.
The sequences o f the 3 most closely related NTR species identified in the BLAST search were submitted for 
secondary structural predictions via the online nnpredict facility o f Vector NTI 6. The top panel gives the 
sequence o f E.Coli NTR and the mutated and deleted region is highlighted in blue. In the screen-shot, a mn 
of H corresponds to a predicted helix, while a run of E corresponds to a strand. A dash indicates no 
prediction. There was no conservation of predicted secondary structural features across the species in this 
region, while other regions are predicted to form long tracts o f helices that appear quite well conserved.
I
■  J
R
o
a
\
1
1-ffi
ll
n
i/i
i *iu -q <
> 9 I 
P X X  
C 5 h 
X 2 5 
5 d WU13 i)
IX t
P c 5
(1 OH 6 AH 
>0 «
H 6 (1
M W 51 pp 
3 5 5  
A5  0 
f f l j H 
(15 A2 0 > Dffd 
1155  
n H  
A 5> 5
II H H >>a e i)
O' h (J j  
H 3 !> H
H > 5 J
p 5 H H
X 5 H  2 
H £ P J
5 0 2 A 
0 P 5 hIX > p 
5fl 2 n 
ll ! H X  
AP > A
s \\:X >XI 
X2 I! 2
3  o n § m 
» 1 1 3 5 
S 5 5  I) D 
» P h C >
! i « '
p P P 2 2 
S  0 I H  5 
h i  2 5  > 
>  p P X A 
^ X  3 P > 
g h S i  > 
M 2 2 >
2 > 5 5 h 
8 0 0 C I)
3  h  fl p  p 
n’ t)  n w  >i 
g 5 x X 5 
Z  £ I p x
>E I I 
(ESI 
Q 32 32 I 
' J i l l  
Q 32 K 32 
^  32 32 33 
3  32 32 32 
f  I 32 32 
^  ! 33 33 
^  ! 32 33 
E 
E 
I
E I
IP E 
IP E 
 ^W 3 32 
A IP E E 
■? 3 3 32 
 ^3 3 3 
< 32 3 3 
l 3 I 3 
(IIis i i 
CE I I 
- E E E 
23 I E IP .2 I EW 
* I WE 
^  I IP E 
t  I EE 
g I EE 
P I I E 
ftE I E
0 E E E
1 E 3 3 
3 E 3 3 
CEESii
! 1K B I E 
MEE 
E I
0 E I E I 
UEEE I 
g l EE I
Z I E I I
*1 
IP
I E IP
I E IP 
E IP 
E IP
31
Q
1
11
g ?
£
3  S I
qsis
i M-r Jfrt
1 4;
> 9  II
p x  x
ll 9  -I
x  a 9
9 0 P 
II C II 
U X II
p C 9 
II II h0 a >
> p (iHUH
P P 9
a p p
3 9  9  
A 9  H 
9  J h 
H 9  A
a (i >
p  9 «  
n 9  9
a |> 9 
n p £
> u i
9  H 05 U 
H 3
h  6 9  P 
p  9  h  P 
X 9  h  I) 
h S P H
x  3 a a
9  P 9 h  
C X > P 
M a n  
I) o H x  
d p  >  a
s  h ;
N  ll o £ p
p] a  1 3 9  
9 9  9  ll
m « h a >
1 < 5  9  n 
J x  f i  9  a  
t § p  p x a
< t 11 I IH  9 ^> a i) > 
>  p p  > a 
^  9P p ? 
h  3 a  ? 
p d a s ?a > 9 9 h
# ii t  d •)
3 > d P P 
9  h t) p  > 
I) 9  X P 9 
60 i  C P X
Ala i i CIS I
9 1  a  i 
■a a  i a  
S a  a  a  
a  a  a  
a  a  a  
i a  a
»1S 5 
s  i a  a
9  IP 
?M
I “ I y
l l  I
a
i 5
i s
,  a
a  a  
a  a  a  
p  a  a  
p  a  a
a 
a 
aii i
a
a a  p  
. s  a a  p  
r  a  w a  
ip a 
a  a  
a  a  
i a  
i a  
a  a
a a  
*  a  a  a  u
i a  ip
i a  ip
i a  ip
i a  ip
i a  a
i a  i
i a  i
i a  a
i t  i a  i i
R
ft]
o
I
II
-gl
if
m
d
* a PJ U|
t
> 9 1) a;a i a
P X X 3 a i i
c a n 9  a i a
X 3 9 ■a a i i
9 i  p 5 a a a
U 5 ll a a a a 
S a a all X (1
p a 9 }  i a  a 
5 i a s  
*  i i a
n (i h
0 a n
> p i 9 U  l 1
h 3 « ( M i l
P P 9 H IP 1 1
a  p p 11 IP 1 1
<  9 9 9 11 
It] P -i 9 > 
N c £ 9 n 
Cn X X 9 a  
S  p  p x a
N 11 ll H 9
(i, a  a 9 > 
>  p p  > a  
^  x  > p > 
D h  >, a  pU (P £ > 
3 > 9 5  h 
# n d i! i) 
3 h d p p 
o' p n > p 
a 9 X V 9 
69 5 « P X
- a a a i 
E a a p  i 
.2 a a p i 
*■ a a a i 
.2 i w a i 
■3 i a a i 
o a a a i 
a a i a i 
&a i a i 
s a a a i
2 a a i i
3 a a i i 
fj a a i i
s 1 £1 1 r  i a i i
B i a i i
» a a i ip
>,a w a ip
C a w i u
a  a  
d  a  33 
o au x 4
69 i a  i i
i a  ip
i i ip
i a  ip
i a  i
i a  i
a  i i
Alan E. Bilsland, 2002 Chapter 5: Adenovirus delivery of NTR vectors 164
(a)
NTR
(b)
Figure 5.13: Western blot analysis of expressed NTR in WI-38 and C33-A cells.
Protein  w as ex trac ted  from  cells in fected  w ith 50p .f.u ./ce ll o f  N T R  viruses. 2 0 p g  protein  w as run out by 
SD S -P A G E  and b lo tted  onto  n itrocellu lose  filters. F ilters w ere probed  w ith the rabbit an ti-N T R  an tibody  
R 36, then w ith the H R P-con jugated  an ti-rabb it secondary . L ane 1, C 33 -A -hT E R C -N T R  stab le  cell line 
protein . Lanes 2, 3, 4, C 33-A  cells in fected  w ith A d-hT E R C -N T R  (2), A d-hT E R T -N T R  (3), or m ock 
infected . T he resu lts are consisten t w ith the band  in tensities observed  in northern  b lo ts. L anes 5, 6, 7, W I-38  
cells in fected  w ith  A d-hT E R C -N T R  (5), A d-hT E R T -N T R  (6) or m ock in fected  (7). C ontro l m em brane 
sta ined  w ith am ido  b lack  is show n in (b). T he band  in tensities ind icated  that, w h ile  W I-38  ce lls  w ere  m ore 
in fectab le  than C 33-A  (F igures 5.1 and 5 .2), the hT E R C  and hT E R T  prom oters cou ld  not d rive  high level 
N TR  expression  in these cells. In contrast, hT E R C  and hT E R T  drove high level N T R  expression  in C 33-A .
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Figure 5.14: Cervical carcinoma and ovarian adenocarcinoma cells are efficiently sensitised 
to CB1954 after infection with Ad-hTERC-NTR and Ad-hTERT-NTR.
C 33-A  and A 2780  cells w ere either m ock infected  or in fected  w ith a titra tion  o f  10 and 50p .f.u ./ce ll o f  each 
o f  A d-hT E R C -N T R , A d-hT E R T -N T R , o r the contro l v irus A d-C M V -L acZ . C ells w ere in fected  for 1 hour 
then rep lated  into 96 w ell p lates fo r M T T  assay and incubated  for 2 days. T he ce lls  w ere challenged  w ith a 
titration  o f  C B 1954  for 24 hours then a llow ed to recover fo r a fu rther 3 days p rior to M T T  assay. Each data 
poin t is the m ean and standard  error derived  from  trip lica te  p la tes for a rep resen ta tive  experim en t. All 
experim en ts w ere repeated  at least 3 tim es. D ata analysis w as perfo rm ed  using  the S oftm ax  2 .32  m icrotitre 
p late analysis softw are. T he sensitisa tion  o f  these cell lines to C B 1954  is m anifested  by a v irus dose 
dependen t sh ift o f  the cu rves aw ay from  the m ock infected  curve (filled  squares).
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Figure 5.15: Cytotoxicity curves of the cell lines that are not sensitised to CB1954 by 
transduction with Ad-hTERC-NTR and Ad-hTERT-NTR.
W I-38, 5 6 3 7  and  H M E C  cells w ere either m ock in fected  or in fected  w ith a titra tion  o f  10 and 50p .f.u ./cell o f 
each o f A d-hT E R C -N T R , A d-hT E R T -N T R , o r the con tro l v irus A d-C M V -L acZ . C ells  w ere infected  fo r 1 
hour then rep la ted  into 96 w ell p lates fo r M T T  assay and incubated  for 2 days. T he ce lls  w ere challenged  
w ith a titra tion  o f  C B 1954  for 24 hours then a llow ed  to recover fo r a fu rther 3 days p rio r to M T T  assay. E ach 
data po in t is the m ean and standard  erro r derived  from  trip licate  p la tes fo r a rep resen ta tive  experim ent. A ll 
experim en ts w ere  repeated  at least 3 tim es. D ata analy sis w as perform ed using  the Softm ax  2 .32  m icro titre  
plate analysis  softw are. T he lack o f  sensitisa tion  o f  these  cell lines to C B 1954  is m an ifested  by cu rves for 
adenovirus in fected  cells that are tightly  packed together w ith the m ock in fected  curve (filled  squares).
Figure 5.16: Representative parallel cytotoxicity and infectivity assay in C33-A cells.
In order to assess the dual dependence of sensitisation to CB1954 on promoter activity and infectivity, all 
cells tested were infected with a titration of 10 or 50p.f.u. per cell o f each o f the NTR viruses in addition to 
the CMV-LacZ virus. On the day o f drug addition, the LacZ infected cells were stained with X-Gal to give an 
indication o f the proportion of infected cells on the day of drug administration. The figure shows the 
summary o f a single representative experiment, including the percentage o f infected cells and 
photomicrographs of X-Gal stained cells, in addition to the cytotoxicity curves, IC50 values and the 
derivation o f the sensitisation value from the IC50 values. All experiments were repeated at least 3 times and 
cell lines expected to have low promoter activities were assayed in parallel with a cell line having high 
promoter activity.
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C e l l s  i n f e c t e d  by a d e n o v i r u s  v e c t o r s  o n  t he  
d a y  o f C B 1 9 5 4  c h a l l e n g e
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Figure 5.17: Summary of infectivity and sensitisation in cell lines infected with Ad-hTERC- 
NTR and Ad-hTERT-NTR.
Cell lines w ere  either m ock infected , or infected with 10 or 50p .f.u ./cell o f e ither A d-hT E R C -N T R , A d- 
hT E R T -N T R , or A d-C M V -L acZ  for 1 hour. A fter infection, cells w ere replated  and M T T  or infectiv ity  
assays w ere  perfo rm ed  as described  earlier. Infectivity values in the upper panel are the m eans and standard  
errors derived  from 2 independent experim ents in each cell line and independent values w ere derived  from  
the m ean proportion  o f  X -G al stained cells in 5 random  fields at X 20 objective (approx im ate ly  500-1000  
cells). IC 50  values fo r C B 1954  cyto toxicity  in individual experim en ts are derived  from  the m ean 
concen tra tion  o f  drug, taken across trip licate  plates, necessary to reduce the cell density  to 50%  o f  control 
(un trea ted ) ce lls. T he sensitisa tion  value in individual experim ents is taken to be the fold d ifference  betw een 
the 1C50 o f  the m ock in fected  cells and the IC 50 value o f the curve fo r any single treatm ent. A ll cy to tox icity  
experim en ts w ere repeated  at least 3 tim es and the data given in the low er panel are the m eans and standard  
errors derived  from  3 independent experim ents.
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Tumour volume of C33-A xenografts following Ad-NTR 
infection and CB1954 challenge
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Figure 5.18: Ad-hTERC-NTR and Ad-hTERT-NTR sensitise human cervical carcinoma cells 
to CB1954 induced cytotoxicity in vivo.
10 C 33-A  ce lls  per m ouse w ere in jected  subcu taneously  into the flanks o f  6 g roups o f  6 fem ale athym ic 
nude m ice and allow ed to develop  for 14 days until tum our d iam eters w ere approxim ately  5m m . A t this tim e 
(day 0), 4 g roups o f m ice w ere in jected  in tra-tum ourally  w ith a total o f  4x10  pf.u. c ither o f A d-hT E R C -N T R  
or A d-hT E R T -N T R  (2 g roups fo r each v irus). T he fo llow ing  day (day 1), 3 g roups (1 d rug  only  group and 1 
each o f the  v iru s in jected  g roups) w ere in travenously  in jected  w ith 80m g/kg  C B 1954 and the m ean tum our 
volum es o f  all groups w ere m on ito red  daily  fo r 7 days. R esults given are the m ean tum our volum es and 
standard  e rro rs  at each tim e point derived  from  6 m ice per g roup  by the form ula vo lu m e= d 3x jt/6. A  c lear 
reduction in tum our vo lum e ov er the course o f  the experim en t is ev iden t in the groups in jected  w ith both 
v irus and d rug , but not in any o f  the contro l g roups.
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CELL LINE MOCK 
IC50 (s.e.) |aM
hTERC 10 P.F.U. 
IC50 (s.e.) [xM
hTERC 50 PJ-U. 
IC50 (s.e.) nM
hTERT 10 P.F.U. 
IC50 (s.e.) [aM
hTERT 50 P.F.U. 
IC50 (s.e.) nM
C33-A 176.13 (10.08) 33.43 (14.56) 9.76 (2.75) 63.13(17.07) 35.86 (13.32)
WI-38 153.62 (48.53) 178.09 (68.05) 164.72 (55.21) 148.6 (54.76) 174.12 (74.09)
A2780 28.5 (13.92) 10.69 (3.66) 3.85 (1.45) 17.73 (4.39) 10.86 (0.64)
5637 102.86 (14.25) 93.55 (16.06) 73.36 (14.59) 112.61 (19.96) 103.17 (22.4)
HMEC 31.67 (11.21) 45.38 (20.54) 36.02 (11.27) 27.76 (6.27) 29.65 (4.5)
Table 5.1: IC50 values for CB1954 cytotoxicity in cell lines infected with Ad-hTERC-NTR and 
Ad-hTERT-NTR.
Relative cell densities were calculated from optical density measurements at 570nm to measure the quantity 
of MTT-formazan in individual wells. For an independent experiment, each IC50 value was calculated from 
the mean value of the 50% y-intercept determined from triplicate plates. IC50 values in the table are the 
means and standard errors, given in brackets, for each virus and multiplicity of infection calculated from 3 
independent experiments.
CHAPTER 6
SUMMARY OF EXPERIMENTAL 
RESULTS AND FINAL 
DISCUSSION
• Validation of the use of hTERC and hTERT 
promoters for transcriptionally directed cancer 
gene therapy.
• Final discussion.
Alan E. Bilsland, 2002 Chapter 6: Discussion 172
6 SUMMARY OF EXPERIMENTAL RESULTS AND 
FINAL DISCUSSION
6.1 Summary of experimental results
A major aim of this thesis was to examine the transcriptional regulation of hTERC and 
hTERT promoters and to determine whether the sequences are useful in the context of an 
anticancer gene therapy approach. The hTERC and hTERT sub-units are differentially 
regulated at a transcriptional level between normal and cancer cells and the expression of 
the sub-units is a major factor that determines whether telomerase is active in the cell. The 
data presented in chapter 3 show clear differentials in the activity of hTERC and hTERT 
promoter fragments in normal and cancer cells that validate the promoters for use in 
cytotoxic gene therapy.
It would be expected that the expression of a pro-drug activating enzyme under the control 
of these sequences would selectively activate the pro-drug to significant levels in cancer 
cells with high promoter activity. This indeed appears to be the case in stable cell lines 
harbouring hTERC-NTR and hTERT-NTR expression constructs. In this model, the 
response of cells to CB1954 challenge fell into two groups, apparently dependent upon 
promoter activity: those cell lines that had high promoter activities and were sensitised to 
CB1954, and those cells that had low promoter activities and were not. The sensitivity of 
two cell lines to telomerase-nitroreductase gene therapy was retained in xenograft models, 
resulting in significant reductions in tumour volume upon challenge with CB1954. In both 
xenograft models, the reduction in tumour volume mirrored the shape of the cytotoxicity 
curves determined by in vitro cytotoxicity assay, confirming that the promoter dependent 
sensitisation to CB1954 is retained in vivo. These data, presented in chapter 4, were 
encouraging for the further development of the telomerase-nitroreductase gene therapy 
model and the model was extended by cloning the expression constructs into an adenovirus 
backbone.
Infectivity assays showed that adenovirus was a highly efficient gene delivery vehicle in 
most of the cell lines used in this model and gene expression analysis indicated that NTR 
RNA and protein was expressed in a promoter dependent manner in cell lines infected with 
adenovirus gene therapy vectors. Northern analysis and sequencing of cDNA confirmed
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that the major expression product was a splice variant with a 187bp deletion from the 
expected sequence. The variant encodes a 22 amino acid deletion with a further 5 amino 
acid mutation. The mutation is not expected to abrogate the function of NTR, as it is distal 
from the site of catalysis, but two deleted residues contact the internal electron donor 
molecule to stabilise binding suggesting that the efficiency of catalysis could theoretically 
be reduced. However, functional studies of CB1954 induced cytotoxicity in Ad-NTR 
infected cell lines indicated that functional NTR was expressed.
A cervical carcinoma cell line and an ovarian adenocarcinoma cell line could be efficiently 
targeted by infection with Ad-hTERC-NTR and Ad-hTERT-NTR followed by CB1954 
challenge, while a further three mortal and immortal cell strains with low promoter 
activities were not sensitised to CB1954. Thus, Ad-hTERC-NTR and Ad-hTERT-NTR 
sensitise human cancer cells to CB1954 to an extent that is partly dependent on promoter 
activity and partly dependent on infection efficiency.
In order to make a more detailed analysis of the possible functional effects of the mutation, 
it would be necessary to perform a comparative enzyme activity assay using a defined 
proportion of adenovirus infected cells compared with a similar proportion of stable cells 
mixed with the necessary proportion of NTR negative cells. An assay for NTR enzyme 
activity based on menadione and cytochrome P450 reduction has previously been 
described (Plumb et al. 1994). However, the degree of sensitisation observed in the 
cervical cell line was comparable with that observed in stable cell lines harbouring the 
plasmid DNA NTR expression constructs despite the infection of less than 100% of cells 
and, taking into account the low infectivity of the ovarian cell line, the degree of 
sensitisation observed was also comparable to the stable cell line model. This indicated 
that the catalytic function of NTR was not adversely affected by the deletion, in terms of 
its ability to bioactivate CB1954 resulting in cell death. Additionally, C33-A xenografts 
infected with telomerase-nitroreductase adenovirus gene therapy vectors showed decreases 
in tumour volume on challenge with CB1954 that were comparable with those seen in 
xenografts established from stable hTERC-NTR and hTERT-NTR expressing cell lines. 
Thus, the functional evidence suggests that NTR activity was not significantly affected by 
the mutation.
The data presented in this study confirm that a therapeutic window for exploitation by 
cytotoxic gene therapy exists in the differential telomerase promoter activities between
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normal and cancer cells and support the further development of telomerase-nitroreductase 
gene therapy vectors.
6.2 Final discussion.
Cancer is a major worldwide health problem. In the UK, cancer accounts for 
approximately 24% of all fatalities annually. Conventional systemic anticancer 
chemotherapeutics are limited in their efficacy by a low therapeutic ratio resulting in dose 
limiting toxicity to normal tissue. Often, this is because the targets and mechanisms of 
action of conventional chemotherapeutic agents are not directed against malignant cells, 
but rather cells that are in cycle. For this reason, the identification and exploitation of 
novel mechanism based targets for the treatment of cancer is a major aim of cancer 
research. Cytotoxic gene therapy represents an attractive approach for management of 
malignant disease as it promises to allow tumour specific expression of therapeutic 
constructs, thereby enhancing the therapeutic ratio.
The association of telomerase activity and telomerase sub-unit expression with human 
cancer is unique in its prevalence and specificity (Kim et al. 1994; Hiyama et al. 1995; 
Shay et al. 1997; Soder et al. 1998; Sarvesvaran et al. 1999; Hiyama et al. 2001). 
Telomerase promoter constructs have now been used to direct the cancer cell specific 
expression of a number of therapeutic transgenes including HSTK (Majumdar et al. 2001), 
diptheria toxin (Abdul-Ghani et al. 2000), Bax (Gu et al. 2000), caspase 8 (Koga et al. 
2000), caspase 6 (Komata et al. 2001), FADD (Koga et al. 2001), and the noradrenaline 
transporter gene that facilitates the uptake of 131I-MIBG (Boyd et al. 2001). Because of the 
many attractive features of the nitroreductase/CB1954 system, the addition of hTERC- 
NTR and hTERT-NTR expression systems to this potential anticancer armoury is an 
exciting development (Plumb et al. 2001).
Current gene therapy systems are limited by a requirement for increased efficiency and 
selectivity of delivery to the target in situ. However, several key advances of the last 
decade in adenovirus-based gene transfer technology may be expected to help overcome 
the current limitations to efficacious anti-cancer gene therapy when appropriately 
combined with cytotoxic gene therapy approaches.
The development of high-capacity vectors allows for longer transgene persistence at the 
site of infection coupled with the possible development of vectors encoding multiple
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tumour targeting expression cassettes (reviewed in Morsy et al. 1999). The enhanced 
efficacy of a double suicide gene therapy approach has previously been demonstrated 
using a combination of cytosine deaminase and viral thymidine kinase genes (Uckert et al. 
1998).
The identification of the primary receptor, hCAR (Bergelson et al. 1997), and the integrin 
mediated internalisation pathway of adenoviruses (Wickham et al. 1993) has allowed the 
development of novel technologies designed to retarget adenoviruses to other cellular 
receptors. Wickham and colleagues defined the hCAR/knob contact residues (Kirby et al. 
1999; Roelvink et al. 1999; Kirby et al. 2000), and recent mutational experiments have 
seen the development of vectors with both hCAR and integrin specificity completely 
ablated (Einfeld et al. 2001). Such vectors effectively represent a “blank page” on which 
completely novel targeting specificities may be engineered. Interestingly, the exposed HI 
loop of the adenovirus knob domain is not involved either in the primary receptor 
interaction, or in the interactions required for the essential trimerisation of fiber (Krasnykh 
et al. 1998) and contains a unique restriction site that facilitates easy cloning of sequences 
of interest (Mizuguchi et al. 2001). Thus, this region of the molecule is an attractive site 
for incorporation of novel binding specificities. The validity of this approach for tumour 
targeted delivery of cancer therapeutics will therefore rely mainly upon the identification 
of tumour associated cell surface markers that may enable the more effective systemic 
administration of adenoviral vectors. Adenoviruses have been targeted to a number of 
alternative receptors using genetic approaches, or with the use of bispecific antibodies 
(Douglas et al. 1996; Gu et al. 1999; Haisma et al. 1999; Dmitriev et al. 2000).
Recent studies have seen the development of chimeric viral vectors, a method for 
combining attractive features of two viruses in completely novel constructs (reviewed in 
Reynolds et al. 1999). This approach has at its heart an extension of the pseudo-typing 
approach that has been used to confer new virus tropism, in the case of adenoviral vectors, 
by generating capsid combinations derived from two different adenovirus serotypes 
(Zabner et al. 1999). In a recent study, two adenoviral constructs were generated 
incorporating retroviral packaging and integration functions in separate vectors. Infection 
of an ovarian carcinoma cell line with both adenoviruses resulted in the transient 
production of a retrovirus producer cell line. Xenografts generated from a mixture of 
producer cells and virgin tumour cells showed stable incorporation of a GFP transgene 
encoded in the retroviral sequence (Feng et al. 1997). Alternative approaches to the 
development of chimeric vectors include mixing viral and non-viral gene delivery
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technologies. For example, the enhancement of efficiency of transfection of naked plasmid 
DNA by co-intemalisation with adenovirus or adenovirus capsid components is well 
documented (Seth et al. 1994).
A final development in adenovirus gene delivery technology that may be expected to allow 
for local enhancement of infectivity at the target site is the development of selectively 
replicating adenoviral vectors. Interestingly, a patent application has recently been filed 
by the Geron Corporation of California for the development of an adenoviral vector in 
which expression of the El region is restricted by the use of the hTERT promoter (Morin 
et al, World Intellectual Property Organisation publication number WO 00/46355).
Although the development and refinement of advanced generation gene delivery systems 
will be central to the realisation of cytotoxic gene therapy systems that are of genuine 
therapeutic value, their necessity does not outweigh the requirement for efficient tumour 
specific expression systems. Rather, it is the combination of these technologies that may 
herald the dawn of a new era in anticancer therapeutics. From this point of view, 
telomerase is an excellent candidate for the development of tumour specific therapeutic 
gene expression systems.
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